felin
alimentari
lymphoma
lgal
frequent
digest
neoplasia
cat
characteris
infiltr
neoplast
small
typic
small
intestin
rise
preval
diseas
grow
concern
clinician
due
similar
inflammatori
bowel
diseas
ibd
establish
diagnosi
challeng
may
requir
extens
histolog
immunohistochemistri
clonal
analys
howev
diagnost
test
broadli
avail
aim
studi
therefor
determin
whether
usual
clinic
andor
paraclin
paramet
may
differenti
lgal
ibd
prospect
studi
conduct
referr
centr
juli
februari
owner
gave
consent
investig
cat
includ
final
diagnosi
lgal
ibd
base
histolog
immunohistochem
clonal
analys
intestin
biopsi
cat
underw
standard
diagnost
workup
includ
histori
physic
examin
biochem
analys
complet
blood
count
cobalamin
dosag
urinalysi
abdomin
ultrasonographi
valu
express
percentag
median
statist
analys
perform
use
wilcoxon
fisher
exact
test
eighteen
cat
includ
group
frequent
breed
repres
lgal
ibd
median
age
weight
similar
group
vs
year
vs
kg
lgal
ibd
respect
neuter
male
lgal
compar
ibd
vs
median
durat
clinic
sign
higher
cat
lgal
cat
ibd
vs
day
p
diarrhoea
significantli
frequent
lgal
group
vs
hypocobalaminemia
pgml
strongli
associ
lgal
vs
median
serum
albumin
concentr
compar
group
vs
gl
lgal
ibd
respect
major
ultrasonograph
find
includ
diffus
thicken
intestin
musculari
layer
group
slight
abdomin
effus
jejun
lymphadenomegali
defin
thick
superior
mm
frequent
note
lgal
vs
vs
respect
knowledg
first
prospect
studi
compar
cat
diagnos
lgal
ibd
result
indic
paraclin
data
hypocobalaminemia
abdomin
effus
jejun
lymph
node
thicken
seem
associ
lgal
prompt
clinician
investig
emerg
diseas
disclosur
disclosur
report
cat
differenti
inflammatori
bowel
diseas
ibd
alimentari
lymphoma
lgal
definit
challeng
clinician
final
diagnosi
major
issu
treatment
prognosi
differ
date
lgal
characteris
base
upon
combin
morpholog
immunohistochem
analys
moreov
clonal
assess
help
question
case
therefor
perform
extens
histopatholog
molecular
character
cat
diagnos
lgal
ibd
identifi
differenti
featur
entiti
prospect
studi
conduct
owner
complianc
referr
centr
juli
februari
cat
includ
final
diagnosi
lgal
ibd
haematoxylin
eosin
stain
immunohistochemistri
use
antibodi
carri
intestin
biopsi
marker
express
lamina
propria
lymphocyt
iel
assess
separ
quantifi
use
scale
blind
read
perform
two
veterinari
pathologist
one
pathologist
specialis
human
digest
prolif
disord
sampl
subject
clonal
test
base
pcr
target
region
receptor
gamma
eighteen
cat
diagnos
lgal
localis
duodenum
jejunum
ileum
cat
ibd
localis
duodenum
jejunum
ileum
includ
villou
atrophi
lamina
propria
high
cellular
densiti
p
lymphocyt
cryptiti
p
significantli
frequent
lgal
group
gradient
cellular
strongli
associ
lgal
vs
contrast
express
level
lamina
propria
iel
significantli
increas
lgal
case
p
reflect
monomorph
featur
tumor
cell
popul
differ
express
detect
median
valu
lamina
propria
iel
significantli
higher
lgal
group
p
clonal
assess
reveal
monoclon
tcrg
rearrang
lgal
case
ibd
case
knowledg
first
prospect
histolog
immunohistochem
characteris
reli
separ
analysi
mucos
compart
cat
diagnos
lgal
ibd
base
result
measur
could
interest
differenti
similar
clinic
entiti
clonal
test
interpret
caution
light
histopatholog
data
disclosur
disclosur
report
gastrointestin
gi
lymphoma
inflammatori
bowel
diseas
ibd
common
debilit
disord
cat
similar
clinic
find
often
show
intestin
thicken
abdomin
ultrasound
diagnosi
differenti
gi
lymphoma
ibd
requir
histopatholog
evalu
biopsi
sampl
taken
gi
tract
obtain
either
via
laparotomi
surgic
biopsi
mucos
biopsi
obtain
endoscop
latter
howev
still
difficult
conclus
differenti
ibd
gi
lymphoma
purpos
studi
compar
degre
hypoalbuminaemia
cat
gi
lymphoma
ibd
hypothesi
cat
gi
lymphoma
would
lower
serum
albumin
concentr
comparison
ibd
record
client
own
cat
diagnos
either
gi
lymphoma
ibd
histopatholog
endoscop
deriv
mucos
biopsi
retrospect
evalu
cat
diagnos
gi
lymphoma
ibd
gi
lymphoma
group
age
rang
year
median
wherea
ibd
group
age
rang
year
median
statist
differ
group
gi
lymphoma
group
serum
albumin
concentr
rang
gdl
median
gdl
wherea
ibd
group
serum
albumin
concentr
rang
gdl
median
gdl
statist
differ
group
p
studi
conclud
cat
gi
lymphoma
lower
serum
albumin
concentr
cat
ibd
therefor
serum
albumin
concentr
use
biomark
aid
differenti
gi
lymphoma
ibd
cat
disclosur
disclosur
report
although
antibiot
promot
antimicrobi
resist
advers
drug
reaction
commonli
use
dog
uncompl
acut
diarrhea
ad
studi
perform
prove
benefici
effect
antimicrobi
ad
thu
aim
studi
evalu
potenti
benefit
amoxicillin
clavulan
dog
ad
effect
proport
resist
fecal
e
coli
sixteen
dog
ad
randomli
divid
treatment
amoxicillin
clavulan
po
day
placebo
group
lactos
powder
day
dog
receiv
standardis
symptomat
therapi
diet
sever
clinic
sign
base
diseas
activ
index
compar
furthermor
semiquantit
measur
e
coli
fecal
sampl
day
perform
everi
dog
improv
clinic
activ
score
insignific
diseas
within
day
median
day
present
signific
differ
treatment
group
concern
diseas
activ
score
individu
paramet
activ
appetit
stool
constist
defec
frequenc
observ
proport
fecal
ecoli
increas
significantli
day
day
antibiot
group
day
microbi
resist
e
coli
significantli
higher
versu
antibiot
compar
placebo
group
dog
ad
recov
within
day
symptomat
treatment
diet
clinic
relev
benefit
treatment
amoxicillin
clavulan
could
observ
studi
disclosur
disclosur
report
peopl
faecal
microbi
transplant
fmt
cure
recurr
clostridium
coliti
possibl
recoveri
lost
microbiota
divers
similar
fmt
microbiota
interact
recipi
sick
dog
report
author
hypothes
singl
fmt
would
temporarili
increas
microbiota
divers
aim
determin
fmt
substanti
alter
microbiota
divers
month
hypothesi
test
canin
haemorrhag
diarrhoea
syndrom
hd
model
associ
gut
dysbiosi
eight
dog
clinic
sign
hd
ratio
random
receiv
fmt
recipi
salin
control
via
colonoscopi
pielou
alpha
bacteri
divers
index
pabdi
compar
sequenc
bacteri
ribosom
rna
gene
faecal
sampl
recipi
control
match
donor
obtain
admiss
fmt
discharg
recheck
also
compar
previous
valid
hd
clinic
score
recipi
control
recipi
pabdi
differ
substanti
time
admiss
discharg
p
similar
donor
pabdi
discharg
p
howev
recipi
pabdi
differ
time
admiss
recheck
p
contrast
pabdi
donor
control
chang
point
studi
hd
clinic
score
differ
recipi
control
p
conclus
fmt
transient
alter
recipi
bacteri
divers
studi
requir
determin
number
repeat
fmt
procedur
lead
increas
bacteri
divers
disclosur
disclosur
report
recent
studi
suggest
signific
associ
c
perfringen
encod
netf
toxin
netf
acut
haemorrhag
diarrhoea
syndrom
ahd
dog
noth
known
persist
netf
time
patient
studi
aim
evalu
presenc
netf
concurr
clinic
sign
dog
ahd
dog
ahd
without
sign
sepsi
treat
symptomat
without
antibiot
faecal
sampl
test
netf
pcr
day
clinic
sign
assess
daili
first
day
use
canin
haemorrhag
diarrhoea
sever
index
chdsi
statist
analysi
signific
p
perform
test
number
dog
posit
netf
time
point
friedman
test
comparison
chdsi
time
day
dog
posit
netf
percentag
dog
significantli
lower
day
compar
day
p
dog
posit
day
day
day
day
day
day
mean
chdsi
standard
deviat
indic
sever
ahd
mean
chdsi
decreas
significantli
day
compar
day
stay
day
indic
rapid
recoveri
conclus
rapid
decreas
netf
fast
clinic
recoveri
observ
dog
asept
ahd
without
antibiot
treatment
disclosur
disclosur
report
dog
hemolyt
anemia
often
administ
glucocorticoid
clopidogrel
although
medic
caus
gastrointestin
bleed
peopl
gastrointestin
effect
combin
therapi
dog
unknown
aim
studi
compar
gastrointestin
chang
among
dog
administ
clopidogrel
prednison
combin
therapi
trial
perform
use
healthi
adult
dog
median
age
year
rang
dog
random
group
placebo
clopidogrel
prednison
combin
prednisoneclopidogrel
po
day
attitud
food
intak
vomit
fecal
score
determin
daili
endoscopi
perform
baselin
day
mucos
hemorrhag
punctat
eros
pe
invas
eros
ie
ulcer
gastric
bodi
cardia
incisura
antrum
numer
blind
investig
jcw
jt
valu
assign
lesion
region
bleed
defin
hemorrhag
pe
ie
ulcer
result
compar
among
group
use
mix
model
repeat
measur
anova
gener
estim
equat
proport
odd
model
p
consid
signific
clinic
sign
differ
among
treatment
group
time
bleed
pe
ie
differ
group
week
group
week
pe
analysi
reveal
significantli
increas
lesion
score
time
prednison
day
peie
day
peie
prednisoneclopidogrel
day
peie
day
peie
group
versu
placebo
day
peie
day
peie
clopidogrel
day
peie
day
peie
group
ulcer
occur
prednison
prednisoneclopidogrel
group
dog
receiv
prednison
prednisoneclopidogrel
time
like
respect
develop
bleed
dog
receiv
placebo
gastrointestin
bleed
occur
commonli
healthi
dog
administ
prednison
prednisoneclopidogrel
therapi
clopidogrel
monotherapi
though
lesion
sever
mani
case
accompani
chang
attitud
food
intak
vomit
fecal
score
disclosur
disclosur
report
gastrointestin
sign
aag
occur
dog
receiv
metronidazol
peopl
combin
antibiot
therapi
increas
risk
aag
synbiot
administr
decreas
aag
occurr
object
studi
compar
aag
dog
administ
antibiot
follow
placebo
synbiot
random
washout
perform
use
healthi
research
dog
baselin
period
dog
receiv
enrofloxacin
qd
metronidazol
bid
food
week
one
hour
dose
antibiot
dog
administ
placebo
synbiot
mean
food
intak
day
hyporexia
food
intak
vomit
diarrhea
fecal
score
mean
fecal
score
per
week
compar
group
use
mix
model
repeat
measur
anova
p
consid
signific
two
dog
exclud
high
baselin
fecal
score
per
group
dog
withdrawn
treatment
period
due
sever
aag
hyporexia
vomit
diarrhea
occur
respect
dog
receiv
placebo
food
intak
differ
treatment
period
p
less
derang
food
intak
dog
receiv
synbiot
although
day
hyporexia
differ
treatment
group
less
common
period
day
vomit
p
fecal
score
p
differ
week
treatment
treatment
receiv
fecal
score
significantli
lower
period
p
enrofloxacinmetronidazol
administr
result
unexpectedli
high
incid
aag
healthi
dog
administr
synbiot
hour
antibiot
mitig
food
intak
derang
period
effect
suggest
clinic
effect
synbiot
persist
week
discontinu
decreas
aag
dog
subsequ
receiv
antibiot
alon
disclosur
disclosur
report
project
support
grant
nutramax
laboratori
veterinari
scienc
inc
lancast
sc
funder
involv
design
perform
studi
write
abstract
decis
submit
present
two
investig
jcw
jss
declar
past
receipt
honorarium
nutramax
laboratori
public
speak
educ
materi
pathogenesi
canin
inflammatori
bowel
diseas
ibd
like
involv
complex
interact
mucos
immun
system
intestin
microbiota
one
studi
compar
intestin
microbiota
dog
ibd
diarrhea
treatment
studi
report
chang
microbi
commun
structur
follow
glucocorticoid
therapi
object
studi
evalu
effect
oral
prednison
spatial
distribut
mucos
bacteria
ibd
dog
eight
dog
diagnos
ibd
cibdai
score
treat
immunosuppress
dose
glucocorticoid
oral
prednison
mgkg
po
everi
hour
day
taper
gradual
mgkg
week
typic
protocol
induct
clinic
remiss
mucos
microbiota
endoscop
intestin
biopsi
ibd
dog
control
dog
evalu
fluoresc
situ
hybrid
fish
target
rrna
gene
total
bacteria
organ
individu
bacteri
speci
shown
relev
caninehuman
ibd
epitheli
tight
junction
protein
tjp
express
studi
use
immunohistochemistri
investig
effect
drug
therapi
intestin
barrier
integr
ibd
dog
show
reduct
gi
sign
follow
week
prednison
therapi
compar
baselin
cibdai
score
p
microbiota
intestin
healthi
diseas
dog
abund
free
adher
mucu
ibd
dog
diagnosi
total
number
posit
bacteria
faecalibacterium
spp
streptococcu
spp
decreas
p
compar
healthi
dog
spatial
distribut
mucos
bacteria
significantli
differ
p
ibd
dog
follow
prednison
therapi
higher
number
total
bacteria
bifidobacterium
spp
faecalibacterium
spp
streptococcu
spp
detect
predominantli
within
adher
mucu
compar
mucos
compart
rel
bacteri
group
number
mucos
enterobacteriacea
decreas
p
ibd
dog
express
tjp
occludin
zonulin
increas
p
ibd
versu
healthi
dog
howev
occludin
increas
p
ibd
dog
follow
prednison
therapi
conclus
spatial
distribut
mucos
bacteria
differ
ibd
dog
healthi
dog
respons
glucocorticoid
administr
oral
prednison
therapi
associ
posit
clinic
outcom
chang
microbi
commun
structur
tjp
express
analysi
intestin
microbiota
use
fish
provid
valuabl
insight
abund
spatial
distribut
mucos
bacteria
interact
close
intestin
epithelium
disclosur
disclosur
report
chronic
inflammatori
enteropathi
cie
import
group
diseas
dog
innat
immun
play
key
role
cie
pathogenesi
receptor
advanc
glycat
end
product
rage
belong
innat
immun
system
receptor
recogn
endogen
molecular
structur
releas
inflamm
tissu
damag
pilot
studi
system
concentr
decoy
receptor
srage
solubl
rage
decreas
dog
cie
normal
dog
clinic
remiss
induct
therapi
howev
associ
serum
srage
diseas
sever
inflammatori
biomark
extens
studi
canin
cie
studi
aim
evalu
serum
srage
concentr
larg
group
dog
cie
serum
fecal
sampl
dog
diagnos
cie
use
studi
serum
srage
concentr
measur
elisa
compar
among
differ
group
dog
use
group
comparison
potenti
relationship
serum
srage
level
clinic
diseas
activ
ccecai
score
system
serum
fecal
inflammatori
marker
concentr
histolog
lesion
sever
grade
system
assess
use
spearman
correl
coeffici
statist
signific
set
p
serum
srage
concentr
rang
ngl
median
ngl
cie
dog
dog
serum
srage
concentr
ngl
previous
best
separ
cie
dog
healthi
control
serum
srage
level
associ
sever
clinic
sign
ccecai
score
serum
crp
serum
fecal
calprotectin
fecal
concentr
p
serum
srage
concentr
tend
invers
correl
statist
signific
associ
reach
overal
histolog
score
associ
serum
srage
level
microscop
lesion
duodenum
sever
dog
serum
srage
level
ngl
serum
srage
significantli
invers
correl
sever
lymphoplasmacyt
infiltr
gastric
antrum
duodenum
crypt
dilat
neutrophil
infiltr
duodenum
studi
confirm
major
cie
dog
decreas
serum
srage
concentr
suggest
sragerag
axi
play
role
canin
cie
srage
like
function
decoy
receptor
research
warrant
assess
gastrointestin
particularli
duoden
mucos
express
rage
dog
cie
healthi
control
disclosur
disclosur
report
dr
steiner
dr
suchodolski
director
gastrointestin
laboratori
texa
univers
crp
calprotectin
test
offer
basi
diagnosi
canin
chronic
enteropathi
ce
challeng
requir
thorough
clinic
laboratori
histolog
evalu
nevertheless
disord
relat
ce
retrospect
classifi
respons
sequenti
therapeut
trial
convinc
evid
suggest
endocannabinoid
ecb
system
express
gut
ecb
modul
major
gastrointestin
function
purpos
studi
estim
plasma
level
arachidonoylethanolamid
anandamid
aea
palmitoylethanolamid
pea
oleoylethanolamid
oea
healthi
dog
ascertain
potenti
diagnost
marker
canin
ce
dog
ce
divid
group
food
respons
fre
antibiot
respons
enteropathi
idiopath
inflammatori
bowel
diseas
ibd
protein
lose
enteropathi
ple
plasmat
aea
pea
oea
level
determin
liquid
chromatographymass
spectrometri
data
express
pmolml
median
interquartil
rang
compar
use
test
diagnost
accuraci
assess
consid
signific
healthi
dog
control
plasma
level
aea
pea
oea
respect
dog
ce
show
significantli
higher
p
pea
compar
control
statist
differ
found
aea
oeain
particular
comparison
among
control
fre
ibd
ple
group
fre
show
higher
level
pea
p
oea
p
higher
level
p
ibd
group
show
increas
p
pea
p
ple
dog
increas
concentr
p
decreas
amount
oea
p
pea
p
overal
accuraci
exclud
sensit
specif
predict
lr
sensit
specif
ibd
high
auc
addit
plasmat
oea
show
good
accuraci
auc
exclud
sensit
specif
predict
lr
sensit
specif
fre
potenti
limit
sampl
size
lack
ecb
analysi
intestin
biopsi
yet
conclud
oea
may
promis
diagnost
tool
differenti
fre
ibd
dog
chronic
gastrointestin
sign
present
disclosur
disclosur
report
commonli
accept
dog
suffer
inflammatori
bowel
diseas
ibd
enteropathi
ple
need
aggress
immunosuppress
treatment
dog
ibd
ple
hospit
treatment
follow
algorithm
assess
respons
diet
antibiot
prednisolon
first
immunosuppress
sli
ad
initi
respons
satisfactori
hypothesis
result
approach
challeng
need
sli
mani
case
file
dog
diagnos
ple
retrospect
analys
exclus
criteria
lack
initi
serum
albumin
sa
valu
lack
histopatholog
diagnosi
diagnosi
compat
ibd
intestin
lymphoma
intestin
adenocarcinoma
intussuscept
granulomat
coliti
nutrit
deficit
signific
intestin
bleed
contribut
protein
loss
signific
concurr
diseas
pln
endocrinopathi
epi
remain
dog
fn
mn
fe
mean
age
sd
initi
mean
sa
sd
lowest
record
sa
diagnosi
mean
sd
dog
concurr
hypoglobulinaemia
hypocholesterolaemia
total
ionis
hypocalcaemia
total
hypomagnesaemia
serum
cobalamin
low
dog
accord
treatment
algorithm
dog
treat
diet
alon
dog
diet
antibiot
dog
diet
antibiot
prednisolon
dog
subsequ
need
sli
case
cyclosporin
dog
receiv
anoth
sli
cyclophosphamid
mycophenol
chlorambucil
overal
time
sa
rose
median
day
rang
day
median
time
day
rang
day
dog
deceas
end
studi
differ
dog
without
sli
regard
clinicopatholog
data
kruskal
walli
test
correl
variabl
treatment
requir
time
normalis
sa
outcom
could
detect
conclus
contrari
previou
literatur
sli
need
major
dog
suggest
treatment
approach
often
use
ibd
without
ple
appropri
case
might
lower
cost
drug
substanti
addit
none
clinicopatholog
paramet
routin
assess
case
correl
prognosi
outcom
illustr
lack
use
marker
predict
clinic
cours
dog
disclosur
disclosur
report
studi
aim
determin
effect
bodi
condit
fat
depot
troglitazon
fatti
acid
secret
adiponectin
tumor
necrosi
adipos
tissu
healthi
cat
subcutan
viscer
adipos
tissu
sampl
collect
healthi
intact
femal
cat
bodi
condit
score
bc
rang
determin
concentr
adiponectin
measur
matur
adipocyt
cultur
concentr
measur
stromovascular
cell
svc
cultur
follow
treatment
control
medium
troglitazon
eicosapentaeno
acid
epa
arachidon
acid
aa
palmit
acid
svc
viscer
origin
secret
higher
concentr
correspond
cell
subcutan
origin
aa
treatment
increas
secret
subcutan
p
respect
viscer
p
respect
deriv
svc
epa
treatment
increas
secret
subcutan
deriv
svc
respect
viscer
deriv
svc
p
signific
effect
medium
adiponectin
concentr
observ
follow
troglitazon
treatment
fatti
acid
treatment
bc
signific
effect
medium
concentr
adiponectin
studi
demonstr
higher
basal
secret
viscer
compar
subcutan
adipos
tissu
stimulatori
effect
aa
secret
stimulatori
effect
epa
felin
adipos
tissu
disclosur
disclosur
report
echocardiograph
estim
left
atrial
la
size
index
aorta
la
ao
continu
cornerston
determin
cardiac
diseas
sever
dog
cat
howev
refer
limit
establish
healthi
dog
singl
point
cardiac
cycl
therefor
refer
limit
la
ao
healthi
adult
dog
variou
breed
point
cardiac
cycl
three
left
atrial
measur
obtain
echocardiograph
prior
mitral
valv
open
right
parastern
view
aortic
valv
closur
lamax
onset
atrial
systol
lap
lamin
right
parastern
short
axi
view
three
diastol
left
ventricular
lv
dimens
obtain
short
axi
view
measur
averag
la
ao
calcul
lamax
lv
measur
index
aortic
measur
previous
describ
wla
wlv
dog
consid
la
enlarg
wla
andor
wlv
within
previous
establish
refer
interv
refer
interv
calcul
nonparametr
dog
includ
analysi
upper
refer
limit
la
aomax
obtain
view
ci
short
axi
ci
long
axi
margin
greater
origin
propos
dog
la
aomax
greater
limit
dog
la
aomax
greater
long
axi
limit
upper
refer
limit
la
aomin
la
aop
ci
respect
studi
provid
robust
refer
limit
la
ao
obtain
echocardiograph
imag
margin
larger
origin
propos
disclosur
disclosur
report
left
atrial
size
la
import
prognost
indic
canin
cardiac
diseas
wide
use
unidimension
echocardiograph
method
estim
la
left
atrial
ratio
la
ao
use
short
axi
plane
level
root
aorta
howev
variabl
ratio
report
measur
may
vari
consider
even
among
highli
train
cardiologist
human
imag
modal
comput
tomographi
angiographi
mcta
use
refer
method
measur
la
mcta
limit
variabl
therefor
provid
accur
reproduc
evalu
left
atrial
morpholog
border
compar
echocardiographi
dog
hypothes
poor
correl
la
ao
calcul
echocardiographi
la
aou
mcta
la
aomcta
align
right
parastern
short
axi
view
investig
hypothesi
compar
echocardiograph
mcta
measur
la
ao
la
aou
la
aomcta
respect
dog
measur
la
ao
perform
use
hansson
method
level
agreement
modal
variabl
calcul
singl
centr
prospect
studi
approv
local
veterinari
ethic
review
committe
dog
variou
breed
undergo
anaesthetis
thorac
mcta
variou
diagnost
purpos
enrol
previou
studi
left
atrial
volum
elig
dog
underw
physic
examin
includ
blood
pressur
measur
prior
anaesthesia
cardiac
auscult
ensur
heart
murmur
present
echocardiographi
perform
immedi
follow
mcta
measur
la
ao
obtain
identifi
frame
onset
qr
complex
frame
immedi
aortic
valv
closur
respect
agreement
la
aou
la
aomcta
evalu
use
analysi
pearson
correl
coeffici
variat
cv
calcul
quantifi
variabl
correl
la
aou
la
aomcta
moder
wherea
correl
p
echocardiographi
underestim
la
ao
compar
mcta
bia
limit
agreement
variabl
la
aou
la
aomcta
adequ
cv
conclus
data
demonstr
measur
la
aou
superior
estim
la
aou
measur
ratio
underestim
compar
la
aomcta
disclosur
disclosur
report
left
atrial
size
la
aid
clinic
heart
diseas
left
atrial
ratio
short
axi
view
commonli
use
assess
la
unidirect
measur
might
repres
chang
dimens
therefor
measur
la
volum
lav
recommend
evalu
la
method
biplan
area
length
method
alm
biplan
method
disk
mod
estim
lav
assum
la
fix
shape
altern
echocardiographi
measur
lav
without
geometr
assumpt
veterinari
medicin
none
compar
volumetr
gold
standard
like
comput
tomographi
angiographi
mcta
correl
well
cardiac
magnet
reson
imag
hypothesis
estim
lav
accur
alm
mod
correl
strongli
use
mcta
gold
standard
investig
hypothesi
compar
maximum
minimum
lav
lavmax
lavmin
respect
identifi
frame
immedi
prior
mitral
valv
open
immediatli
mitral
valv
closur
respect
alm
mod
compar
mcta
dog
level
agreement
variabl
calcul
singl
centr
prospect
studi
approv
local
veterinari
ethic
review
committe
dog
variou
breed
undergo
anaesthetis
thorac
mcta
variou
diagnost
purpos
enrol
elig
dog
underw
physic
examin
includ
blood
pressur
measur
prior
anaesthesia
cardiac
auscult
ensur
heart
murmur
present
echocardiographi
immedi
follow
mcta
agreement
alm
mod
mcta
evalu
use
analysi
express
bia
limit
agreement
loa
correl
calcul
along
coeffici
variat
cv
quantifi
variabl
alm
mod
correl
mcta
lavmax
lavmin
respect
p
bias
lavmax
loa
lavmin
loa
minim
reflect
systemat
underestim
convers
mod
loa
loa
alm
loa
loa
systemat
overestim
lav
variabl
lavmax
lavmin
adequ
use
alm
mod
mcta
cv
conclus
assess
lav
simpl
accur
feasibl
method
measur
la
superior
accuraci
alm
mod
dog
without
cardiac
diseas
disclosur
disclosur
report
tomographi
post
mortem
imag
modal
provid
imag
could
use
tool
imag
cardiomyopathi
left
ventricular
mass
lvm
import
variabl
cardiomyopathi
classif
prospect
studi
aim
assess
lvm
cat
undergo
routin
necropsi
heart
excis
immers
potassium
hour
whole
heart
scan
reconstruct
isotrop
volum
allow
virtual
dissect
felin
heart
plane
mean
cohort
voxel
size
micron
lvm
determin
use
differ
method
compar
actual
lvm
alvm
alvm
determin
weigh
left
ventricl
dissect
great
vessel
atria
right
ventricl
free
wall
method
better
agreement
alvm
use
mass
determin
cat
hypertroph
cardiomyopathi
method
base
imag
heart
manual
trace
endocardi
epicardi
border
multipl
slice
base
apex
method
use
autom
softwar
calcul
ventricular
surfac
area
volum
reconstruct
whole
left
ventricl
lvm
obtain
method
multipli
total
volum
myocardi
densiti
data
report
mean
ci
alvm
cardiomyopath
heart
hcm
rcm
dcm
greater
g
ci
g
ci
g
ci
greater
method
underestim
lvm
mean
bia
g
la
g
la
greater
hcm
normal
cat
g
vs
g
regress
equat
predict
alvm
alvm
use
determin
lvm
although
underestim
alvm
approxim
studi
may
attribut
tissu
prepar
techniqu
mass
determin
calcul
factor
disclosur
disclosur
report
studi
fund
clinic
studi
fund
jch
ic
oja
fund
nation
institut
health
research
nihr
mrc
rcr
great
ormond
street
hospit
children
chariti
nihr
gosh
biomed
research
centr
pgc
fund
daniel
bravo
andreu
pulmon
stenosi
ps
common
congenit
cardiac
diseas
dog
accur
size
pulmon
annulu
routin
perform
intraop
angiographi
essenti
success
balloon
valvuloplasti
dog
valvular
ps
without
annular
hypoplasia
bulldog
subvalvular
ps
associ
aberr
coronari
arteri
ca
aberr
ca
suspect
balloon
valvuloplasti
might
contraind
comput
tomographi
angiographi
cta
complementari
way
earli
plan
intervent
treatment
aim
prospect
observ
studi
therefor
report
cta
find
prior
balloon
valvuloplasti
total
dog
australian
english
french
bulldog
diagnos
ps
age
month
weigh
kg
enrol
dog
plan
undergo
possibl
balloon
valvuloplasti
anaesthet
directli
cta
contrast
medium
inject
protocol
individu
tailor
total
inject
time
equal
sum
diagnost
scan
delay
scan
durat
first
mlkg
undilut
contrast
medium
mgiml
administ
two
third
total
inject
time
directli
follow
mlkg
dilut
contrast
medium
one
third
total
inject
time
ct
scan
trigger
manual
singl
breath
hold
contrast
bolu
reach
descend
aorta
dog
sagitt
plane
imag
optim
visual
pulmon
annulu
compar
aortic
annulu
transvers
plain
ten
dog
consid
annular
hypoplasia
aortic
annulu
pulmon
annulu
ca
could
assess
dog
dog
aberr
ca
detect
dog
singl
right
coronari
ostium
prepulmon
left
ca
bulldog
chihuahua
dog
singl
left
coronari
ostium
prepulmon
right
ca
bulldog
german
shorthair
pointer
total
dog
except
dog
aberr
ca
subsequ
underw
balloon
valvuloplasti
dog
suspect
ps
morpholog
could
confirm
fluoroscopi
conclus
cta
complementari
quick
diagnost
method
may
provid
addit
relev
inform
size
pulmon
ostium
assess
ca
anatomi
prior
balloon
valvuloplasti
also
aberr
ca
part
pathophysiolog
ps
disclosur
disclosur
report
accessori
pathway
ap
muscular
bundl
connect
atrial
ventricular
myocardium
dog
ap
mostli
conduct
mediat
atrioventricular
reciproc
tachycardia
avrt
radiofrequ
cathet
ablat
rfca
first
line
therapi
peopl
veterinari
medicin
data
suggest
safe
success
dog
object
studi
confirm
anatom
distribut
ap
electrophysiolog
characterist
larg
canin
popul
evalu
success
complic
rate
rfca
record
dog
retrospect
review
dog
present
clinic
sign
electrocardiograph
evid
ventricular
vpe
andor
avrt
physic
examin
ecg
thorac
radiographi
echocardiogram
electrophysiolog
map
perform
presenc
locat
ap
conduct
pattern
refractori
period
ap
av
node
type
induc
supraventricular
arrhythmia
cycl
length
induc
avrt
consid
presenc
ap
confirm
presenc
vpe
sinu
rhythm
atrial
pace
andor
presenc
rapid
activ
supraventricular
tachycardia
ventricular
pace
ap
local
radiofrequ
energi
deliv
convent
gener
procedur
consid
success
recurr
note
minut
total
ap
identifi
singl
multipl
case
conduct
along
ap
unidirect
retrograd
bidirect
retrograd
decrement
properti
note
case
ap
mediat
orthodrom
avrt
case
perman
junction
reciproc
tachycardia
one
case
avrt
induc
dog
rfca
attempt
success
rate
within
month
recurr
tachycardia
occur
case
follow
second
success
ablat
mortal
observ
major
complic
pacemak
implant
identifi
dog
studi
show
ap
distribut
characterist
dog
similar
previous
report
also
success
complic
rate
rfca
appear
similar
human
rfca
consid
first
line
therapi
dog
perform
high
success
rate
low
incid
complic
disclosur
disclosur
report
previou
studi
demonstr
murmur
intens
associ
stenosi
sever
dog
pulmon
aortic
stenosi
howev
anecdot
breed
provid
challeng
auscult
other
easili
auscult
cardiologist
suggest
could
affect
interpret
murmur
intens
estim
diseas
sever
dog
difficult
auscult
would
expect
sever
diseas
murmur
intens
suggest
dog
easili
auscult
would
expect
less
sever
diseas
murmur
intens
suggest
especi
end
murmur
scale
retrospect
examin
murmur
intens
dog
pulmon
aortic
stenosi
present
cardiolog
center
evalu
effect
breed
abil
predict
diseas
sever
breed
repres
individu
use
examin
breed
effect
dog
repres
breed
soft
murmur
dog
repres
breed
moder
murmur
dog
repres
breed
loud
murmur
dog
repres
breed
palpabl
murmur
found
associ
breed
diseas
sever
level
murmur
intens
power
analys
suggest
detect
least
moder
effect
one
exist
nine
dog
soft
murmur
stenos
variou
breed
usual
associ
auscult
difficulti
data
suggest
despit
perceiv
difficulti
auscult
certain
breed
issu
affect
clinician
abil
estim
diseas
sever
disclosur
disclosur
report
mitral
valv
repair
mvr
consid
treatment
option
sever
myxomat
mitral
valv
diseas
dog
signific
cardiac
revers
remodel
crr
repair
report
although
predispos
breed
progress
diseas
investig
breed
characterist
outcom
cardiac
revers
remodel
mvr
remain
unclear
hypothes
differ
breed
characterist
crr
mvr
insight
suitabl
surgic
time
obtain
consecut
medic
record
dog
underw
mvr
novemb
juli
jasmin
veterinari
cardiovascular
medic
center
review
breed
age
sex
bodi
weight
heart
failur
classif
presenc
cough
vertebr
heart
sum
vh
postop
echocardiograph
paramet
includ
left
atrial
ventricular
size
fraction
shorten
fs
sever
regurgit
number
cardiac
medic
use
obtain
postop
examin
perform
month
surgeri
dog
divid
three
king
charl
spaniel
ckcss
chihuahua
paramet
compar
amongst
group
total
dog
includ
analysi
exclus
dog
die
postop
review
dog
miss
data
dog
underw
secondari
surgeri
overal
surviv
rate
month
surgeri
multipl
comparison
analysi
ckcss
significantli
younger
higher
bodi
weight
preoper
vh
postop
normal
left
ventricular
diamet
lower
postop
fs
compar
amongst
group
although
postop
number
cardiac
medic
ckcss
tend
high
signific
differ
observ
amongst
group
although
heart
failur
classif
differ
amongst
group
ckcss
significantli
younger
dog
group
therefor
progress
mitral
regurgit
consid
occur
earlier
age
ckcss
find
consist
previou
report
stronger
postop
irrevers
cardiac
dilat
systol
dysfunct
observ
ckcss
amongst
group
similar
reduct
regurgit
could
explain
sever
myocardi
remodel
find
might
hard
detect
preoper
regurgit
result
suggest
mvr
recommend
earlier
ckcss
compar
breed
minim
lv
systol
dysfunct
dilat
surgeri
disclosur
disclosur
report
human
suffer
chronic
heart
failur
chf
iron
defici
common
comorbid
intraven
iron
therapi
significantli
improv
exercis
capac
qualiti
life
consequ
european
societi
cardiolog
guidelin
recommend
intraven
iron
therapi
symptomat
patient
chf
iron
defici
defin
serum
ferritin
ferritin
transferrin
satur
dog
unknown
iron
defici
compar
comorbid
requir
supplement
therefor
aim
studi
evalu
iron
statu
dog
variou
stage
chronic
heart
failur
multicent
prospect
studi
dog
myxomat
mitral
valv
diseas
mmvd
dilat
cardiomyopathi
dcm
chief
class
includ
compar
healthi
dog
diseas
stage
base
clinic
radiolog
echocardiograph
examin
cardiovascular
integr
control
group
base
anamnesi
clinic
examin
echocardiographi
laboratori
examin
includ
biochem
analysi
complet
blood
count
includ
iron
statu
assess
base
serum
iron
ferritin
tsat
total
iron
bind
capac
tibc
test
use
statist
analysi
increas
sever
heart
failur
serum
iron
tsat
significantli
decreas
medium
rang
tsat
healthi
control
class
specif
dog
significantli
lower
tsat
compar
healthi
control
p
dog
p
differ
observ
tibc
ferritin
decreas
serum
iron
concentr
tsat
support
hypothesi
iron
defici
may
present
dog
heart
failur
normal
ferritin
rule
iron
defici
tsat
consid
reliabl
diagnost
marker
human
suffer
chf
inflammatori
mediat
affect
ferritin
newer
paramet
consid
sensit
assess
iron
statu
human
dog
affect
degre
heart
failur
dog
conclus
studi
provid
evid
iron
defici
comorbid
dog
advanc
heart
failur
howev
difficult
assess
also
dog
affect
qualiti
life
therefor
routin
screen
iron
defici
heart
failur
dog
iron
supplement
may
recommend
time
disclosur
disclosur
report
betschart
former
employe
vifor
pharma
burckhardt
employe
vifor
pharma
studi
partial
fund
unrestrict
research
grant
vifor
pharma
moniqu
wenger
marri
toni
glau
stress
transport
veterinari
visit
impact
comprehens
evalu
limit
diagnost
test
cat
oral
anxiolyt
drug
avail
prescript
howev
disadvantag
limit
use
recent
oral
trazodon
administ
cat
prior
veterinari
visit
decreas
anxieti
greater
placebo
well
toler
trazodon
promis
drug
reduc
veterinari
care
relat
anxieti
cat
effect
echocardiograph
hemodynam
variabl
unknown
purpos
studi
evalu
effect
oral
trazodon
echocardiograph
variabl
heart
rate
blood
pressur
healthi
cat
domest
cat
year
age
recruit
cat
consid
healthi
basi
physic
examin
complet
blood
count
blood
chemistri
profil
urinalysi
total
thyroid
level
blood
pressur
measur
doppler
method
screen
transthorac
echocardiogram
simultan
electrocardiogram
cat
discharg
hospit
screen
evalu
return
separ
visit
within
one
week
physic
examin
baselin
echocardiogram
blood
pressur
measur
perform
prior
trazodon
administr
echocardiograph
variabl
assess
includ
left
ventricular
intern
diamet
systol
diastol
interventricular
left
ventricular
free
wall
thick
systol
diastol
left
atrial
size
left
auricular
function
left
ventricular
diastol
function
assess
spectral
doppler
transmitr
pulmonari
venou
flow
veloc
tissu
doppler
profil
subsequ
mg
trazodon
administ
oral
cat
minut
physic
examin
echocardiographi
blood
pressur
measur
repeat
mean
echocardiograph
hemodynam
variabl
calcul
exam
cat
variabl
code
separ
group
data
analyz
repeat
measur
anova
signific
set
p
twelv
healthi
cat
evalu
mean
time
repeat
evalu
trazodon
minut
mean
trazodon
dose
mgkg
minimum
mgkg
maximum
mgkg
trazodon
safe
administ
sed
effect
observ
cat
signific
differ
echocardiograph
variabl
trazodon
administr
mean
blood
pressur
significantli
decreas
trazodon
mmhg
mmhg
p
signific
chang
heart
rate
result
studi
suggest
trazodon
well
toler
may
aid
obtain
transthorac
echocardiogram
trazodon
significantli
lower
system
blood
pressur
without
affect
heart
rate
echocardiograph
variabl
healthi
cat
disclosur
disclosur
report
hypersomatotrop
hs
caus
revers
left
ventricular
hypertrophi
lvh
human
cat
estim
preval
hs
among
uk
diabet
cat
howev
recent
hs
also
identifi
cat
given
high
preval
felin
hypertroph
cardiomyopathi
hcm
similar
hs
increas
age
given
date
two
hcm
associ
mutat
identifi
hypothesis
hs
may
import
phenocopi
hcm
felin
popul
identifi
treatment
hs
cure
cardiomyopathi
aim
studi
establish
preval
hs
popul
uk
cat
lvh
therefor
presumpt
diagnos
hcm
sixti
six
cat
previous
diagnos
hcm
two
referr
hospit
includ
retrospect
inclus
criteria
diagnosi
hcm
cardiolog
diplom
base
left
ventricular
wall
thick
diastol
echocardiographi
hypertens
bp
mmhg
hyperthyroid
serum
caus
lvh
aortic
stenosi
exclud
cat
consid
base
normal
blood
glucos
andor
fructosamin
concentr
absenc
glycosuria
serum
concentr
measur
duplic
residu
sampl
frozen
maximum
year
use
valid
radioimmunoassay
hs
defin
mean
concentr
posit
predict
valu
hs
concentr
rang
four
cat
serum
concentr
consist
hs
two
cat
present
lvh
dilat
atria
spontan
contrast
pleural
effus
complex
arrhythmia
cat
evid
reduc
motion
thin
one
segment
left
ventricular
free
wall
third
cat
present
lvh
enlarg
left
atrium
spontan
contrast
pulmonari
oedema
final
cat
murmur
lvh
normal
size
left
atrium
preval
hs
establish
cohort
uk
cat
initi
diagnos
hcm
estim
million
cat
uk
hcm
result
suggest
fact
suffer
cardiomyopathi
due
excess
growth
hormon
signific
clinic
impact
sinc
medic
surgic
manag
hs
lead
resolut
lvh
restor
health
disclosur
disclosur
report
studi
support
ecvim
clinic
studi
fund
grant
hypertroph
cardiomyopathi
hcm
common
cardiomyopathi
cat
human
heterogen
genet
heart
diseas
character
left
ventricular
hypertrophi
absenc
anoth
diseas
could
explain
wall
thicken
consid
famili
diseas
autosom
domin
transmiss
human
caus
mutat
mainli
sarcomer
gene
associ
hcm
cat
two
causal
mutat
affect
myosin
protein
bind
c
gene
describ
main
coon
ragdol
aim
studi
identifi
possibl
caus
mutat
could
associ
hcm
differ
breed
next
gener
sequenc
b
explor
relationship
genotyp
phenotyp
nine
cat
hcm
year
male
shorthair
control
year
male
shorthair
coon
forest
includ
hcm
defin
lvh
caus
lvh
exclud
dna
extract
peripher
blood
sampl
routin
haematolog
sampl
custom
panel
gene
associ
hcm
de
flnc
gla
pln
ttr
sequenc
next
gener
sequenc
variant
classifi
pathogen
present
control
popul
conserv
domain
affect
cat
new
causal
variant
previous
describ
flnc
present
control
identifi
variant
missens
de
flnc
affect
splice
c
flnc
c
affect
cat
carrier
least
one
variant
carrier
one
variant
signal
clinic
find
diagnosi
asymptomat
congest
heart
failur
cardiac
murmur
echocardiograph
phenotyp
affect
cat
basilar
septal
bulg
obstruct
hcm
heterogen
hypertrophi
fals
tendon
independ
variant
detect
conclus
studi
describ
heterogen
novel
variant
new
gene
associ
hcm
cat
main
gen
involv
affect
cat
correl
breed
variant
describ
disclosur
disclosur
report
financi
support
spanish
cardiolog
societi
sociedad
de
cardiomyopathi
cm
common
heart
diseas
cat
diseas
present
variabl
predict
diseas
cours
difficult
particularli
due
lack
knowledg
underli
pathogenesi
congest
heart
failur
chf
arteri
thromboembol
common
late
consequ
associ
felin
cardiomyopathi
studi
use
proteom
techniqu
aim
identifi
novel
serum
biomark
felin
primari
cardiomyopathi
congest
heart
failur
find
may
aid
understand
diseas
pathogenesi
assist
diseas
diagnosi
prognosi
manag
studi
popul
compris
cat
diagnos
chf
cm
cat
asymptomat
cm
healthi
cat
serum
proteom
profil
differ
cat
group
obtain
use
liquid
mass
spectrometri
techniqu
wilcoxon
test
bonferroni
correct
use
statist
analysi
differenti
protein
express
total
serum
protein
found
differenti
express
chf
healthi
control
cat
seventeen
protein
upregul
chf
mainli
involv
lipoprotein
metabol
inflamm
coagul
pathway
apolipoprotein
acut
phase
protein
ceruloplasmin
prothrombin
platelet
factor
serin
proteas
inhibitor
significantli
higher
chf
cat
compar
healthi
control
p
ten
protein
downregul
chf
tetranectin
protein
regul
fibrinolysi
proteolysi
significantli
lower
chf
cat
compar
healthi
control
p
human
medicin
biomark
recent
associ
coronari
arteri
diseas
subsequ
bioinformat
analysi
gene
ontolog
predict
best
candid
biomark
primarili
associ
extracellular
matrix
organ
metabol
result
suggest
system
inflamm
coagul
abnorm
extracellular
matrix
remodel
occur
felin
cardiomyopathi
particularli
chf
identif
biomark
provid
new
insight
felin
cardiomyopathi
research
disclosur
disclosur
report
studi
fund
veterinari
fund
small
grant
scheme
univers
glasgow
uk
proteom
work
bioinformat
analysi
conduct
laboratori
proteom
era
chair
project
vetmedzg
univers
zagreb
faculti
veterinari
medicin
caus
plasma
variat
cardiac
biomark
natriuret
peptid
fulli
evalu
healthi
cat
object
investig
effect
breed
signal
variabl
concentr
healthi
cat
use
quantit
elisa
compar
point
care
test
poc
healthi
cat
birman
norwegian
forest
domest
shorthair
cat
includ
absenc
heart
diseas
signific
diseas
ensur
physic
examin
measur
systol
blood
pressur
echocardiographi
hematolog
blood
biochemistri
concentr
analys
elisa
refer
laboratori
poc
test
analys
visual
inspect
autom
method
consid
posit
pmoll
data
analys
use
test
regress
analys
concentr
cat
pmoll
iqr
signific
effect
bodi
weight
age
concentr
median
concentr
twice
high
male
pmoll
iqr
compar
femal
cat
pmoll
iqr
p
three
cat
pmoll
elisa
two
posit
use
visual
inspect
poc
test
one
cat
titr
pmoll
lower
titr
posit
poc
test
automat
analys
sex
breed
bodi
weight
age
influenc
concentr
healthi
cat
visual
inspect
poc
test
show
higher
agreement
elisa
compar
use
autom
analysi
disclosur
disclosur
report
cardiac
biomark
like
natriuret
peptid
ntprobnp
use
diagnost
tool
clinic
assess
heart
diseas
dog
paramet
influenc
extracardiac
factor
human
differ
type
physic
activ
durat
train
physic
condit
shown
affect
ntprobnp
aim
studi
compar
ntprobnp
level
two
dog
breed
differ
physic
activ
train
prospect
cohort
studi
seven
untrain
german
shepherd
dog
gsd
enter
militari
servic
seven
scandinavian
hound
sh
use
competit
race
examin
latter
underw
three
week
train
paus
enter
studi
dog
echocardiograph
examin
baselin
ntprobnp
measur
baselin
exercis
gsd
exercis
minut
protect
train
activ
ie
high
intens
interv
train
sh
run
continu
minut
biker
attach
two
month
schedul
train
ntprobnp
level
reassess
condit
nonparametr
test
use
statist
analysi
data
report
median
rang
baselin
normal
lv
diamet
diastol
lvddn
versu
p
ntprobnp
versu
pmoll
p
higher
sh
gsh
group
show
similar
signific
increas
ntprobnp
physic
exercis
sh
p
gsh
p
increas
group
differ
two
month
train
ntprobnp
level
rest
similar
compar
baselin
still
higher
sh
gsd
p
exercis
higher
sh
significantli
p
wherea
lower
significantli
gsd
p
exercis
induc
chang
group
signific
p
conclus
ntprobnp
level
higher
sh
compar
gsd
train
exercis
affect
ntprobnp
dog
depend
intens
train
type
exercis
echocardiograph
sh
larger
heart
gsd
higher
ntprobnp
reflect
higher
wall
tension
eccentr
hypertrophi
athlet
dog
may
sign
inappropri
compensatori
hypertrophi
altern
factor
like
excit
excit
associ
manipul
upcom
exercis
may
caus
mild
transient
increas
wall
tension
disclosur
disclosur
report
studi
partial
financ
idexx
diavet
ag
switzerland
studi
partial
financ
swiss
arm
forc
diagnost
investig
heart
murmur
dyspnea
dog
requir
diagnost
imag
procedur
thorac
radiograph
examin
tre
cardiac
ultrasound
cu
procedur
repres
high
cumul
cost
asymptomat
dog
mitral
valv
diseas
dog
cardiac
enlarg
requir
cu
sometim
treatment
wherea
dog
without
cardiac
enlarg
dog
dyspnea
cardiac
origin
benefit
cu
wherea
dog
dyspnea
tre
inform
use
cardiac
biomark
patient
stratif
propos
option
acceler
diagnost
process
limit
diagnost
procedur
cost
cardiac
troponin
ctni
biomark
myocardi
damag
use
diagnost
prognost
purpos
main
limit
ctni
veterinari
cardiolog
lack
bedsid
analyz
high
lower
detect
limit
analyz
aim
studi
evalu
interest
highli
sensit
ctni
bedsid
analyz
categor
patient
prospect
recruit
popul
dog
mitral
insuffici
andor
dyspnea
popul
dog
cu
tre
perform
prospect
recruit
observ
studi
measur
ctni
perform
use
highli
sensit
bedsid
analyz
minivida
biomerieux
addit
popul
dog
without
symptom
normal
cu
prospect
includ
control
group
dog
present
mitral
insuffici
mi
correspond
acvim
classif
n
c
period
dog
dyspnea
recruit
correspond
mostli
inflammatoryinfecti
diseas
pulmonari
neoplasia
cardiac
troponin
valu
significantli
lower
dog
acvim
mi
control
group
compar
acvim
symptomat
dog
mi
p
dog
dyspnea
present
significantli
lower
ctni
compar
symptomat
dog
mi
p
dog
asymptomat
mi
valu
ngl
identifi
dog
cardiac
enlarg
sensibl
specif
respect
dog
dyspnea
valu
ngl
identifi
dog
cardiac
diseas
sensibl
specif
respect
studi
suggest
ctni
could
propos
screen
test
dog
mi
dyspnea
particularli
exclus
test
highli
sensit
bedsid
analyz
use
disclosur
disclosur
report
analyz
furnitur
ctni
measur
provid
biomerieux
left
atrial
la
function
import
determin
left
ventricular
lv
fill
play
key
role
maintain
optim
cardiac
perform
la
size
neg
associ
prognosi
dog
mitral
valv
diseas
mvd
pimobendan
phosphodiesteras
iii
inhibitor
posit
inotrop
vasodil
effect
report
decreas
la
pressur
overal
heart
size
dog
mvd
base
epic
studi
dog
stage
mvd
shown
benefit
administr
pimobendan
studi
sought
investig
effect
pimobendan
la
function
dog
stage
mvd
twenti
dog
stage
mvd
retrospect
includ
left
atrial
function
assess
prior
month
start
pimobendan
dog
echocardiograph
right
parastern
long
axi
chamber
view
optimis
la
record
assess
la
diamet
volum
simpson
method
phase
la
function
cycl
one
frame
open
mitral
valv
immedi
p
wave
ecg
one
frame
closur
mitral
valv
use
variabl
assess
complet
passiv
activ
la
function
previous
describ
puls
wave
tissu
doppler
imag
left
ventricular
longitudin
myocardi
veloc
associ
atrial
contract
level
interventricular
septum
lv
free
wall
also
use
indic
la
function
variabl
assess
tdi
septum
tdi
free
la
wall
significantli
increas
pimobendan
administr
p
p
respect
wherea
la
complet
ef
significantli
decreas
treatment
none
variabl
assess
la
function
la
size
significantli
differ
pre
post
pimobendan
administr
veloc
mitral
valv
regurgit
significantli
increas
p
post
institut
pimobendan
treatment
estim
la
function
tdi
dog
mvd
improv
treatment
pimobendan
suggest
effect
drug
la
function
although
difficult
separ
effect
improv
left
ventricl
function
decreas
la
complet
ef
may
reflect
reduc
mitral
regurgit
fraction
despit
reduct
lv
size
document
decreas
la
size
short
studi
disclosur
disclosur
report
use
pimobendan
may
consid
manag
acut
pulmonari
edema
refractori
congest
heart
failur
chf
howev
risk
continu
pimobendan
overdos
yet
well
investig
dog
stabl
chf
observ
studi
evalu
potenti
effect
overdos
pimobendan
cardiotox
chronic
therapi
myxomat
mitral
valv
diseas
mmvd
refer
dog
mmvd
eight
dog
treat
regimen
overdos
pimobendan
case
patient
daili
day
among
patient
treat
recommend
dosag
pimobendan
daili
day
control
select
base
match
variabl
signalmentmed
histori
physic
examin
find
sever
chf
initi
analysi
homogen
case
control
group
comprehens
blood
test
profil
cbc
serum
biochemistri
sdma
electrocardiograph
radiograph
echocardiograph
data
collect
serum
cardiac
troponin
ctni
qtc
interv
valu
formula
van
de
water
compar
group
addit
two
endpoint
analyz
assess
relationship
dosag
durat
administr
pimobendan
case
patient
patient
group
overdos
use
pimobendan
show
significantli
higher
level
ctni
ngml
longer
qtc
interv
msec
control
ctni
ngml
qtc
msec
p
regress
analysi
adjust
durat
pimobendan
administr
case
patient
reveal
ctni
level
qtc
interv
highli
correl
dosag
p
adjust
respect
significantli
elev
ctni
level
prolong
qtc
interv
strong
correl
dosag
durat
improp
overdos
pimobendan
case
patient
group
indic
myocardi
damag
indic
cardiac
fatigu
disclosur
disclosur
report
fibrosi
extracellular
matrix
remodel
caus
role
pathophysiolog
cardiac
diseas
differ
origin
cellular
level
fibrot
process
prior
clinic
manifest
symptom
current
biomark
abl
detect
fibrosi
remodel
peripher
blood
sampl
despit
advantag
cardiac
diagnost
monitor
therapi
previous
use
microarray
method
identifi
gene
express
profil
repres
fibrot
inflammatori
process
peripher
whole
blood
cardiomyopathi
model
dog
success
select
fibrosi
relat
gene
express
level
blood
sampl
clearli
differenti
clinic
case
healthi
dog
microrna
key
regul
gene
express
highli
stabl
molecul
thu
ideal
biomark
candid
base
previou
result
use
sampl
aim
investig
cardiac
whole
blood
express
level
select
microrna
directli
involv
cardiac
fibrosi
heart
failur
select
panel
consist
differ
microrna
key
regulatori
role
fibrosi
remodel
impair
contractil
locat
gene
code
differ
isoform
myosin
heavi
chain
relat
impair
contractil
key
role
regul
fibrosi
import
regul
cardiac
hypertrophi
whole
blood
left
ventricular
sampl
tachypac
dog
healthi
control
whole
blood
sampl
surplu
materi
canin
clinic
patient
differ
sever
etiolog
heart
failur
caus
cardiomyopathi
collect
rna
stabil
solut
rna
integr
confirm
capillari
electrophoresi
rin
express
select
microrna
measur
normal
snrna
ddct
method
data
evalu
made
descript
statist
mann
whitney
model
whilst
heart
blood
sampl
heart
sampl
blood
sampl
whilst
show
opposit
tendenc
blood
sampl
clinic
patient
express
pattern
could
observ
result
signific
p
except
base
select
microrna
clinic
case
could
clearli
differenti
healthi
dog
use
microrna
express
profil
blood
sampl
moreov
clinic
asymptomat
case
tachycardiomyopathi
could
identifi
result
suggest
peripher
blood
may
potenti
indic
earli
fibrosi
dog
disclosur
disclosur
report
malign
arrhythmia
poorli
defin
caus
sudden
cardiac
death
scd
dog
although
scd
describ
dilat
cardiomyopathi
arrhythmogen
cardiomyopathi
hypertroph
cardiomyopathi
myocard
well
inherit
congenit
arrhythm
disord
german
shepherd
rhodesian
ridgeback
springer
spaniel
respect
contextu
holter
monitor
data
avail
veterinari
literatur
aim
case
seri
describ
termin
arrhythmia
record
holter
monitor
dog
moment
experienc
scd
databas
holter
referr
center
retrospect
search
dog
experienc
scd
holter
monitor
januari
juli
fifteen
dog
differ
breed
includ
studi
holter
analysi
includ
domin
rhythm
record
preval
arrhythmia
period
preced
death
termin
arrhythmia
caus
scd
clinic
data
echocardiograph
diagnosi
also
consid
mean
age
year
median
year
mean
bodi
weight
kg
median
dog
caus
scd
consist
ventricular
prematur
complex
vpc
acceler
idioventricular
rhythm
aivr
ventricular
tachycardia
vt
degener
ventricular
fibril
vf
two
dog
complet
atrioventricular
block
avb
preced
vf
dog
asystol
caus
cardiac
arrest
final
dog
low
penetr
atrial
fibril
follow
ventricular
arrest
electromechan
dissoci
ten
dog
affect
varieti
structur
heart
diseas
dilat
cardiomyopathi
arrhythmogen
right
ventricular
cardiomyopathi
myxomat
mitral
valv
diseas
myocard
echocardiograph
examin
detect
structur
abnorm
remain
dog
sotalol
antiarrhythm
therapi
time
record
dog
agreement
data
previous
report
human
present
studi
show
vpc
aivr
vt
complet
avb
degener
vf
asystol
common
caus
scd
dog
addit
fact
studi
popul
underli
structur
heart
diseas
suggest
presenc
anatom
substrat
associ
modul
autonom
nervou
system
trigger
increas
risk
sustain
ventricular
arrhythmia
degener
vf
author
knowledg
first
report
detail
caus
arrhythmia
scd
extend
seri
dog
disclosur
disclosur
report
time
rpt
ecg
paramet
repres
time
qr
complex
onset
q
r
wave
apex
peak
r
r
wave
present
repres
time
excit
spread
endocardi
epicardi
surfac
human
medicin
right
ventricular
rpt
measur
lead
upper
normal
limit
ms
left
ventricular
rpt
measur
lead
upper
normal
limit
ms
aim
studi
defin
durat
rpt
normal
dog
differ
thorac
conform
record
thirti
healthi
dog
retrospect
review
dog
underw
physic
examin
thorac
radiographi
electrocardiogram
use
lead
system
describ
santilli
echocardiogram
dog
alloc
three
group
accord
thorac
index
thorax
diamet
x
thorax
diamet
brachymorph
dolichomorph
mesomorph
ecg
three
measur
perform
normal
test
use
evalu
differ
morphotyp
lead
nonparametr
analysi
varianc
perform
kruska
walli
test
data
normal
distribut
brachymorph
morphotyp
rpt
median
durat
rang
ms
ms
ms
ms
ms
ms
mesomorph
morphotyp
rpt
median
durat
rang
ms
ms
ms
ms
ms
ms
dolichomorph
morphotyp
rpt
median
durat
rang
ms
ms
ms
ms
ms
ms
precordi
lead
rpt
statist
differ
morphotyp
p
lead
rpt
statist
shorter
p
compar
morphotyp
result
demonstr
differ
rpt
durat
differ
morphotyp
differ
precordi
lead
explain
fact
read
right
ventricl
read
left
ventricl
data
use
refer
normal
rpt
dog
studi
need
evalu
use
rpt
cardiac
diseas
disclosur
disclosur
report
success
treatment
hyperthyroid
human
requir
effect
uptak
thyroid
gland
deliv
radioabl
effect
sought
analyz
effect
uptak
subsequ
outcom
hyperthyroid
cat
prospect
includ
cat
refer
anim
endocrin
clinic
treatment
follow
quantit
thyroid
scintigraphi
calcul
thyroid
volum
percent
thyroid
uptak
pertechnet
cat
administ
radioiodin
dose
base
algorithm
consid
serum
concentr
percent
uptak
pertechnet
calcul
thyroid
volum
hour
later
determin
percent
thyroid
uptak
measur
radioact
count
directli
skin
surfac
thyroid
tumor
correct
background
thigh
count
thyroid
radioact
count
per
minut
compar
activ
measur
standard
contain
evalu
effect
uptak
final
outcom
cat
divid
quartil
base
thyroid
uptak
valu
recheck
examin
perform
month
median
month
four
outcom
determin
base
serum
concentr
tsh
concentr
euthyroid
normal
normal
tsh
overt
hypothyroid
low
high
tsh
subclin
hypothyroid
high
tsh
persist
hyperthyroid
high
suppress
tsh
hyperthyroid
cat
thyroid
uptak
valu
rang
median
cat
lowest
uptak
quartil
twice
incid
persist
hyperthyroid
cat
quartil
vs
p
contrast
cat
highest
uptak
quartil
higher
incid
iatrogen
hypothyroid
vs
p
cat
uptak
quartil
treat
similar
dose
radioiodin
median
dose
mci
conclus
thyroid
uptak
valu
affect
success
outcom
hyperthyroid
cat
treat
radioiodin
cat
low
thyroid
uptak
valu
chanc
treatment
failur
wherea
cat
highest
uptak
predispos
develop
iatrogen
hypothyroid
disclosur
disclosur
report
diagnosi
felin
primari
hyperaldosteron
pha
remain
challeng
especi
case
concurr
azotaemia
human
medicin
losartan
suppress
test
use
safe
accur
test
hyperaldosteron
diagnosi
aim
studi
determin
oral
telmisartan
administr
suppress
aldosteron
secret
healthi
cat
cat
pha
follow
ethic
committe
approv
healthi
cat
receiv
telmisartan
administr
per
os
serum
aldosteron
concentr
pac
potassium
concentr
systol
blood
pressur
measur
oral
administr
telmisartan
six
cat
pha
also
test
percentag
rel
variat
pac
calcul
result
express
median
rang
variabl
compar
wilcoxon
test
test
baselin
pac
significantli
higher
p
pha
cat
pmoll
rang
healthi
cat
pmoll
healthi
cat
telmisartan
administr
result
signific
decreas
pac
compar
p
rel
variat
respect
signific
decreas
pac
identifi
pha
cat
systol
blood
pressur
significantli
decreas
signific
variat
potassium
concentr
identifi
result
suggest
oral
telmisartan
administr
suppress
aldosteron
concentr
healthi
cat
pha
cat
studi
need
evalu
suppress
test
cat
secondari
hyperaldosteron
disclosur
disclosur
report
financi
support
resid
program
v
fabr
royal
canin
pheochromocytoma
rel
common
dog
carri
guard
prognosi
outcom
adrenalectomi
import
predictor
surviv
although
younger
age
absenc
vascular
invas
may
also
associ
favour
prognosi
current
histolog
criteria
predict
malign
behaviour
dog
similar
human
latter
character
tumor
refin
pheochromocytoma
adren
gland
scale
score
pass
includ
microscop
featur
immunohistochem
analysi
aim
studi
investig
pass
sever
immunohistochem
marker
use
human
medicin
dog
pheochromocytoma
underw
adrenalectomi
patholog
record
dog
pheochromocytoma
review
identifi
treat
surgic
tumor
collect
section
stain
haematoxylin
eosin
appli
pass
chromogranin
prolifer
marker
tumor
suppressor
gene
product
product
vascular
endotheli
growth
factor
vegf
protein
result
pass
immunohistochemistri
compar
surgic
outcom
age
frequenc
capsular
vascular
invas
caus
tumor
addit
pass
assess
relat
immunohistochem
find
dog
pheochromocytoma
includ
pass
differ
base
surgic
outcom
age
vascular
capsular
invas
immunohistochemistri
also
differ
variabl
tumor
show
express
cell
lower
pass
lower
express
vs
tumor
posit
higher
pass
neg
vs
associ
immunohistochem
marker
identifi
conclus
dog
pheochromocytoma
surviv
age
vascular
capsular
invas
link
result
pass
select
immunohistochem
marker
lower
pass
dog
elev
express
suggest
pheochromocytoma
high
rate
morpholog
chang
higher
pass
tumor
may
indic
pheochromocytoma
develop
morpholog
chang
acquir
express
overal
use
pass
present
immunohistochem
marker
limit
clinic
valu
dog
pheochromocytoma
disclosur
disclosur
report
thyroid
autoantibodi
use
marker
autoimmun
thyroid
human
dog
human
presenc
associ
per
year
progress
subclin
thyroid
hypothyroid
sever
survey
studi
shown
increas
preval
posit
thyroglobulin
autoantibodi
tgaa
dog
thyroid
test
result
indic
primari
hypothyroid
versu
euthyroid
dog
implic
posit
tgaa
result
otherwis
normal
concentr
thyroid
hormon
tsh
subclin
thyroid
subsequ
progress
hypothyroid
dog
less
clear
object
studi
defin
outcom
thyroid
statu
dog
subclin
thyroid
interv
purebr
dog
subclin
thyroid
specif
tgaa
bind
normal
concentr
tsh
identifi
orthoped
foundat
anim
ofa
thyroid
registri
databas
owner
invit
arrang
submiss
serum
sampl
veterinarian
along
inclus
medic
histori
form
includ
subsequ
treatment
serum
sampl
obtain
dog
subclin
thyroid
met
inclus
criteria
studi
popul
includ
femal
male
dog
breed
english
setter
boxer
rhodesian
ridgeback
dalmatian
frequent
averag
age
studi
complet
year
sd
year
rang
mean
time
year
initi
test
sd
year
rang
time
retest
dog
progress
hypothyroid
treat
thyroxin
percent
maintain
posit
equivoc
tgaa
result
remain
euthyroid
dog
tgaa
result
normal
dog
remain
euthyroid
initi
thyroxin
supplement
follow
result
usual
alway
base
suggest
clinic
sign
decreas
thyroid
hormon
subsequ
test
result
suggest
major
dog
elev
thyroglobulin
autoantibodi
either
exhibit
persist
autoimmun
thyroid
continu
risk
hypothyroid
progress
hypothyroid
disclosur
disclosur
report
work
support
grant
orthoped
foundat
anim
canin
health
foundat
chf
bkp
krr
haptoglobin
increas
untreat
case
canin
hyperadrenocortic
hac
reduc
follow
trilostan
treatment
hypothesis
haptoglobin
measur
may
assist
therapeut
monitor
hac
first
part
studi
compar
haptoglobin
concentr
two
sampl
obtain
hour
apart
known
cortisol
concentr
second
part
compar
haptoglobin
cortisol
concentr
monitor
hac
studi
cortisol
measur
use
chemiluminesc
assay
siemen
immulit
part
normal
therapeut
monitor
protocol
institut
haptoglobin
measur
use
enzymat
method
adapt
abx
pentra
pair
residu
store
sampl
obtain
hour
apart
administr
trilostan
coeffici
variat
haptoglobin
measur
low
rang
even
clinic
signific
differ
cortisol
concentr
rang
pair
sampl
greater
case
hac
receiv
consist
dose
trilostan
two
week
blood
sampl
clinic
score
use
owner
questionnair
case
categoris
unwel
control
unwel
dog
exclud
analysi
regardless
control
hac
haptoglobin
measur
part
normal
monitor
use
commerci
avail
immunoturbidimetr
assay
avacta
laboratori
wetherbi
sampl
obtain
dog
one
dog
note
particularli
anxiou
sampl
point
cortisol
concentr
exclud
subsequ
analysi
mann
whitney
test
demonstr
signific
differ
cortisol
haptoglobin
dog
classifi
control
uncontrol
signific
correl
haptoglobin
concentr
owner
score
p
wherea
cortisol
concentr
significantli
correl
score
roc
analysi
suggest
previous
establish
refer
rang
haptoglobin
could
serv
use
target
rang
therapeut
monitor
similar
analysi
cortisol
consist
current
therapeut
rang
haptoglobin
investig
ancillari
method
monitor
trilostan
therapi
refer
rang
haptoglobin
extend
nearli
detect
method
cortisol
still
need
one
advantag
haptoglobin
appear
unaffect
chang
cortisol
disclosur
disclosur
report
dechra
pharmaceut
directli
support
studi
also
provid
indirect
support
first
author
glasgow
univers
provid
haptoglobin
cortisol
measur
commerci
basi
siemen
anipoc
woodley
boehring
mani
compani
support
work
one
institut
directli
involv
fund
project
exenatid
analogu
proven
benefici
diabet
peopl
clinic
experi
cat
limit
effect
function
bcf
diabet
cat
unclear
diabet
cat
diagnos
month
recruit
randomis
clinic
trial
assess
effect
monthli
exenatid
extend
releas
eer
bydureon
astrazeneca
inject
glycaem
control
bcf
cat
exclud
screen
identifi
relev
condit
cat
treat
protamin
zinc
insulin
prozinc
boehring
ingelheim
fed
diet
randomis
eer
sq
q
day
placebo
salin
diabet
control
bcf
assess
use
fructosamin
insulin
peak
respons
ipr
total
insulin
secret
ti
calcul
glucagon
stimul
test
insulin
baselin
min
post
iv
glucagon
respect
enrol
bodi
condit
score
bc
fructosamin
compar
group
linear
mix
effect
model
assess
effect
treatment
group
trial
timepoint
enrol
bc
glycaem
control
bcf
signific
p
eleven
cat
receiv
eer
receiv
placebo
group
similar
enrol
apart
higher
bc
mean
vs
signific
effect
treatment
group
enrol
bc
iprti
fructosamin
ipr
ti
significantli
increas
fructosamin
decreas
success
trial
timepoint
eer
affect
bcf
glycaem
control
howev
inadvert
randomis
lean
cat
eer
mean
use
eer
obes
cat
could
assess
disclosur
disclosur
report
katarina
hazuchova
phd
clinic
trial
part
fund
boehring
ingelheim
diabet
remiss
clinic
studi
took
place
receiv
support
purina
diagnos
canin
hyperadrenocortic
hac
complic
dynam
adren
function
test
low
specif
andor
less
perfect
sensit
anecdot
hac
incorrectli
diagnos
exclud
key
clinic
laboratori
featur
overlook
disregard
aim
studi
construct
educ
visual
aid
assist
clinician
balanc
appropri
weight
clinic
laboratori
observ
support
judgement
diagnosi
hac
first
aid
version
compris
grid
arrang
column
includ
list
relev
observ
one
column
record
observ
known
support
diagnosi
hac
eg
thin
skin
polyuria
polydipsia
posit
adren
function
test
would
support
nai
eg
signific
weight
loss
absenc
stress
leukogram
refer
interv
alkalin
phosphatas
activ
neg
suppress
test
lddst
row
divid
observ
convey
mild
moder
strong
support
respect
diagnosi
second
aid
version
includ
numer
weight
specif
observ
allow
calcul
score
indic
whether
hac
like
unlik
equivoc
initi
deriv
small
develop
dataset
perform
summari
score
assess
use
anonymis
valid
dataset
suspect
hac
case
ucd
veterinari
hospit
classifi
hac
nai
diagnosi
hac
support
document
improv
treatment
examin
independ
expert
review
medic
record
diagnosi
nai
support
altern
diagnosi
spontan
resolut
clinic
sign
absenc
progress
onset
addit
clinic
sign
period
year
sensit
score
rang
depend
whether
equivoc
result
treat
posit
neg
hac
specif
area
rocc
indic
adjust
could
improv
diagnost
sensit
four
fals
neg
score
complex
case
hac
diagnos
face
neg
lddst
advers
affect
sensit
conclus
educ
visual
judgement
aid
develop
support
hac
diagnosi
first
opinion
practic
modifi
gener
numer
score
tool
good
specif
less
good
sensit
like
reflect
author
concern
rather
futur
improv
valu
weight
could
improv
diagnost
accuraci
hac
diagnost
judgement
primari
care
practic
disclosur
disclosur
report
studi
support
dechra
one
author
employ
dechra
associ
studi
diabet
mellitu
dm
domest
shorthair
cat
identifi
singl
nucleotid
polymorph
snp
end
chromosom
gene
encod
enzym
involv
insulin
signal
locat
close
snp
select
candid
diabet
suscept
gene
haplotyp
identifi
within
put
promot
associ
studi
residu
blood
sampl
use
pcr
report
assay
use
investig
potenti
impact
snp
gene
express
dna
sequenc
carri
two
variant
promot
haplotyp
variant
haplotyp
variant
haplotyp
amplifi
pcr
clone
separ
vector
contain
firefli
luciferas
fluc
prlcmv
vector
contain
renilla
luciferas
rluc
use
control
vector
cho
cell
enabl
normalis
fluc
activ
posit
neg
promoterless
control
includ
differ
normalis
luminesc
compar
recombin
plasmid
fluc
rluc
mean
se
variant
variant
promot
haplotyp
influenc
gene
express
cho
cell
compar
variant
preval
cat
might
due
lack
function
impact
polymorph
result
experiment
system
use
experi
requir
assess
function
consequ
promot
genet
variabl
cell
express
insulin
receptor
disclosur
disclosur
report
katarina
hazuchova
phd
well
particular
project
within
phd
fund
boehring
ingelheim
studi
assess
outcom
predictor
dog
thyroid
tumor
undergo
thyroidectomi
median
surviv
rang
day
larger
tumor
local
invas
excis
thyroid
lobe
neg
affect
outcom
wherea
adjuv
chemotherapi
improv
surviv
metastasi
associ
poor
outcom
aim
present
studi
calcul
surviv
identifi
prognost
factor
larg
seri
dog
thyroid
tumor
treat
thyroidectomi
medic
record
dog
thyroid
tumor
underw
thyroidectomi
review
dog
follow
variabl
collect
admiss
determin
influenc
overal
surviv
defin
time
surgeri
death
age
gender
breed
tsh
concentr
unilater
bilater
lobectomi
type
surgeri
thyroidectomi
combin
muscular
jugular
vein
resect
institut
surgeri
perform
tumor
major
diamet
histolog
type
presenc
thrombosi
metastasi
administr
adjuv
chemotherapi
median
surviv
calcul
outcom
predictor
studi
use
cox
proport
hazard
model
final
model
built
stepwis
delet
guid
akaik
inform
criterion
dog
includ
median
age
year
rang
male
femal
crossbre
except
one
adenoma
tumor
carcinoma
median
surviv
day
rang
live
day
day
univari
analysi
older
age
presenc
thrombosi
presenc
metastasi
associ
shorter
surviv
multivari
model
metastasi
significantli
associ
surviv
dog
metastasi
hazard
ratio
hr
confid
interv
ci
compar
without
metastasi
identifi
case
live
day
dog
thrombosi
tend
increas
risk
death
hr
dog
thyroid
tumor
undergo
thyroidectomi
long
life
expect
metastasi
may
carri
poor
outcom
although
extend
surviv
observ
differ
previou
studi
size
tumor
local
invas
bilater
thyroidectomi
affect
outcom
disclosur
disclosur
report
analysi
erythrocyt
membran
lipidom
repres
power
diagnost
tool
assess
quantiti
qualiti
fatti
acid
membran
fatti
acid
remodel
associ
differ
physiolog
patholog
condit
sever
studi
shown
modif
fatti
acid
also
phospholipid
content
cell
membran
human
diabet
patient
anim
model
diabet
howev
systemat
studi
membran
fatti
acid
dog
evalu
membran
homeostasi
yet
establish
aim
present
studi
evalu
erythrocyt
membran
lipidom
profil
healthi
dog
hd
chang
membran
lipidom
dog
newli
diagnos
diabet
mellitu
dm
erythrocyt
membran
isol
blood
sampl
dog
cluster
satur
sfa
palmit
stearic
mufa
palmitol
oleic
vaccen
polyunsatur
pufa
linol
arachidon
epa
dha
fatti
acid
determin
relev
lipid
paramet
sfamufa
sfapufa
pufa
balanc
unsatur
peroxid
index
calcul
healthi
dog
age
month
median
male
neuter
femal
steril
dm
dog
age
month
median
male
femal
steril
among
fatti
acid
median
show
wider
variabl
hd
minimum
signific
differ
observ
regard
age
epa
level
intact
femal
signific
lower
p
compar
steril
subject
intact
male
palmit
arachidon
acid
show
less
sd
variabl
respect
medium
bodi
size
dog
kg
compar
small
kg
larg
kg
dog
respect
comparison
hd
dm
dog
show
increas
concentr
mufa
p
specif
palmitol
p
oleic
p
acid
show
higher
level
differ
observ
vaccen
acid
epa
concentr
dm
dog
higher
p
compar
hd
potenti
studi
limit
sampl
size
lack
data
geriatr
healthi
dog
present
data
suggest
variabl
express
erythrocyt
membran
healthi
dog
probabl
due
individu
dietari
variat
furthermor
preliminari
result
suggest
involv
pathway
canin
diabet
mellitu
involv
higher
transform
acceler
desaturas
enzymat
activ
disclosur
disclosur
report
hypophys
well
describ
group
diseas
human
case
report
dog
resembl
lymphocyt
hypophys
human
although
common
assumpt
lymphocyt
normal
present
pituitari
gland
dog
pauciti
studi
confirm
lymphocyt
found
pituitari
gland
human
hors
without
clinic
suspicion
hypophys
aim
present
studi
investig
occurr
lymphocyt
pituitari
gland
dog
without
clinic
suspicion
pituitari
diseas
pituitari
tissu
collect
routin
necropsi
dog
without
clinic
suspicion
pituitari
diseas
studi
perform
depart
biomed
scienc
veterinari
public
health
swedish
univers
agricultur
scienc
uppsala
pituitari
tissu
fix
formalin
pituitari
gland
sagitt
incis
embed
paraffin
section
stain
haematoxylin
eosin
h
e
sequenti
section
subject
immunohistochemistri
use
primari
antibodi
specif
marker
marker
indirect
procedur
use
diaminobenzidin
chromogen
use
detect
bind
number
cell
per
area
unit
cpa
determin
par
tuberali
par
distali
par
intermedia
infundibulum
lobu
nervosu
two
dog
exclud
presenc
metastat
malign
lymphoma
pituitari
adenoma
pituitari
gland
remain
dog
occasion
scatter
cell
found
immunohistochemistri
cpa
differ
significantli
part
pituitari
gland
p
highest
cpa
found
par
tuberali
median
cpa
rang
lowest
cpa
found
infundibulum
median
cpa
rang
dog
detect
cell
pituitari
gland
present
small
number
median
total
cell
number
cellssect
rang
cellssect
studi
show
common
find
cell
pituitari
gland
necropsi
dog
clinic
suspicion
pituitari
diseas
region
differ
cell
densiti
highest
densiti
par
tuberali
contrast
cell
gener
absent
present
small
number
disclosur
disclosur
report
employeesalari
djurakuten
aktiebolag
swedish
univers
agricultur
scienc
anicura
anim
hospit
nation
veterinari
institut
grantsresearch
fakulteten
stipendiesamfond
agria
och
skk
research
foundat
speak
consult
veta
bolaget
swedish
medic
product
agenc
anicura
anim
hospit
anicura
falu
anim
hospit
anim
hospit
gothenburg
evidensia
anim
hospit
helsingborg
haning
anim
clinic
royal
canin
swedish
breeder
club
gift
hospit
travel
support
travel
grant
veterinari
product
glycem
variabl
repres
swing
blood
glucos
level
includ
episod
hyperglycemia
throughout
day
differ
day
glucos
fluctuat
shown
one
risk
factor
complic
human
far
knowledg
glycem
variabl
cat
scarc
continu
glucos
monitor
system
cgm
introduc
veterinari
medicin
year
ago
use
tool
evalu
glycem
situat
measur
interstiti
glucos
continu
day
night
seven
day
aim
studi
evalu
continu
glucos
monitor
profil
healthi
diabet
cat
compar
glycem
variabl
day
night
six
healthi
eleven
diabet
cat
includ
cgm
medtron
place
dorsolater
neck
area
calibr
glucos
measur
obtain
everi
hour
valid
portabl
blood
glucos
meter
abbott
glucos
measur
achiev
everi
five
minut
day
night
defin
time
approx
hour
insulin
inject
andor
feed
mean
glucos
concentr
standard
deviat
sd
coeffici
variat
cv
determin
assess
glycem
variabl
addit
minimum
maximum
glucos
concentr
identifi
data
analys
nonparametr
test
p
valu
report
median
rang
healthi
cat
mean
glucos
concentr
significantli
lower
day
mmoll
night
mmoll
also
sd
day
significantli
lower
night
signific
differ
day
night
regard
minimum
maximum
glucos
concentr
cv
diabet
cat
minimum
glucos
concentr
day
mmoll
significantli
lower
night
mmoll
signific
differ
day
night
regard
mean
maximum
glucos
concentr
sd
cv
healthi
cat
lower
mean
minimum
maximum
glucos
concentr
sd
day
night
diabet
cat
cv
differ
conclus
healthi
cat
show
higher
glycem
variabl
night
absolut
differ
small
glycem
variabl
diabet
cat
differ
day
night
glycem
variabl
diabet
cat
higher
compar
healthi
cat
irrespect
time
day
disclosur
disclosur
report
aim
studi
valid
human
assay
serum
fructosamin
sf
glycat
hemoglobin
dog
comparison
abil
sf
reflect
glycem
control
dog
diabet
mellitu
sf
nitrotetrazol
blue
method
fructosamin
sentinel
diagnost
blood
analyz
autom
chemistri
analyz
au
linear
precis
accuraci
determin
refer
interv
sf
establish
healthi
dog
use
percentil
method
perform
sf
assess
glycem
control
evalu
correl
two
variabl
clinic
score
studi
diabet
dog
treat
insulin
clinic
score
use
classifi
diabet
dog
good
ggc
moder
mgc
poor
pgc
glycem
control
set
basi
stabil
bodi
weight
presenc
poliuriapolydipsia
median
glucos
blood
glucos
curv
bgc
blood
glucos
nadir
overal
evalu
bgc
averag
interassay
coeffici
variat
cv
respect
averag
interassay
cv
sf
respect
excel
accuraci
obtain
assay
r
refer
interv
sf
diabet
dog
sf
significantli
correl
also
correl
clinic
score
respect
roc
curv
analysi
sf
distinguish
ggc
mgcpgc
dog
show
auc
respect
valu
sf
discrimin
dog
ggc
mgcpgc
dog
respect
roc
curv
analysi
sf
distinguish
pgc
ggcmgc
dog
show
auc
respect
valu
sf
respect
discrimin
dog
pgc
ggcmgc
dog
use
clinic
score
refer
method
sf
identifi
correctli
glycem
control
ggcmgcpgc
case
respect
conclus
sf
similar
perform
classifi
glicem
control
neither
two
paramet
use
sole
indic
glycem
control
must
alway
evalu
associ
histori
physic
find
bgc
result
disclosur
disclosur
report
spontan
primari
hypothyroid
appear
extrem
rare
clinic
disord
adult
cat
report
case
last
year
given
pauciti
data
regard
felin
hypothyroid
sought
describ
histori
clinic
featur
includ
presenc
absenc
goiter
diagnost
test
treatment
outcom
adult
cat
spontan
primari
hypothyroid
prospect
case
seri
includ
adult
cat
spontan
hypothyroid
refer
evalu
period
march
septemb
follow
march
case
collect
data
cat
signal
clinic
sign
result
physic
examin
routin
laboratori
thyroid
hormon
test
thyroid
imag
thyroid
scintigraphi
ultrasound
subsequ
treat
cat
levothyroxin
evalu
respons
treatment
cat
rang
year
breed
predilect
cat
male
cat
initi
test
sign
hypothyroid
chang
lethargi
obes
other
test
routin
thyroid
monitor
palpabl
thyroid
nodul
four
azotem
serum
creatinin
mgdl
six
cat
low
serum
thyroxin
free
concentr
wherea
cat
high
hormon
tsh
concentr
cat
thyroid
scintigraphi
reveal
bilater
goiter
intens
radionuclid
uptak
imag
show
visibl
thyroid
tissu
levothyroxin
treatment
serum
concentr
increas
tsh
fell
high
serum
creatinin
normal
azotem
cat
repeat
imag
show
reduct
goiter
size
conclus
primari
hypothyroid
develop
adult
cat
higher
preval
previous
assum
cat
appear
develop
goitrou
form
hypothyroid
associ
thyroid
hyperplasia
wherea
thyroid
atrophi
appear
less
common
levothyroxin
replac
clinic
laboratori
abnorm
eg
azotem
improv
resolv
although
condit
rare
suspect
document
case
repres
tip
iceberg
cat
affect
syndrom
mild
clinic
sign
display
cat
lack
awar
condit
first
opinion
clinician
heighten
awar
adult
hypothyroid
develop
cat
togeth
increas
screen
disord
ultim
determin
condit
inde
rare
common
current
thought
disclosur
disclosur
report
sensit
serum
creatinin
scr
detect
earli
chronic
kidney
diseas
poor
perform
even
wors
hyperthyroid
due
poor
muscl
mass
hyperfiltr
serum
symmetr
dimethylarginin
ssdma
sensit
renal
biomark
dog
cat
recent
studi
show
rel
low
ssdma
sensit
reveal
mask
azotemia
hyperthyroid
cat
object
studi
provid
ssdma
glomerular
filtrat
rate
gfr
hyperthyroid
cat
treat
radioiodin
ten
hyperthyroid
cat
prospect
includ
scr
ssdma
idexx
sdmatm
test
gfr
plasma
exogen
creatinin
clearanc
measur
month
within
month
mean
month
radioiodin
treatment
nine
cat
finish
studi
cat
die
unrel
caus
serum
creatinin
significantli
increas
p
increas
p
cat
remain
scr
studi
signific
decreas
gfr
seen
p
serum
sdma
significantli
differ
time
serum
sdma
increas
treatment
cat
cat
normal
gfr
time
ssdma
normalis
treatment
cat
normal
gfr
normal
ssdma
gfr
borderlin
low
mlminkg
increas
ssdma
cat
gfr
low
mlminkg
normal
ssdma
also
cat
gfr
borderlin
low
cat
increas
ssdma
gfr
low
cat
increas
ssdma
interestingli
cat
borderlin
low
low
gfr
normal
ssdma
hypothyroid
remain
cat
euthyroid
borderlin
low
low
abnorm
gfr
seen
cat
month
treatment
hyperthyroid
cat
subsequ
serum
sdma
correctli
identifi
half
patient
abnorm
gfr
remain
cat
abnorm
gfr
normal
ssdma
hypothyroid
might
contribut
gfr
declin
small
popul
cat
ssdma
identifi
cat
low
gfr
prior
treatment
better
biomark
scr
identifi
cat
lower
gfr
treatment
disclosur
disclosur
report
studi
support
idexx
laboratori
inc
human
dog
baselin
differ
lung
microbiota
lm
associ
import
clinic
featur
chronic
lung
diseas
cld
grow
evid
alter
lm
contribut
diseas
pathogenesi
common
use
antibiot
drug
throughout
manag
cld
like
repres
major
confound
factor
studi
lm
howev
effect
antibiot
treatment
lm
healthi
individu
specif
investig
yet
aim
present
studi
assess
short
effect
oral
treatment
larg
spectrum
antimicrobi
drug
lm
healthi
dog
six
healthi
experiment
beagl
dog
includ
amoxycillinclavulan
acid
ac
administ
dose
mgkg
twice
daili
day
dog
bronchoalveolar
lavag
fluid
balf
collect
differ
timepoint
administr
ac
immedi
well
day
interrupt
ac
balf
total
differenti
cell
count
obtain
metagenet
analys
perform
hypervari
region
rdna
total
bacteri
dna
extract
sequenc
miseq
illumina
sequenc
taxonom
assign
microbiota
commun
analysi
done
mothur
otu
cluster
distanc
statist
comparison
event
microbiota
commun
balf
cell
count
made
use
friedman
test
bonferroni
correct
statist
differ
bacteri
popul
rel
abund
timepoint
assess
use
mix
linear
model
fdr
correct
multipl
comparison
administr
ac
induc
signific
chang
balf
cellular
count
effect
rich
even
alpha
divers
bacteroidet
proteobacteria
abund
increas
mean
respect
p
decreas
p
firmicut
abund
decreas
p
increas
p
actinobacteria
abund
increas
compar
compar
respect
p
fail
show
signific
differ
timepoint
level
genera
speci
conclus
healthi
dog
oral
administr
commonli
use
larg
spectrum
antimicrobi
drug
induc
signific
chang
microbi
popul
abund
phyla
level
chang
normal
within
week
discontinu
drug
disclosur
disclosur
report
human
medicin
administr
inhal
drug
chronic
respiratori
diseas
use
long
time
proven
efficaci
low
system
side
effect
veterinari
medicin
treatment
modal
gain
popular
last
year
although
still
littl
inform
distribut
effect
drug
lower
airway
dog
cat
aim
studi
compar
pulmonari
deposit
nebul
radiopharmaceut
agent
three
differ
inhal
devic
healthi
dog
order
detect
possibl
differ
drug
deposit
ten
healthi
beagl
includ
prospect
studi
dog
inhal
dose
nebul
acid
follow
devic
tightli
fit
mask
children
mask
origin
correspond
nose
mask
wash
period
treatment
least
week
inhal
bowl
fill
gbq
inhal
time
five
minut
immedi
afterward
dog
scan
planar
scintigraphi
right
later
left
later
sternal
recumb
deposit
head
region
upper
airway
mouth
lung
stomach
well
distribut
record
quantifi
manual
isocontour
region
interest
roi
analysi
deposit
calcul
percentag
deliv
dose
roi
compar
median
percentag
uptak
lung
use
mask
mask
nose
mask
rang
rang
rang
respect
combin
median
uptak
head
region
stomach
rang
rang
rang
respect
although
mask
group
highest
median
uptak
lung
differ
statist
signific
inhal
procedur
well
toler
devic
studi
suggest
inhal
nasal
inhal
devic
provid
similar
deposit
nebul
lung
spacer
intend
use
small
children
adapt
mask
perform
equal
expens
chamber
specif
design
dog
disclosur
disclosur
report
intralumin
stent
use
treat
tracheal
collaps
estc
dog
refractori
medic
treatment
studi
object
evalu
new
techniqu
estim
size
intralumin
use
tracheal
stent
report
surviv
complic
dog
present
dyspnoea
due
estc
confirm
endoscopi
treat
intralumin
stent
fluoroscop
guidanc
includ
retrospect
studi
stent
size
select
base
later
radiograph
perform
gener
anaesthesia
spontan
breath
stent
chosen
ideal
mm
larger
laryng
diamet
cover
trachea
cm
caudal
cricoid
cm
cranial
carina
dog
clinic
sign
radiograph
endoscopi
possibl
prefer
week
outcom
assess
via
owner
questionnair
dog
median
age
rang
year
includ
dog
surviv
discharg
lost
median
surviv
time
day
rang
dog
initi
show
partial
complet
resolut
clinic
sign
control
radiograph
reveal
stent
fractur
dog
none
stent
migrat
stent
length
significantli
shorter
compar
endoscopi
reveal
tracheobronch
granul
tissu
format
owner
satisfi
clinic
improv
pet
qualiti
life
present
estim
techniqu
straightforward
method
achiev
satisfi
result
good
outcom
overal
client
satisfact
disclosur
disclosur
report
use
pattern
abnorm
respir
local
respiratori
diseas
origin
dog
cat
aim
studi
identifi
associ
respiratori
clinic
sign
diseas
local
dog
cat
dog
cat
abnorm
breath
pattern
present
fregi
univers
missouri
univers
pennsylvania
veterinari
hospit
recruit
period
anim
includ
case
investig
allow
respiratori
diseas
local
definit
diagnosi
thorac
radiograph
minim
bloodwork
mandatori
inclus
associ
respiratori
sign
diseas
local
evalu
via
logist
regress
sensit
specif
likelihood
ratio
calcul
eighteen
dog
cat
includ
decreas
nasal
airflow
accur
local
diseas
nasal
caviti
although
stertor
specif
pharyng
diseas
also
associ
nasal
diseas
speci
well
laryng
diseas
dog
although
stridor
specif
laryng
diseas
also
associ
nasal
tracheal
diseas
inspiratori
effort
associ
diseas
goos
honk
wheez
specif
less
sensit
tracheal
sensit
tracheal
diseas
expiratori
effort
expiratori
snap
cough
specif
bronchial
local
especi
cat
crackl
increas
respiratori
rate
refer
pulmonari
diseas
speci
combin
attenu
lungcardiac
sound
paradox
breath
specif
pleural
diseas
pattern
abnorm
respir
local
origin
respiratori
diseas
use
tailor
subsequ
diagnost
evalu
disclosur
disclosur
report
treatment
canin
idiopath
rhiniti
may
frustrat
underli
caus
identifi
treatment
respons
often
limit
aim
retrospect
observ
studi
look
tomodensitometr
ct
rhinoscop
histopatholog
paramet
would
associ
treatment
respons
risk
relaps
canin
idiopath
rhiniti
dog
final
diagnosi
idiopath
rhiniti
appropri
diagnost
includ
ct
mri
andor
rhinoscopi
histopatholog
screen
period
inform
regard
treatment
respons
relaps
gather
owner
local
veterinarian
associ
treatment
respons
risk
relaps
screen
across
ct
rhinoscop
histopatholog
find
via
logist
regress
calcul
predict
probabl
spearman
rank
correl
fifti
dog
includ
studi
dog
treat
corticosteroid
dog
antimicrobi
dog
satisfactori
overal
treatment
respons
failur
partial
remiss
complet
remiss
irregular
nasopharyng
mucos
surfac
rhinoscopi
presenc
mucou
exud
histopatholog
associ
wors
overal
treatment
respons
respect
dog
relaps
treatment
discontinu
high
neg
correl
treatment
respons
risk
relaps
spearman
p
furthermor
risk
relaps
significantli
associ
intens
exud
histopatholog
relaps
common
among
dog
idiopath
rhiniti
may
anticip
treatment
respons
incomplet
exud
observ
histolog
nasal
biopsi
disclosur
disclosur
report
human
be
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
acut
pancreat
ap
repres
import
complic
high
mortal
rate
knowledg
clinic
veterinari
studi
topic
aim
present
studi
evalu
pulmonari
complic
canin
ap
associ
outcom
ap
diagnosi
made
compat
clinic
sign
laboratori
paramet
abnorm
snap
cpl
test
posit
abdomin
ultrasound
within
hour
admiss
thorac
radiographi
perform
patient
use
digit
radiolog
equip
subgrad
base
pulmonari
pattern
normal
interstiti
alveolar
admiss
arteri
blood
sampl
obtain
dorsal
pedal
arteri
room
air
analyz
abl
seri
radiomet
denmark
aliard
diagnos
use
current
veterinari
consensu
acut
onset
hour
respiratori
distress
rd
tachypnea
labour
breath
rest
known
risk
factor
evid
pulmonari
capillari
leak
without
cardiac
diseas
evid
ineffici
ga
exchang
dog
divid
group
accord
outcom
day
admiss
survivor
normal
distribut
assess
use
test
welch
use
compar
p
gradient
outcom
meanwhil
ph
compar
outcom
use
exact
test
use
compar
presenc
radiograph
abnorm
rd
aliard
outcom
odd
ratio
calcul
dog
owner
consent
admit
veterinari
teach
hospit
prospect
enrol
ten
dog
die
studi
period
two
dog
euthan
due
poor
prognosi
progress
diseas
ten
dog
show
rd
associ
poor
outcom
ci
nineteen
dog
show
radiograph
alter
alveolar
pattern
interstiti
pattern
associ
death
show
lower
level
survivor
p
gradient
ph
similar
group
ali
diagnos
seven
dog
dog
ard
presenc
ali
associ
poor
outcom
dog
ap
pulmonari
complic
seem
frequent
associ
risk
death
moreov
aliard
may
sever
pulmonari
complic
affect
prognosi
well
human
medicin
disclosur
disclosur
report
immun
mediat
haemolyt
anaemia
imha
associ
high
risk
thromboembol
dog
imha
hypercoagul
measur
thromboelastographi
teg
platelet
map
pm
use
assess
platelet
function
human
patient
treat
aspirin
clopidogrel
aim
studi
compar
efficaci
aspirin
versu
clopidogrel
inhibit
platelet
activ
dog
primari
imha
pimha
b
determin
teg
andor
pm
reliabl
monitor
treatment
respons
prospect
doubl
blind
studi
includ
dog
pimha
random
receiv
aspirin
load
dose
po
sid
n
clopidogrel
load
dose
mgkg
mgkg
po
sid
addit
standard
therapi
teg
haematocrit
hct
platelet
count
plt
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
fibrinogen
concentr
antithrombin
activ
measur
day
commenc
treatment
pm
perform
day
defin
inhibit
thromboxan
activ
stimul
arachidon
acid
aa
aspirin
group
inhibit
activ
clopidogrel
group
day
statist
analysi
test
use
determin
normal
variabl
meet
assumpt
loge
transform
restrict
maximum
likelihood
model
run
measur
fix
effect
treatment
day
interact
random
effect
patient
signific
set
p
signific
differ
identifi
two
group
time
point
includ
higher
teg
g
clot
strength
clopidogrel
group
lower
pm
maaa
pm
gaa
g
gener
aspirin
group
respect
mean
platelet
platelet
significantli
differ
group
overal
mean
inhibit
aspirin
clopidogrel
aspirin
clopidogrel
day
four
dog
aspirin
group
dog
clopidogrel
group
overal
signific
differ
efficaci
aspirin
clopidogrel
teg
reliabl
monitor
treatment
respons
dog
pimha
pm
reliabl
detect
monitor
respons
treatment
help
adjust
treatment
individu
dog
disclosur
disclosur
report
conflict
interest
author
declar
potenti
conflict
interest
regard
research
authorship
andor
public
articl
fund
author
receiv
research
grant
canin
research
foundat
holroyd
street
seaford
vic
australia
clopidogrel
commonli
administ
dog
receiv
glucocorticoid
hemolyt
anemia
impact
sustain
therapi
platelet
reactiv
current
unknown
aim
studi
compar
platelet
reactiv
among
dog
receiv
sustain
clopidogrel
prednison
combin
therapi
trial
perform
use
healthi
dog
random
treatment
group
placebo
prednison
mgkgd
clopidogrel
mgkgd
combin
prednisoneclopidogrel
therapi
po
day
complet
blood
count
manual
platelet
count
closur
time
collagenadp
area
curv
auc
aggregometri
adptest
determin
baselin
day
day
platelet
reactiv
categor
control
closur
time
increas
compar
baselin
auc
control
base
auc
subcategor
adequ
excess
control
closur
time
auc
platelet
reactiv
control
degre
control
compar
among
group
use
mix
model
repeat
measur
anova
gener
estim
equat
proport
odd
model
fisher
exact
test
appropri
p
consid
signific
dog
normal
hematocrit
platelet
count
timepoint
signific
p
group
week
group
week
interact
present
closur
time
auc
due
signific
differ
clopidogrel
prednisoneclopidogrel
group
compar
placebo
prednison
group
base
closur
time
day
significantli
dog
adequ
control
clopidogrel
prednisoneclopidogrel
group
versu
placebo
prednison
group
day
dog
clopidogrel
prednisoneclopidogrel
group
character
control
base
aggregometri
versu
dog
placebo
prednison
group
dog
receiv
prednisoneclopidogrel
time
like
time
day
day
dog
receiv
clopidogrel
monotherapi
day
day
base
human
monitor
standard
clopidogrel
therapeut
efficaci
decreas
sustain
administr
dog
prednison
increas
antiplatelet
effect
clopidogrel
therapi
increas
risk
overcontrol
dosag
current
use
manag
hemolyt
anemia
platelet
reactiv
monitor
sustain
clopidogrel
therapi
avoid
undertreat
disclosur
disclosur
report
establish
caus
pyrexia
dog
prove
challeng
previous
studi
analys
diagnos
dog
age
present
reproduc
pyrexia
diseas
identifi
commonli
respons
dog
follow
infecti
neoplast
miscellan
disord
human
medicin
pyrexia
children
analys
separ
reveal
increas
tendenc
diagnosi
infecti
collagen
disord
compar
adult
aim
studi
describ
diagnos
juvenil
dog
present
pyrexia
singl
referr
centr
clinic
record
dog
age
month
present
pyrexia
reproduc
hospitalis
retrospect
review
signal
histori
includ
previou
treatment
diagnosi
record
diagnos
categoris
inflammatori
infecti
congenit
neoplast
miscellan
one
hundr
forti
case
identifi
breed
commonli
record
beagl
border
colli
labrador
retriev
median
age
present
month
rang
month
prior
present
dog
receiv
combin
antibiot
steroid
seventeen
dog
receiv
medic
present
diagnosi
reach
case
case
pyrexia
resolv
hospitalis
without
treatment
four
dog
prednisolon
commenc
base
high
suspicion
diseas
remain
dog
die
investig
complet
dog
secur
diagnosi
inflammatori
diseas
identifi
case
infecti
diseas
case
congenit
disord
dog
neoplasia
one
dog
inflammatori
diseas
group
steroid
respons
srma
diagnos
dog
total
diagnos
case
polyarthr
impa
identifi
dog
metaphys
osteopathi
diagnos
eight
dog
dog
concurr
inflammatori
dermatopathi
infecti
diseas
diagnos
patient
includ
abscess
aspir
pneumonia
pyothorax
haemorrhag
gastroenter
congenit
disord
trap
neutrophil
syndrom
metaphys
osteomyel
congenit
hypocobalaminaemia
opportunist
infect
four
dog
border
colli
one
dog
diagnos
polyostot
lymphoma
studi
identifi
inflammatori
diseas
particular
srma
impa
metaphys
osteopathi
commonli
diagnos
popul
pyrex
juvenil
dog
consid
dog
respond
antibiot
congenit
disord
consid
border
colli
disclosur
disclosur
report
vicki
black
intern
medicin
resid
sponsor
boehring
ingelheim
fiona
whitworth
disclosur
sophi
adamanto
speaker
fee
bsava
isfm
evecc
ivecc
vet
bayer
consult
pet
blood
bank
vet
bayer
grant
pet
plan
petsav
bsava
langford
vet
acvecc
human
dog
alik
risk
mortal
increas
age
increas
uniform
individu
age
risk
mortal
human
risk
mortal
advers
outcom
elderli
peopl
increasingli
assess
mean
frailti
index
fi
index
calcul
consid
checklist
multidimension
health
deficit
eg
symptom
sign
laboratori
abnorm
potenti
accumul
age
individu
calcul
fi
actual
number
deficit
individu
count
divid
total
number
deficit
includ
checklist
human
fi
show
moder
accuraci
predict
near
term
less
month
mortal
specif
fi
develop
also
mice
develop
fi
comput
consid
deficit
divid
two
part
first
question
focus
gener
health
statu
report
owner
wherea
second
question
report
result
clinic
evalu
subject
along
find
diagnost
laboratori
test
perform
routin
clinic
evalu
dog
present
facil
januari
august
includ
inclus
criteria
includ
complet
clinic
evalu
subject
recent
less
month
blood
analysi
fatal
exclud
studi
mortal
assess
six
month
fi
administ
dog
belong
sever
differ
breed
match
inclus
criteria
mean
age
year
develop
fi
high
diagnost
accuraci
predict
near
term
mortal
six
month
area
curv
confid
interv
ci
use
valu
sensit
ci
specif
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
moder
r
ci
signific
p
correl
frailti
index
age
use
fi
could
provid
new
interest
inform
regard
age
process
dog
disclosur
disclosur
report
chronic
kidney
diseas
ckd
common
slowli
progress
irrevers
disord
domest
cat
felin
ckd
character
histolog
tubulointerstiti
inflamm
fibrosi
howev
molecular
pathway
associ
progress
thoroughli
character
group
recent
describ
model
felin
ckd
util
unilater
vivo
ischemia
induc
renal
chang
mimick
natur
occur
diseas
object
studi
character
renal
transcriptom
ischem
model
felin
ckd
use
rna
sequenc
hypothes
tissu
cat
experiment
ckd
would
display
increas
genet
express
molecular
pathway
associ
inflamm
fibrosi
cat
undergon
unilater
renal
ischemia
tissu
contralater
ie
kidney
would
show
differenti
genet
express
compar
tissu
control
cat
studi
includ
bilater
renal
tissu
sampl
bank
cat
underw
temporari
unilater
renal
ischemia
six
month
prior
tissu
collect
n
healthi
cat
control
group
n
ckd
model
cat
tissu
ischem
kidney
ik
group
contralater
kidney
nik
group
evalu
illumina
short
read
sequenc
technolog
use
produc
transcriptom
sequenc
renal
tissu
read
map
refer
felin
genom
differenti
express
analysi
conduct
edger
fals
discoveri
rate
fdr
gene
ontolog
analysi
perform
use
panther
classif
system
fisher
exact
test
fdr
multipl
test
correct
test
control
group
ik
group
exhibit
upregul
downregul
gene
nik
group
display
upregul
downregul
gene
compar
nik
group
upregul
gene
downregul
gene
ik
group
gene
associ
gene
ontolog
categori
collagen
bind
eg
transform
growth
factor
matrix
metalloproteinas
mmp
metalloendopeptidas
activ
eg
chemokin
activ
migrat
posit
regul
macrophag
chemotaxi
overrepres
ik
group
vs
control
gene
associ
extracellular
matrix
eg
tissu
inhibitor
metalloproteinas
connect
tissu
growth
factor
upregul
ik
nik
tissu
result
studi
suggest
six
month
renal
ischemia
upregul
inflammatori
pathway
persist
addit
unilater
ischem
injuri
differenti
alter
gene
express
kidney
disclosur
disclosur
report
bianca
lourenco
recipi
scholarship
boehring
ingelheim
resid
scholar
program
variou
consequ
canin
hyperadrenocortic
renal
function
describ
urinari
marker
glomerular
tubular
dysfunct
urin
ratio
upc
glomerular
filtrat
rate
gfr
known
increas
dog
hyperadrenocortic
symmetr
dimethylarginin
sdma
may
detect
earli
kidney
dysfunct
dog
hyperadrenocortic
aim
studi
compar
renal
function
time
diagnosi
among
dog
hyperadrenocortic
pdh
elderli
healthi
dog
control
dog
low
dose
dexamethason
suppress
test
neg
use
commerci
avail
test
follow
ethic
committe
approv
dog
prospect
enrol
dog
pdh
control
dog
healthi
dog
dog
urinari
tract
infect
receiv
drug
potenti
affect
kidney
function
exclud
dog
underw
physic
examin
blood
pressur
measur
routin
urinalysi
upc
urinari
protein
sodium
dodecyl
gel
electrophoresi
well
serum
urea
creatinin
scr
sdma
measur
comparison
made
group
use
test
quantit
variabl
fisher
test
distribut
categor
variabl
preval
proteinuria
magnitud
upc
significantli
higher
pdh
dog
healthi
dog
significantli
differ
control
dog
seven
dog
pdh
control
dog
healthi
dog
scr
concentr
lower
pdh
dog
healthi
dog
control
dog
differ
sdma
valu
detect
group
proteinur
non
proteinur
dog
surea
differ
group
serum
sdma
normal
healthi
dog
scr
normal
dog
pdh
among
seven
dog
pdh
proteinuria
moder
mmhg
sever
hypertens
mmhg
found
dog
respect
abnorm
pattern
found
glomerular
mix
pattern
pdh
dog
glomerular
mix
pattern
control
dog
healthi
dog
although
pdh
dog
like
proteinuria
renal
dysfunct
evid
base
sdma
level
proteinuria
partial
glomerular
origin
proteinur
dog
evalu
result
need
confirm
larger
cohort
longitudin
studi
requir
identifi
sdma
increas
treatment
pdh
quantit
qualit
follow
proteinuria
especi
proteinur
dog
disclosur
disclosur
report
coyn
r
murphi
employe
idexx
laboratori
inc
measur
biochem
paramet
perform
idexx
laboratori
free
charg
resid
program
present
author
mm
sponsor
royal
canin
gfr
measur
consid
gold
standard
assess
renal
function
given
direct
proportion
function
renal
mass
although
wide
use
research
set
littl
publish
clinic
util
aim
studi
describ
clinic
util
gfr
measur
dog
royal
veterinari
colleg
offer
gfr
servic
sinc
use
sampl
iohexol
clearanc
addit
serum
sampl
submiss
clinic
data
pertain
patient
request
part
laboratori
submiss
facilit
gfr
interpret
gfr
result
record
review
submit
practic
contact
order
obtain
outcom
data
descript
analysi
provid
preliminari
assess
clinic
util
gfr
measur
canin
gfr
assess
perform
common
reason
submiss
screen
chronic
kidney
diseas
ckd
cutan
renal
glomerular
vasculopathi
carboplatin
dose
adjust
clinic
laboratori
find
prompt
gfr
measur
includ
polyuriapolydipsia
urinari
incontin
proteinuria
isosthenuria
data
avail
final
diagnosi
dog
gfr
confirm
ckd
dog
psychogen
polydipsia
dog
aliv
dog
diedwer
euthanis
death
attribut
ckd
three
dog
develop
azotaem
ckd
period
median
time
onset
day
studi
suggest
gfr
measur
use
distinguish
dog
kidney
diseas
dog
psychogen
polydipsia
disclosur
disclosur
report
ludov
pelligand
affili
deltadot
concept
develop
partnership
share
companyrvc
invest
result
employ
postdoctor
research
year
develop
gfr
servic
increas
preval
antimicrobi
resist
report
urinari
tract
infect
dog
particularli
receiv
antimicrobi
previou
day
high
rate
multidrug
resist
mdr
observ
urinari
isol
human
chronic
kidney
diseas
ckd
dog
ckd
frequenc
resist
among
urinari
isol
unknown
aim
studi
describ
antimicrobi
suscept
pattern
urinari
tract
isol
found
dog
ckd
aerob
bacteri
isol
growth
suscept
data
collect
retrospect
urin
cultur
dog
ckd
signific
bacteriuria
seen
two
veterinari
teach
hospit
januari
june
signific
bacteriuria
defin
find
growth
least
cfuml
urin
collect
cystocentesi
treatment
antimicrobi
within
one
month
preced
sampl
exclus
criteria
mdr
defin
resist
one
agent
least
three
separ
antimicrobi
categori
wild
type
bacteria
would
normal
suscept
wherea
possibl
resist
xdr
defin
resist
except
fewer
antimicrobi
categori
test
dog
posit
urin
cultur
ckd
recruit
repres
total
isol
common
isol
escherichia
coli
isol
coagulas
neg
staphylococci
isol
among
isol
suscept
test
antimicrobi
mdr
possibl
xdr
resist
test
antimicrobi
escherichia
coli
suscept
test
antimicrobi
case
mdr
case
possibl
xdr
case
none
resist
drug
test
escherichia
coli
percent
suscept
fluoroquinolon
cephalosporin
aminoglycosid
tetracyclin
penicillin
inhibitor
penicillin
spectrum
cephalosporin
polymyxin
result
present
studi
suggest
mdr
frequent
dog
ckd
bacteriuria
even
recent
antimicrobi
treatment
administ
find
suggest
urin
cultur
suscept
test
indic
dog
ckd
high
rate
resist
penicillin
spectrum
cephalosporin
found
convers
low
frequenc
resist
could
consid
treatment
disclosur
disclosur
report
klebsiella
pneumonia
major
nosocomi
pathogen
second
common
enterobactereacea
caus
uti
human
companion
anim
ca
may
becom
infect
k
pneumonia
clonal
lineag
howev
littl
known
role
reservoir
studi
aim
evalu
k
pneumonia
faecal
colon
healthi
ca
household
member
compar
clonal
related
clinic
strain
human
companion
anim
uti
faecal
sampl
dog
cat
belong
household
total
human
collect
steril
contain
inform
consent
sampl
plate
onto
macconkey
agar
plate
mck
without
cefotaxim
meropenem
supplement
neg
sampl
enrich
prior
plate
posit
k
pneumonia
coloni
isol
per
posit
plate
clonal
related
faecal
k
pneumonia
isol
compar
xbai
restrict
pfge
clinic
k
pneumonia
uti
ca
human
uti
human
uti
diceupgma
toler
use
k
pneumonia
colon
detect
dog
human
cefotaxim
meropenem
supplement
mck
plate
neg
k
pneumonia
overal
dog
human
colon
singl
strain
two
household
k
pneumonia
colon
human
dog
simultan
pfge
analysi
reveal
one
household
two
dog
share
similar
k
pneumonia
one
human
fourteen
uniqu
k
pneumonia
pulsetyp
obtain
faecal
sampl
percent
faecal
strain
three
human
two
dog
cluster
uti
k
pneumomia
dice
index
five
faecal
strain
cluster
strain
caus
uti
human
one
faecal
strain
dog
dog
similar
one
faecal
strain
unrel
human
human
b
furthermor
dog
human
b
faecal
strain
cluster
two
one
hospit
acquir
uti
k
pneumonia
note
dog
strain
similar
uti
k
pneumonia
studi
show
dog
may
becom
colon
clonal
relat
k
pneumonia
uropathogen
strain
human
furthermor
dog
human
may
share
k
pneumonia
within
household
result
highlight
role
dog
reservoir
k
pneumonia
human
viceversa
disclosur
disclosur
report
financi
support
ciisa
fct
project
ab
cm
hold
fct
phd
grant
respect
allopurinol
consensu
leishmaniostat
drug
increas
risk
xanthin
urolithiasi
slight
nro
urolithiasi
few
report
describ
urinari
obstruct
pyonephrosi
due
xanthin
lithiasi
one
retrospect
studi
show
lithiasi
renal
miner
xanthinuria
leishmanian
dog
treat
allopurinol
author
experi
preval
seem
underestim
aim
prospect
control
studi
evalu
preval
leishmania
dog
treat
allopurinol
endem
area
dog
recruit
inclus
criteria
definit
diagnosi
leishmaniasi
allopurinol
treatment
least
one
month
control
dog
clinic
healthi
neg
serolog
test
leishmania
infantum
exclus
criteria
sever
hepat
diseas
breed
predispos
nro
urolithiasi
low
purin
diet
complet
clinic
blood
analysi
data
collect
abdomin
ultrasonographi
systemat
perform
calculi
millimet
identifi
abdomin
radiograph
complet
studi
imag
record
secondli
blindli
review
board
certifi
radiologist
dog
urin
collect
classic
urinalysi
xanthin
measur
urin
xanthinecreatinin
uxc
ratio
infrar
spectrometri
urin
sediment
forti
dog
includ
median
durat
allopurinol
treatment
year
rang
month
year
urolithiasi
present
dog
kidney
vs
bladder
stone
less
mm
struvit
crystal
lithiasi
highli
suspect
xanthin
lithiasi
slight
nro
featur
high
xanthinuria
high
uxc
ratio
identif
xanthin
sediment
infrar
spectrometri
dog
amount
renal
nro
urolithiasi
seem
increas
durat
allopurinol
treatment
dog
treat
sinc
least
year
slight
nro
renal
lithiasi
studi
show
unexpectedli
high
preval
slight
nro
urolithiasi
highli
suspect
xanthin
lithiasi
treat
allopurinol
close
monitor
side
effect
highli
recommend
ureter
obstruct
seen
could
induc
treatment
adapt
disclosur
disclosur
report
financi
support
provid
royal
canin
extracorpor
blood
purif
techniqu
becom
standard
procedur
small
anim
medicin
therapeut
plasma
exchang
tpe
techniqu
use
increasingli
remov
pathogen
weight
product
circul
blood
includ
antibodi
pathogen
protein
toxin
aim
studi
describ
techniqu
tpe
metabol
physiolog
chang
associ
treatment
medic
record
dog
treat
tpe
vetsuiss
faculti
bern
review
retrospect
collect
data
includ
signal
treatment
indic
prescript
clinic
laboratori
paramet
associ
procedur
descript
statist
data
present
median
interquartil
rang
iqr
procedur
comparison
perform
test
use
cutoff
statist
signific
dog
treat
tpe
includ
male
intact
femal
intact
age
iqr
weight
kg
iqr
main
indic
tpe
immun
diseas
dog
hemolyt
anemia
thrombocytopenia
pulmonari
hemorrhag
neuromuscular
diseas
indic
includ
polysystem
diseas
dog
sepsi
microangiopathi
hyperviscos
dog
leishmaniasi
treatment
perform
durat
min
treatment
dose
plasma
volum
exchang
replac
fluid
consist
fresh
frozen
plasma
exchang
volum
human
albumin
volum
he
volum
nacl
volum
treatment
perform
procedur
other
combin
hemodialysi
anticoagul
provid
region
citrat
system
heparin
combin
treatment
result
mildli
increas
systol
blood
pressur
mmhg
mildli
decreas
total
protein
gl
moder
decreas
plasma
fibrinogen
mgdl
sign
citrat
accumul
increas
total
calcium
mmoll
p
decreas
ioniz
calcium
mmoll
p
minor
complic
associ
procedur
observ
treatment
includ
vomit
diarrhea
urticaria
technic
difficulti
due
small
patient
size
sever
complic
seen
treatment
includ
transient
laryng
edema
chemosi
earli
treatment
discontinu
due
technic
problem
view
sever
underli
diseas
complic
benign
tpe
therefor
perform
safe
dog
disclosur
disclosur
report
msd
anim
health
boehring
ingelheim
idexx
hill
pet
nutrit
royal
canin
purina
kidney
diseas
common
companion
anim
tradit
diagnos
serum
creatinin
concentr
scr
blood
urea
nitrogen
urin
specif
graviti
recent
demonstr
kidney
biomark
symmetr
dimethylarginin
sdma
correl
glomerular
filtrat
rate
increas
earlier
scr
acut
kidney
injuri
chronic
kidney
diseas
prospect
studi
compar
accuraci
precis
two
commerci
sdma
assay
idexx
test
manufactur
idexx
laboratori
inc
sdma
elisa
manufactur
dld
diagnostika
gmbh
accuraci
precis
commerci
assay
measur
rel
establish
refer
method
liquid
chromatographymass
spectrometri
anonym
surplu
canin
felin
serum
sampl
submit
idexx
commerci
refer
laboratori
use
studi
thirti
canin
felin
serum
sampl
use
evalu
accuraci
compar
pool
canin
sampl
low
sdma
concentr
pool
felin
sampl
high
sdma
concentr
use
evalu
precis
use
best
fit
linear
model
idexx
test
result
slope
intercept
dld
sdma
elisa
result
slope
intercept
estim
bia
clinic
relev
rang
sdma
idexx
test
dld
sdma
elisa
show
consider
bia
precis
analysi
low
sdma
concentr
sampl
show
total
coeffici
variat
cv
idexx
test
dld
sdma
elisa
high
sdma
concentr
sampl
total
cv
idexx
test
dld
sdma
elisa
studi
idexx
test
accur
precis
dld
sdma
elisa
compar
refer
method
support
conclus
idexx
test
suitabl
clinic
use
diagnosi
monitor
kidney
diseas
dog
cat
disclosur
disclosur
report
studi
fund
idexx
laboratori
inc
jennif
ogeer
donald
mccrann
juli
cross
marilyn
hann
frii
michael
coyn
celest
clement
cori
drake
rachel
murphi
employe
idexx
laboratori
manufactur
idexx
test
idexx
sdma
test
conduct
idexx
commerci
refer
laboratori
subcutan
ureter
bypass
sub
novel
treatment
altern
becom
popular
last
year
treat
ureter
obstruct
cat
howev
current
describ
method
requir
fluoroscop
guidanc
aim
retrospect
studi
describ
method
sub
placement
microsurg
procedur
perform
ureterotomi
stone
remov
cat
ureter
obstruct
treat
sub
placement
correct
placement
intraop
confirm
flush
devic
case
sub
devic
place
without
complic
first
case
string
nephrostomi
tube
lead
urin
leakag
subcutan
tissu
correct
surgic
day
later
second
case
nephrostomi
tube
tip
end
subcapsular
led
commun
pull
back
pelvi
caus
subcapsular
accumul
urin
resolv
month
thirteen
microsurg
ureterotomi
perform
cat
time
sub
placement
one
ureterotomi
complic
extrus
purul
urin
ureterotomi
allow
stone
remov
case
ureterolith
analysi
identifi
calcium
oxal
monohydr
two
cultur
pyelocentesi
posit
preoper
cultur
cystocentesi
neg
frequent
postop
complic
transient
worsen
azotemia
sever
polyuria
seriou
complic
relat
sub
placement
includ
sever
postop
acut
kidney
injuri
requir
day
periton
dialysi
case
commun
pelvi
subcapsular
space
case
subcutan
leakag
discharg
day
surgic
correct
anoth
case
bilater
obstruct
euthan
day
post
surgeri
persist
sever
azotemia
hypotens
coagulopathi
one
case
dysequilibrium
syndrom
suspect
secondari
sever
diuresi
rapid
decreas
azotemia
fifteen
cat
still
aliv
time
write
sub
devic
remain
patent
case
non
patent
devic
present
recurr
hydronephrosi
lead
suspicion
patent
uret
secondari
ureterotomi
perform
time
sub
placement
studi
suggest
sub
safe
procedur
perform
pelvi
pressur
microsurg
ureterotomi
stone
remov
may
avoid
recurr
hydronephrosi
case
sub
devic
obstruct
disclosur
disclosur
report
bacteri
urinari
tract
infect
uti
affect
dog
lifetim
veterinari
patient
collect
urin
cystocentesi
quantit
bacteri
cultur
qbc
current
gold
standard
diagnos
uti
ensur
accur
result
immedi
cultur
recommend
howev
gener
practition
perform
urin
cultur
sampl
must
sent
extern
laboratori
refriger
addit
preserv
boric
acid
tradit
use
previou
veterinari
studi
suggest
method
significantli
increas
number
result
effect
method
preserv
urin
room
temperatur
therefor
desir
use
charcoal
bacteriolog
swab
suggest
laboratori
store
transport
urin
immedi
cultur
possibl
aim
studi
investig
use
standard
bacteriolog
swab
storag
canin
urin
room
temperatur
compar
urin
store
room
temperatur
either
steril
tube
store
bacteriolog
swab
refer
qbc
fresh
sampl
canin
urin
sampl
obtain
cystocentesi
aht
april
februari
prospect
includ
studi
sampl
inocul
within
collect
refer
qbc
bacteriolog
swab
immers
urin
return
origin
tube
urin
sampl
kept
origin
steril
contain
sampl
steril
contain
bacteriolog
swab
store
room
temperatur
urin
sampl
posit
cultur
inocul
standard
qbc
total
urin
sampl
includ
initi
cultur
posit
mix
bacteri
growth
urin
store
steril
contain
bacteriolog
swab
cultur
sampl
collect
ident
sensit
ci
uti
detect
consid
coloni
isol
initi
sampl
sensit
bacteri
speci
detect
urin
store
steril
contain
bacteriolog
swab
respect
sampl
show
growth
bacteri
speci
isol
initi
sampl
contrast
previou
studi
result
current
studi
suggest
use
urin
soak
bacteriolog
swab
steril
contain
reliabl
method
detect
uti
storag
canin
urin
room
temperatur
disclosur
disclosur
report
histopatholog
differenti
canin
intestin
lymphoma
lymphoplasmacellular
enter
difficult
often
requir
addit
diagnost
procedur
specif
microrna
express
pattern
alreadi
detect
differ
tumor
type
human
anim
studi
function
microrna
tumor
cell
may
help
understand
tumor
pathogenesi
aim
studi
compar
microrna
express
pattern
sampl
intestin
lymphoma
lymphoplasmacellular
enter
healthi
gut
tissu
addit
microrna
highli
differenti
express
lymphoma
select
effect
cell
death
cell
prolifer
studi
canin
lymphoma
cell
line
paraffin
embed
sampl
canin
lymphoma
lymphoplasmacellular
enter
normal
gut
tissu
use
group
sampl
select
retrospect
materi
submit
diagnost
purpos
total
rna
extract
microrna
revers
transcrib
pilot
studi
express
differ
microrna
compar
array
two
sampl
per
group
twelv
microrna
highli
differenti
express
lymphoma
group
select
express
compar
sampl
use
singl
microrna
qpcr
assay
five
microrna
transfect
lymphoma
cell
line
cell
viabil
cell
toxic
measur
use
multiplex
cytotox
assay
promega
intestin
lymphoma
display
microrna
express
pattern
differenti
healthi
gut
tissu
lymphoplasmacellular
enter
tumor
sampl
signific
microrna
found
part
cluster
signific
found
microrna
transfect
microrna
distinct
effect
prolifer
microrna
express
pattern
could
prove
use
diagnosi
canin
lymphoma
microrna
cluster
effect
prolifer
canin
cell
lymphoma
cell
overexpress
cluster
shown
induc
lymphoma
mice
high
express
found
human
leukemia
microrna
may
play
role
tumor
format
cell
sever
speci
may
repres
suitabl
target
translat
cancer
research
disclosur
disclosur
report
treatment
canin
splenic
haemangiosarcoma
hsa
includ
surgeri
adjuv
chemotherapi
adjunct
metronom
chemotherapi
mc
shown
result
similar
surviv
compar
anthracyclin
ac
whilst
discord
result
use
mc
time
complet
protocol
aim
studi
assess
time
progress
ttp
median
surviv
time
mst
dog
stage
splenic
hsa
compar
differ
treatment
protocol
medic
record
institut
search
dog
diagnos
surgic
excis
stage
splenic
hsa
treat
adjuv
ac
mc
patient
receiv
mc
follow
complet
protocol
assign
addit
group
anthracyclinemetronom
amc
mst
ttp
assess
compar
prognost
variabl
includ
breed
gender
age
bodi
weight
stage
mitot
index
treatment
type
number
chemotherapi
cycl
acamc
group
dog
includ
median
age
year
rang
median
bodi
weight
kg
rang
patient
underw
splenectomi
follow
adjuv
chemotherapi
dog
receiv
protocol
doxorubicin
dox
epirubicin
epi
pegyl
liposom
encapsul
doxorubicin
dog
receiv
mc
cyclophosphamid
chlorambucil
dog
receiv
epi
dox
follow
mc
protocol
end
amc
group
overal
mst
day
rang
overal
median
ttp
day
rang
mst
day
ac
group
rang
day
mc
group
rang
day
amc
group
rang
surviv
significantli
longer
amc
group
vs
ac
group
p
well
ttp
vs
day
although
differ
could
found
mc
group
vs
ac
amc
group
dog
receiv
treatment
anthracyclin
amc
vs
ac
group
surviv
significantli
longer
vs
day
factor
appear
affect
surviv
ttp
studi
suggest
efficaci
adjuv
mc
may
compar
ac
alon
follow
mc
use
mc
time
complet
protocol
may
abl
significantli
prolong
surviv
ttp
compar
ac
alon
studi
necessari
defin
role
mc
treatment
canin
hsa
disclosur
disclosur
report
insulinoma
common
canin
pancreat
tumour
like
metastasis
region
lymph
node
liver
lung
surgeri
current
prefer
treatment
insulinoma
dog
treat
surgic
surviv
significantli
longer
treat
conserv
median
surviv
day
versu
day
prognost
factor
insulinoma
one
studi
postop
hypoglycaemia
neg
prognost
factor
howev
signific
factor
postop
complic
current
unknown
aim
retrospect
multicentr
studi
report
complic
signific
surviv
follow
surgic
manag
insulinoma
identifi
potenti
prognost
factor
could
predict
subsequ
develop
diabet
mellitu
clinic
record
review
identifi
patient
diagnos
insulinoma
base
histopatholog
total
dog
enrol
three
referr
hospit
europ
cox
regress
use
determin
factor
associ
surviv
relaps
whilst
logist
regress
use
determin
factor
associ
develop
diabet
mellitu
median
age
diagnosi
rang
variou
breed
repres
west
highland
white
terrier
boxer
common
clinic
sign
time
diagnosi
mainli
associ
hypoglycaemia
seizur
collaps
occur
frequent
median
durat
clinic
sign
diagnosi
day
rang
diabet
mellitu
pancreat
common
complic
occur
dog
respect
diabet
mellitu
persist
case
whilst
dog
develop
hyperglycaemia
averag
durat
requir
exogen
insulin
administr
use
logist
regress
factor
found
significantli
associ
develop
diabet
mellitu
presenc
seizur
diagnosi
p
stage
diseas
p
develop
hypoglycaemia
p
pancreat
p
independ
neg
associ
surviv
likelihood
relaps
posit
associ
stage
diseas
hypoglycaemia
pancreat
current
studi
diabet
mellitu
develop
common
previous
report
factor
identifi
might
use
predictor
stage
diseas
hypoglycaemia
pancreat
associ
greater
likelihood
relaps
decreas
surviv
time
could
use
advis
client
prognosi
disclosur
disclosur
report
osteosarcoma
commonest
primari
canin
bone
tumour
increas
incid
seen
irish
wolfhound
iwh
deerhound
greyhound
rottweil
current
treatment
osteosarcoma
amput
adjunct
chemotherapi
knowledg
veterinari
studi
specif
survey
owner
thought
regard
treatment
canin
osteosarcoma
aim
studi
therefor
review
attitud
determin
owner
opinion
treatment
avail
canin
osteosarcoma
part
studi
aim
understand
motiv
behind
select
particular
treatment
particularli
owner
attitud
amput
retrospect
studi
survey
dog
owner
use
bespok
onlin
questionnair
iwh
deerhound
rottweil
greyhound
owner
without
experi
osteosarcoma
survey
alongsid
owner
dog
without
experi
osteosarcoma
owner
dog
affect
osteosarcoma
owner
without
experi
osteosarcoma
respond
experi
osteosarcoma
select
chemotherapi
amput
select
amput
alon
select
chemotherapi
alon
remain
dog
receiv
combin
palli
care
includ
dog
receiv
radiotherapi
well
receiv
convent
analgesia
bisphosphon
glucocorticoid
euthan
soon
diagnosi
owner
choos
treat
dog
felt
dog
toler
amput
well
would
recommend
amput
other
furthermor
felt
dog
toler
chemotherapi
well
would
recommend
chemotherapi
other
respond
select
radiotherapi
part
palli
care
protocol
felt
dog
toler
therapi
well
owner
significantli
less
like
select
amput
osteosarcoma
reason
p
addit
owner
older
dog
significantli
less
like
select
amput
p
conclud
treatment
avail
osteosarcoma
well
receiv
owner
consid
well
toler
dog
studi
indic
good
larg
breed
dog
undergon
amput
thu
goe
way
dispel
dogma
amput
poorli
toler
breed
result
provid
veterinari
surgeon
use
help
owner
make
therapeut
decis
dog
suffer
osteosarcoma
larger
studi
involv
greater
number
dog
wider
rang
breed
help
expand
dataset
determin
whether
opinion
share
owner
dog
affect
osteosarcoma
ultim
provid
extens
therapeut
disclosur
disclosur
report
clusterin
apoliprotein
j
heterodimer
glycoprotein
wide
express
throughout
bodi
import
role
tumourigenesi
apoptosi
immunoregul
human
clusterin
express
associ
anaplast
larg
cell
hodgkin
lymphoma
object
studi
determin
clusterin
express
differ
significantli
dog
high
grade
multicentr
lymphoma
mlsa
healthi
control
popul
potenti
biomark
hypothesis
serum
clusterin
express
would
higher
untreat
dog
lymphoma
comparison
control
clusterin
would
subsequ
decreas
clinic
remiss
follow
success
treatment
twelv
dog
untreat
high
grade
mlsa
compar
twelv
control
dog
third
popul
twelv
dog
msla
treat
chemotherapi
cyclophosphamid
h
protocol
complet
remiss
dog
untreat
popul
stage
iv
stage
v
substag
substag
b
treat
popul
stage
ii
stage
iii
stage
iv
stage
v
substag
substag
b
serum
clusterin
level
dog
determin
use
western
blot
analysi
abcam
antibodi
commerci
canin
clusterin
elisa
kit
biovendor
western
blot
analysi
serum
detect
clusterin
optic
densiti
valu
determin
use
imag
j
softwar
clusterin
express
level
gener
western
blot
analysi
elisa
show
signific
correl
pearson
r
statist
analysi
student
rel
clusterin
level
control
popul
found
clusterin
significantli
higher
untreat
treat
mlsa
popul
assess
western
blot
analysi
addit
clusterin
level
statist
significantli
higher
treat
compar
untreat
mlsa
popul
student
three
popul
directli
compar
via
elisa
untreat
treat
group
significantli
lower
control
test
conclus
serum
clusterin
express
reduc
mlsa
compar
control
popul
partial
recoveri
respons
treatment
clusterin
express
vari
wide
individu
especi
within
control
group
singl
measur
may
insuffici
diagnosi
howev
combin
biomark
clusterin
may
use
diagnosi
monitor
treatment
respons
relaps
disclosur
disclosur
report
human
breast
cancer
transform
growth
regulatori
cell
treg
share
signal
pathway
crucial
impact
sever
tumor
hallmark
step
includ
angiogenesi
facilit
nutrient
exchang
metastasi
result
tumor
progress
canin
mammari
tumor
cmt
topic
well
document
yet
studi
includ
malign
cmt
obtain
surplu
materi
regular
diagnosi
clinic
purpos
studi
immunohistochemistri
tumor
antibodi
santa
cruz
biotechnolog
dilut
clone
ebiosci
dilut
vegf
clone
thermo
scientif
dilut
clone
dako
dilut
express
associ
sever
clinicopatholog
characterist
addit
femal
dog
year
period
elucid
potenti
associ
angiogenesi
clinic
outcom
malign
cmt
high
level
associ
skin
ulcer
p
tumor
necrosi
p
high
mitot
index
p
mark
nuclear
pleomorph
p
poor
tumor
differenti
p
high
histolog
grade
malign
hgm
p
presenc
neoplast
intravascular
emboli
p
presenc
lymph
node
metastas
p
level
posit
correl
intratumor
r
p
vegf
r
p
r
p
tumor
concurr
high
express
marker
associ
paramet
tumor
malign
high
hgm
presenc
neoplast
vascular
emboli
presenc
lymph
node
metastasi
addit
tumor
abund
concurr
high
express
associ
shorter
overal
surviv
os
time
p
interestingli
class
retain
associ
shorter
os
multivari
analysi
aris
independ
predictor
poor
prognosi
hazard
ratio
p
conclus
result
studi
suggest
treg
cell
share
import
pathway
contribut
tumor
angiogeni
cmt
progress
malign
disclosur
disclosur
report
oral
malign
melanoma
omm
local
aggress
oral
tumor
dog
usual
metastas
region
lymph
node
lung
radic
surgic
excis
consid
golden
standard
treatment
multimod
approach
treatment
recommend
chemotherapi
radiat
therapi
immunotherapi
employ
treatment
canin
omm
success
present
studi
evalu
efficaci
multimod
treatment
protocol
canin
omm
combin
cytoreduct
surgeri
electrochemotherapi
bleomycin
ect
gene
electrotransf
plasmid
encod
canin
get
nine
dog
omm
clinic
stage
iii
client
declin
radic
surgeri
previou
surgeri
result
incomplet
excis
includ
five
dog
group
primari
omm
underw
intracapsular
excis
tumor
ect
bleomycin
mgkg
bw
iv
follow
get
inject
two
site
close
tumor
submucos
ect
plate
electrod
use
puls
vcm
puls
durat
frequenc
khz
wherea
get
electrod
mae
chosen
puls
v
puls
durat
ms
four
dog
group
ii
recurrentincomplet
excis
omm
also
treat
ect
get
result
show
object
respons
rate
orr
complet
respons
cr
month
treatment
although
progress
diseas
pd
occur
patient
end
observ
period
month
median
month
achiev
mean
surviv
time
mst
month
group
respect
three
patient
stage
iii
omm
surviv
month
year
euthan
due
reason
achiev
surviv
time
longer
report
surviv
time
stage
iii
omm
treat
radic
surgic
excis
alon
mst
month
combin
radiotherapi
mst
month
addit
observ
declin
percentag
regulatori
cell
treg
peripher
blood
cours
treatment
could
attribut
system
antitumor
respons
due
major
side
effect
treatment
note
therapi
toler
well
patient
conclus
combin
cytoreduct
surgeri
ect
bleo
get
may
benefici
dog
omm
especi
treatment
approach
accept
due
invas
major
surgic
procedur
cost
disclosur
disclosur
report
angiogenesi
essenti
tumor
progress
microvessel
densiti
known
prognost
factor
mani
solid
tumor
recent
therapi
potenti
therapeut
strategi
variou
type
tumor
histolog
assess
report
evalu
angiogenesi
current
veterinari
medicin
reason
evalu
angiogenesi
difficult
patient
without
surgeri
therefor
novel
evalu
method
need
aim
studi
assess
whether
histolog
measur
blood
vessel
associ
mrna
level
endotheli
marker
vwf
endoglin
spontan
canin
tumor
addit
investig
relationship
endotheli
marker
angiogen
factor
vascular
endotheli
growth
factor
vegf
vegf
studi
includ
variou
spontan
canin
tumor
evalu
angiogenesi
section
stain
antibodi
vwf
entir
tumor
section
first
observ
field
select
vascular
area
hotspot
field
hpf
stain
microvessel
count
section
divid
two
group
high
microvessel
count
vessel
hpf
low
microvessel
count
vessel
hpf
mrna
express
level
vwf
endoglin
vegf
gapdh
measur
semiquantit
statist
analysi
perform
u
test
test
statist
signific
set
p
group
high
microvessel
count
show
significantli
higher
mrna
level
vwf
p
endoglin
p
low
microvessel
count
mrna
level
significantli
correl
vwf
mrna
level
p
tend
associ
microvessel
count
p
vegf
mrna
level
correl
microvessel
count
p
vwf
mrna
level
p
studi
show
mrna
level
endotheli
marker
associ
histolog
measur
microvessel
spontan
canin
tumor
although
differ
two
marker
vwf
enoglin
microvessel
count
clear
result
suggest
mrna
measur
sampl
taken
fine
needl
aspir
would
altern
evalu
method
prognost
factor
addit
mrna
level
associ
amount
microvessel
result
indic
measur
mrna
would
use
therapeut
predict
factor
drug
toceranib
disclosur
disclosur
report
felin
coronaviru
fcov
infect
common
household
exact
preval
fcov
german
catteri
howev
unknown
factor
influenc
fcov
preval
aim
studi
determin
fcov
preval
german
catteri
evalu
risk
factor
fcov
infect
faecal
sampl
cat
catteri
across
germani
examin
fcov
polymeras
chain
reaction
pcr
owner
complet
questionnair
identifi
risk
factor
concern
husbandri
breed
manag
addit
faec
examin
presenc
intestin
pathogen
felin
panleukopenia
viru
giardia
speci
spp
tritrichomona
foetu
toxoplasma
gondii
clostridium
perfringen
alpha
toxin
enterotoxin
salmonella
spp
cryptosporidium
spp
campylobact
jejuni
campylobact
coli
pcr
helminth
infest
faecal
flotat
fisher
exact
test
multivari
logist
regress
analysi
use
detect
correl
fcov
infect
risk
factor
preval
fcov
catteri
factor
signific
influenc
multivari
analysi
preval
fcov
shed
regularli
perform
faecal
examin
endoparasit
odd
ratio
confid
interv
ci
detect
clostridium
perfringen
enterotoxin
ci
factor
number
cat
hous
togeth
signific
influenc
presenc
fcov
infect
approxim
two
third
cat
german
catteri
infect
fcov
cat
regularli
examin
endoparasit
less
like
infect
presenc
clostridium
perfringen
enterotoxin
seem
influenc
fcov
shed
disclosur
disclosur
report
dr
christian
leutenegg
head
molecular
diagnost
idexx
laboratori
inc
dr
nikola
pantchev
employ
idexx
laboratori
ludwigsburg
laboratori
perform
pcr
test
studi
idexx
play
role
studi
design
collect
interpret
data
decis
submit
manuscript
public
commerci
conflict
interest
inform
gener
sole
scientif
dissemin
author
declar
compet
interest
felin
immunodefici
viru
fiv
pathogen
domest
cat
worldwid
classifi
alongsid
human
immunodefici
viru
hiv
genu
lentiviru
famili
retrovirida
like
hiv
infect
peopl
fiv
caus
progress
immun
dysfunct
unlik
hiv
natur
clinic
cours
fiv
unpredict
ill
human
result
copathogen
role
copathogen
natur
fiv
infect
poorli
understood
aim
studi
identifi
potenti
viral
copathogen
lymphoma
use
transcriptom
analysi
truseq
librari
prepar
rna
lymphoma
aris
cat
total
rna
sequenc
yield
million
read
per
librari
bioinformat
analys
identifi
eight
read
share
amino
acid
ident
core
protein
surfac
protein
polymeras
hepadnavirus
suggest
novel
viru
presenc
genom
fragment
valid
pcr
sequenc
tumour
dna
entir
genom
subsequ
obtain
pcr
polymeras
surfac
core
x
orf
typic
orthohepadnavirus
identifi
analys
polymeras
protein
reveal
amino
acid
ident
known
orthohepadnavirus
genet
distanc
merit
assign
new
speci
within
genu
orthohepadnaviru
tent
name
domest
cat
hepadnaviru
first
hepadnaviru
infect
identifi
felid
first
report
hepadnaviru
companion
speci
domest
cat
frequent
interact
human
well
pet
wildlif
epidemiolog
pathogen
potenti
novel
hepadnaviru
cat
mammal
includ
human
investig
disclosur
disclosur
report
leishmania
infantum
intracellular
protozoan
parasit
endem
countri
mediterranean
basin
often
high
preval
leishmaniasi
increasingli
diagnos
area
due
reloc
travel
dog
endem
geograph
area
prognosi
leishmaniasi
dog
may
differ
endem
area
due
absenc
appropri
vector
aim
studi
determin
estim
surviv
time
dog
leishmaniasi
netherland
determin
clinic
stage
clinicopatholog
variabl
time
diagnosi
predict
surviv
dog
databas
univers
clinic
companion
anim
faculti
veterinari
medicin
utrecht
univers
interrog
leishmaniasi
patient
includ
dog
diagnosi
leishmaniasi
base
clinic
present
eg
cutan
diseas
clinicopatholog
chang
cytopenia
proteinur
renal
diseas
hyperglobulinemia
combin
confirm
leishmaniasi
posit
titer
presenc
leishmania
amastigot
biopsi
patient
record
review
signal
clinicopatholog
data
moment
diagnosi
incl
complet
blood
count
biochemistri
protein
spectrum
urin
analysi
lastli
canin
leishmania
work
group
clinic
stage
system
class
perform
time
studi
phone
contact
includ
receiv
treatment
date
caus
death
deceas
surviv
curv
compar
group
use
log
rank
test
multivari
analysi
perform
use
cox
proport
hazard
regress
model
total
dog
includ
overal
estim
surviv
time
year
ci
year
estim
surviv
time
differ
class
c
class
dog
univari
analysi
increas
monocyt
plasma
urea
creatinin
concentr
urin
protein
creatinin
ratio
significantli
associ
shorter
surviv
time
multivari
model
identifi
decreas
hematocrit
increas
plasma
creatinin
concentr
total
protein
neg
prognost
factor
conclud
dog
diagnos
treat
leishmaniasi
netherland
gener
long
surviv
time
comparison
compar
cohort
german
studi
presenc
renal
diseas
strong
neg
predictor
surviv
interestingli
clinic
stage
time
diagnosi
seem
predict
surviv
popul
disclosur
disclosur
report
mk
de
jong
cj
piek
employ
depart
clinic
scienc
companion
anim
faculti
veterinari
medicin
utrecht
univers
netherland
mark
increas
incid
acut
canin
leptospirosi
document
switzerland
infect
dog
show
serolog
evid
infect
serogroup
australi
new
tetraval
kill
whole
cell
vaccin
msd
anim
health
introduc
onto
swiss
market
vaccin
includ
serogroup
australi
grippotyphosa
addit
serogroup
canicola
icterohaemorrhagia
present
previous
avail
bival
vaccin
shown
excel
protect
experiment
challeng
dog
heterolog
strain
serogroup
aim
retrospect
longitudin
case
control
vaccin
effici
studi
examin
whether
introduct
associ
reduct
hospit
incid
canin
leptospirosi
dog
leptospirosi
acut
kidney
injuri
due
leptospirosi
treat
vetsuiss
faculti
bern
includ
complet
vaccin
histori
diagnosi
leptospirosi
confirm
base
compat
clinic
find
presenc
least
one
follow
posit
singl
mat
titr
mat
seroconvers
posit
igm
later
flow
assay
posit
urin
strong
clinic
suspicion
confirm
serolog
due
earli
death
control
dog
diagnos
base
convinc
altern
diagnosi
least
neg
serolog
annual
incid
vaccin
effect
compar
group
latter
express
odd
ratio
diagnos
leptospirosi
control
group
show
mark
decreas
dog
vaccin
steep
increas
dog
vaccin
stabl
number
dog
current
vaccin
unvaccin
simultan
number
case
leptospirosi
significantli
decreas
casesi
number
control
case
aki
increas
casesi
dog
aki
diagnos
leptospirosi
vaccin
vs
vaccin
ci
p
vaccin
ci
p
ci
p
result
indic
introduct
associ
mark
reduct
incid
sever
acut
canin
leptospirosi
switzerland
disclosur
disclosur
report
msd
anim
health
financi
support
present
studi
boehringh
ingelheim
speaker
honoraria
vetoquinol
consult
fee
hill
pet
nutrit
speaker
honoraria
royal
canin
speaker
honoraria
purina
meet
support
idexx
consult
fee
speaker
honoraria
vifor
financi
support
studi
henri
schein
anim
health
speaker
honoraria
leptospirosi
complex
zoonot
bacteri
diseas
caus
pathogen
serovar
leptospira
multipl
clinic
sign
dog
nowaday
preval
canin
leptospirosi
spain
undetermin
aim
determin
seropreval
serum
antibodi
dog
spain
know
common
serovar
relationship
area
serovar
studi
record
canin
leptospira
test
data
spain
sinc
idexx
microscop
agglutin
test
mat
perform
inclus
criteria
posit
mat
result
least
one
serovar
bratislava
copenhageni
icterohaemorrhagia
australi
pomona
grippotyphosa
autumnali
canicola
saxkoeb
data
zip
code
posit
accord
biogeograph
area
north
highest
percentag
follow
center
south
mediterranean
northwest
highest
incid
detect
autumn
averag
case
season
gender
avail
posit
male
femal
age
avail
posit
incid
sampl
posit
icterohaemorrhagia
bratislava
grippotyphosa
australi
pomona
autumnali
canicola
saxkoeb
respect
one
hundr
mat
titer
posit
icterohaemorrhagia
bratislava
grippotyphosa
pomona
australi
autumnali
canicola
saxkoeb
respect
dog
mat
titer
divid
serovar
biogeograph
area
icterohaemorrhagia
preval
mediterranean
south
australi
northwest
bratislava
north
grippotyphosa
center
respect
result
demonstr
spain
dog
high
exposur
divers
leptospira
serovar
male
dog
older
year
seem
riskier
posit
diagnosi
increas
autumn
higher
seropreval
north
area
preval
icterohaemorrhagia
bratislava
grippotyphosa
howev
preval
serovar
vari
geograph
area
includ
mat
titer
order
limit
effect
unknown
vaccin
statu
present
studi
disclosur
disclosur
report
indirect
benefit
author
could
benefit
result
studi
experiment
infect
cat
intermitt
shed
pathogen
leptospira
spp
urin
sever
week
far
shed
dna
pathogen
leptospira
spp
document
natur
infect
cat
countri
urinari
shed
infecti
bacteria
climat
southern
chile
temper
raini
high
annual
precipit
repres
ideal
precondit
surviv
leptospira
spp
environ
aim
studi
investig
shed
pathogen
leptospira
spp
outdoor
cat
southern
chile
urin
blood
sampl
outdoor
cat
rural
urban
area
collect
urin
sampl
investig
pathogen
leptospira
spp
immun
magnet
concentr
follow
real
time
pcr
target
gene
urin
sampl
cultur
medium
week
posit
urin
cultur
confirm
pcr
mlst
use
molecularli
character
strain
obtain
posit
cultur
pcr
product
sequenc
afterward
urin
sampl
confid
interv
ci
median
genom
equivalentsml
iqr
rang
ci
urin
sampl
leptospira
spp
could
cultur
appli
mlst
sequenc
pcr
product
l
interrogan
copenhageni
icterohaemorrhagia
identifi
cat
l
interrogan
autumnali
autumnali
cat
outdoor
cat
southern
chile
shed
strain
pathogen
leptospira
spp
possibl
sourc
infect
human
dog
livestock
anim
disclosur
disclosur
report
studi
fund
msd
de
desarollo
universidad
austral
de
chile
bayerisch
hochschulzentrum
lateinamerika
baylat
author
conflict
interest
antimicrobi
resist
emerg
problem
human
veterinari
medicin
antibiot
use
main
driver
resist
develop
goal
studi
evalu
antimicrobi
prescript
cat
switzerland
acut
upper
respiratori
tract
diseas
aurtd
felin
lower
urinari
tract
diseas
flutd
present
two
univers
hospit
eight
privat
veterinari
practic
retrospect
evalu
clinic
histori
diagnost
antimicrobi
therapi
class
dosag
durat
assess
justif
score
js
use
assess
agreement
antimicrobi
prescript
current
guidelin
dosagedur
antimicrobi
wrong
treatment
decis
cat
aurtd
receiv
antibiot
therapi
follow
class
potenti
aminopenicillin
third
gener
cephalosporin
aminopenicillin
tetracyclin
fluoroquinolon
amphenicol
first
gener
cephalosporin
macrolid
receiv
combin
serial
therapi
case
treat
median
day
assess
prudent
use
possibl
antimicrobi
therapi
judg
appropri
inappropri
case
antibiot
therapi
significantli
associ
presenc
lethargi
anorexia
fever
cat
flutd
case
bacteri
cystiti
otherunknown
diagnosi
receiv
antibiot
therapi
follow
class
potenti
aminopenicillin
third
gener
cephalosporin
fluoroquinolon
aminopenicillin
first
gener
cephalosporin
amphenicol
tetracyclin
receiv
combin
serial
therapi
cat
treat
median
day
assess
prudent
use
possibl
antimicrobi
therapi
judg
appropri
inappropri
case
inadequ
diagnost
main
reason
preclud
judgment
bacteriuria
significantli
associ
antibiot
therapi
p
frequenc
antimicrobi
therapi
significantli
differ
univers
hospit
privat
practic
critic
import
antibiot
third
gener
cephalosporin
fluoroquinolon
significantli
often
use
privat
practic
aurtd
flutd
p
result
suggest
overprescript
antibiot
cat
aurtd
flutd
common
third
gener
cephalosporin
frequent
use
studi
highlight
need
promot
antimicrobi
stewardship
small
anim
medicin
support
onlin
tool
wwwantibioticscoutch
base
current
veterinari
guidelin
launch
impact
tool
prescrib
habit
assess
futur
disclosur
disclosur
report
studi
support
swiss
nation
scienc
foundat
project
nonproteinogen
amino
acid
import
constitu
structur
protein
collagen
increas
concentr
urin
serum
associ
degrad
connect
tissu
recent
use
biomark
hepat
fibrosi
human
object
studi
develop
liquid
chromatographi
tandem
mass
spectrometri
method
quantit
determin
endogen
dog
serum
analyt
valid
method
ass
serum
concentr
dog
chronic
hepat
serum
concentr
quantifi
quantiva
tripl
quandrupol
mass
spectromet
thermofish
scientif
follow
valid
variabl
assess
linear
dilut
parallel
precis
variabl
reproduc
variabl
accuraci
recoveri
mix
sampl
known
concentr
valid
method
use
quantifi
concentr
serum
dog
histopatholog
confirm
chronic
hepat
healthi
control
dog
method
quantif
dog
serum
success
develop
observ
expect
ratio
dilut
parallel
sampl
rang
mean
sd
sampl
sampl
coeffici
variat
cv
rang
respect
observ
expect
ratio
mixtur
two
serum
sampl
known
concentr
pair
sampl
rang
mean
sd
concentr
significantli
decreas
serum
dog
chronic
hepat
versu
healthi
control
median
ngml
ngml
p
respect
develop
method
shown
precis
reproduc
quantif
canin
serum
recoveri
limit
affect
accuraci
dog
chronic
hepat
significantli
lower
serum
concentr
healthi
control
possibl
due
abnorm
hepat
amino
acid
metabol
disclosur
disclosur
report
hepat
chronic
hepat
diseas
dog
breed
diseas
due
genet
defect
copper
metabol
other
still
unclear
whether
accumul
primari
secondari
condit
nowaday
report
predispos
dog
increas
retrospect
studi
aim
describ
epidemiolog
factor
clinic
find
dog
hepat
dog
present
french
referr
center
may
march
posit
rhodanin
stain
liver
biopsi
includ
medic
record
retrospect
analyz
age
present
sex
breed
main
clinic
complaint
abdomin
ultrasound
us
find
rhodanin
stain
pattern
total
dog
includ
median
age
present
year
rang
eleven
dog
femal
six
male
sex
predisposit
found
chi
squar
test
dog
name
german
shepherd
labrador
retriev
cocker
spaniel
beauceron
american
staffordshir
terrier
cavali
king
charl
spaniel
mongrel
jack
russel
terrier
west
highland
white
terrier
dalmatian
main
clinic
complaint
incident
find
increas
anorexiadecreas
appetit
weight
loss
polyuriapolydipsia
vomit
jaundic
abdomin
us
perform
dog
main
find
includ
heterogen
mottl
liver
hepatomegali
hypoecho
nodul
microhepatia
rhodanin
stain
pattern
centrilobular
zone
zone
pattern
consid
multifoc
similarli
previou
studi
german
shepherd
terrier
overrepres
less
common
breed
also
report
name
beauceron
american
staffordshir
despit
terrier
previous
associ
diseas
biochem
incident
find
increas
emphas
silent
progress
diseas
although
us
abnorm
inconsist
heterogen
mottl
liver
common
find
centrilobular
pattern
rhodanin
stain
observ
major
case
strengthen
primari
condit
diseas
three
case
distribut
observ
believ
secondari
cholestasi
author
knowledg
first
studi
describ
hepat
beauceron
american
staffordshir
terrier
dog
studi
increas
number
report
breed
affect
hepat
emphas
possibl
multifactori
etiolog
disclosur
fund
project
ciisa
renin
angiotensin
aldosteron
system
raa
physiolog
regul
blood
pressur
electrolyt
balanc
fluid
homeostasi
studi
human
hepat
cirrhosi
shown
raa
activ
increas
sympathet
nervou
activ
hyponatremia
reduc
renal
perfus
hypovolemia
possibl
therapeut
approach
treatment
patient
portal
hypotens
suppress
raa
dog
relationship
raa
cardiac
renal
disord
studi
howev
knowledg
studi
relationship
raa
hepat
diseas
portal
hypotens
evalu
relationship
portal
hypertens
raa
dog
select
dog
histopatholog
diagnos
primari
hypoplasia
portal
vein
phpv
portal
hypertens
diagnosi
portal
hypertens
base
presenc
acquir
portosystem
collater
apsc
dog
congenit
portosystem
shunt
cpss
report
similar
histopatholog
hemodynam
alter
compar
phpv
without
evid
portal
hypertens
thu
dog
diagnos
cpss
evalu
control
diagnosi
cpss
apsc
determin
comput
tomograph
angiographi
gross
evalu
laparoscopi
raa
assess
measur
plasma
renin
activ
plasma
aldosteron
concentr
use
radioimmunoassay
techniqu
blood
sampl
obtain
diagnosi
store
analyz
twelv
dog
diagnos
phpv
portal
hypertens
nine
dog
cpss
includ
studi
signific
differ
median
plasma
aldosteron
concentr
cpss
median
pgml
dog
dog
phpv
median
pgml
p
signific
differ
found
median
plasma
renin
activ
two
group
first
studi
evalu
relationship
raa
portal
hypertens
dog
inactiv
raa
cpss
dog
indic
raa
activ
hemodynam
chang
portosystem
shunt
raa
system
activ
dog
portal
hypertens
thu
suppress
raa
may
therapeut
option
portal
hypertens
dog
disclosur
disclosur
report
biomark
investig
canin
hepatopathi
still
infanc
decreas
serum
oh
vd
increas
protein
crp
von
willebrand
factor
vwf
associ
diseas
sever
human
chronic
inflammatori
hepatopathi
current
prospect
observ
studi
dog
chronic
inflammatori
hepatopathi
investig
whether
chang
serum
concentr
oh
vd
crp
vwf
present
disord
biomark
associ
hepat
copper
level
liver
injuri
marker
ie
alanin
aminotransferas
alt
cholestasi
marker
ie
total
bilirubin
marker
advanc
liver
diseas
ie
fibrinogen
albumin
serum
oh
vd
crp
vwf
determin
prior
liver
biopsi
perform
either
percutan
ultrasound
guidanc
surgic
via
laparoscop
surgeri
laparotomi
data
analyz
normal
log
transform
perform
data
correl
test
use
pearson
correl
test
p
consid
signific
twenti
five
dog
met
inclus
criteria
seventeen
differ
breed
repres
labrador
retriev
terrier
cross
common
breed
median
age
yr
rang
crp
median
ugl
rang
increas
dog
oh
vd
level
median
nmoll
rang
low
dog
dog
increas
vwf
activ
median
rang
activ
low
dog
fibrinogen
median
mgdl
low
mgdl
dog
dog
increas
fibrinogen
albumin
vwf
well
albumin
oh
vd
signific
p
strong
posit
correl
respect
signific
correl
found
dog
chronic
inflammatori
hepatopathi
crp
elev
dog
vwf
activ
oh
vd
serum
level
often
normal
rang
oh
vd
level
decreas
serum
albumin
decreas
may
reflect
loss
hepat
synthet
late
stage
inflammatori
diseas
addit
comparison
biomark
histopatholog
score
grade
well
treatment
outcom
evalu
futur
assess
abil
predict
diseas
sever
outcom
disclosur
disclosur
report
studi
support
companion
anim
health
fund
hepat
encephalopathi
syndrom
neurolog
dysfunct
present
sever
liver
diseas
import
contributor
patient
morbid
canin
commonli
report
associ
congeni
portosystem
shunt
cpss
although
complet
characteris
sever
factor
known
influenc
pathogenesi
name
increas
ammonia
inflamm
manganes
well
alkalosi
hyponatraemia
hypokalaemia
melatonin
hormon
secret
pineal
gland
brain
cell
gastric
mucosa
action
link
regul
circadian
rhythm
enterocyt
integr
free
oxygen
radic
scaveng
amongst
other
major
melatonin
metabolis
liver
recent
melatonin
level
note
significantli
increas
human
liver
cirrhosi
correl
diseas
sever
sever
henc
hypothesis
potenti
contributor
develop
latter
author
knowledg
melatonin
homeostasi
canin
liver
diseas
current
unknown
aim
studi
investig
whether
melatonin
concentr
could
alter
dog
cpss
hypothesi
higher
level
would
present
compar
healthi
control
medic
record
retrospect
review
inclus
two
cohort
dog
confirm
diagnosi
cpss
n
healthi
dog
examin
wellb
appoint
n
canin
competit
immunosorb
assay
use
measur
serum
melatonin
prospect
sampl
use
archiv
surplu
sampl
retain
clinic
diagnost
purpos
inform
owner
consent
surplu
retent
use
research
obtain
time
clinic
sampl
melatonin
concentr
group
assess
normal
test
group
normal
distribut
therefor
data
describ
median
minimum
maximum
rang
differ
group
compar
u
test
statist
signific
level
set
p
concentr
melatonin
cpss
group
pgml
pgml
differ
significantli
p
healthi
control
pgml
pgml
studi
suggest
serum
melatonin
increas
dog
cpss
unlik
play
role
pathogenesi
disclosur
disclosur
report
cat
systol
arteri
blood
pressur
sbp
measur
influenc
white
coat
effect
commonli
misinterpret
arteri
hypertens
aim
studi
compar
sbp
measur
cat
examin
two
differ
handl
condit
investig
possibl
correl
lifestyl
cohabit
anim
use
doppler
method
high
definit
oscillometri
hdo
cat
age
rang
month
year
includ
studi
clinic
healthi
underli
diseas
unrel
arteri
hypertens
histor
data
regard
lifestyl
indoor
outdoor
indoorsoutdoor
cohabit
anim
dog
cat
initi
collect
sbp
measur
perform
use
two
differ
handl
protocol
random
fashion
low
stress
handl
sbp
valu
measur
hdo
doppler
ten
minut
acclimat
quiet
isol
consult
room
diffus
ceva
anim
health
ltd
without
previou
clinic
handl
cat
contact
anim
visit
typic
handl
sbp
measur
consult
room
use
devic
cat
previous
went
clinic
normal
admiss
procedur
common
wait
room
clinic
examin
part
routin
exam
diagnost
process
without
period
acclimat
measur
conduct
observ
omi
minim
restraint
cat
coccyg
arteri
signific
differ
two
differ
handl
condit
sbp
measur
measur
either
doppler
hdo
respect
bland
altman
comparison
analysi
two
measur
method
indic
doppler
provid
systemat
higher
sbp
valu
compar
hdo
handl
condit
ci
use
linear
mix
effect
model
significantli
higher
sbp
valu
observ
indoorsoutdoor
cat
regardless
handl
condit
cohabit
dog
cat
underli
clinic
condit
method
sbp
measur
p
cat
underli
diseas
significantli
higher
sbp
low
stress
handl
sbp
assess
use
doppler
result
studi
suggest
sbp
measur
cat
appar
similar
environ
typic
handl
visit
clinic
furthermor
indoorsoutdoor
live
lifestyl
seem
result
consist
higher
sbp
cat
compar
lifestyl
disclosur
disclosur
report
wish
confirm
known
conflict
interest
associ
public
present
signific
financi
support
work
could
influenc
outcom
confirm
manuscript
read
approv
name
author
person
satisfi
criteria
authorship
list
confirm
order
author
list
manuscript
approv
us
confirm
given
due
consider
protect
intellectu
properti
associ
work
impedi
public
includ
time
public
respect
intellectu
properti
confirm
follow
regul
institut
concern
intellectu
properti
behalf
author
ioannidi
dvm
email
gmailcom
non
blood
pressur
bp
measur
consciou
cat
vital
part
monitor
clinic
healthi
older
individu
patient
medic
diseas
affect
blood
pressur
aim
studi
compar
doppler
ultrasonographi
oscillometri
without
proprietari
optim
bp
measur
consciou
cat
twenti
seven
felin
felin
clinic
univers
veterinari
hospit
includ
prospect
studi
measur
obtain
accord
guidelin
american
colleg
veterinari
intern
medicin
consensu
statement
achiev
standard
condit
devic
oper
accord
manufactur
guidelin
use
altern
first
devic
five
systol
blood
pressur
sbp
measur
obtain
doppler
oscillometr
without
proprietari
optim
devic
averag
prior
statist
analysi
bland
altman
analysi
use
determin
agreement
differ
sbp
plot
mean
pair
measur
bia
defin
mean
differ
two
method
precis
calcul
standard
deviat
sd
differ
limit
agreement
calcul
bia
x
sd
pair
sampl
test
run
determin
whether
statist
signific
mean
differ
sbp
measur
two
method
overal
statist
analysi
achiev
use
excel
minitab
softwar
comparison
method
gave
averag
bia
mmhg
ci
mmhg
lower
limit
agreement
lla
set
mmhg
upper
limit
agreement
ula
differ
upper
lower
limit
mmhg
comparison
produc
averag
bia
mmhg
ci
mmhg
limit
agreement
set
lla
ula
differ
lla
ula
mmhg
indic
bia
oscillometri
without
proprietari
optim
overestim
sbp
mean
differ
two
nibp
devic
significantli
differ
find
studi
suggest
doppler
ultrasonographi
oscillometri
without
proprietari
optim
use
interchang
differ
methodolog
taken
account
use
specif
refer
rang
start
antihypertens
treatment
substag
patient
kidney
diseas
disclosur
disclosur
report
serial
blood
pressur
measur
vital
signific
assess
dog
diseas
medic
known
affect
blood
pressur
doppler
ultrasonographi
devic
use
establish
refer
rang
blood
pressur
recent
discontinu
data
regard
agreement
differ
doppler
ultrasonographi
devic
limit
aim
studi
compar
two
doppler
devic
park
medic
doppler
mano
vet
bp
doppler
measur
systol
blood
pressur
sbp
consciou
dog
forti
canin
univers
veterinari
hospit
includ
prospect
studi
sbp
measur
indirectli
use
standardis
process
accord
american
colleg
veterinari
intern
medicin
guidelin
devic
oper
accord
manufactur
guidelin
use
altern
first
devic
statist
analysi
perform
use
matlab
softwar
along
analysi
scatter
graph
determin
agreement
standard
deviat
sd
devic
abil
detect
hypertens
anim
final
linear
regress
fit
data
evalu
signific
relat
age
cuff
size
heart
rate
mean
differ
two
devic
suggest
good
correl
linear
rank
correl
test
also
perform
sbp
read
r
correl
coeffici
found
suggest
strong
correl
devic
mean
indic
overal
differ
mean
systol
bp
differ
two
devic
show
statist
devic
agreeabl
signific
relat
age
cuff
heart
rate
identifi
studi
suggest
sbp
measur
two
doppler
devic
correl
well
allow
differ
devic
measur
comparison
use
sbp
refer
rang
disclosur
disclosur
report
aim
work
detect
identifi
protein
canin
fece
healthi
boxer
dog
proteom
approach
dog
protein
detect
fece
may
help
investig
eg
pathogenesi
diagnosi
canin
gastrointestin
gi
diseas
first
step
attempt
defin
healthi
proteom
pattern
canin
fece
perform
fece
sampl
two
group
patient
healthi
gi
sign
preprobiot
administr
chang
diet
within
last
month
boxer
dog
includ
studi
polyacrylamid
gel
electrophoresi
liquid
mass
spectrometri
perform
eight
spot
form
consid
interest
due
express
pattern
therefor
select
candid
analysi
consult
swissprot
ncbinr
databas
mascot
sonar
result
allow
us
find
origin
speci
protein
cani
lupi
familiari
flavobacteriacea
bacterium
prochlorococcu
marinu
candida
glabrata
especi
protein
cani
lupi
familiari
result
interest
caus
owe
host
dog
identifi
immunoglobulin
light
chain
isoform
confirm
datum
could
interest
futur
perspect
kind
studi
protein
involv
immun
respons
host
also
kind
tumor
patholog
condit
disclosur
disclosur
report
canin
acut
pancreat
ap
easili
diagnos
via
canin
lipas
test
recent
year
although
sever
blood
test
relat
prognost
factor
ap
identifi
prognost
factor
treatment
still
unclear
studi
aim
identifi
prognost
factor
ap
treatment
subject
includ
patient
ap
underw
hospit
treatment
ap
diagnos
basi
clinic
sign
abnorm
result
concurr
exclus
gastrointestin
diseas
via
ultrasonographi
end
treatment
patient
aliv
die
patient
elev
blood
urea
nitrogen
bun
level
first
visit
risk
death
high
p
odd
ratio
sensit
specif
patient
first
visit
risk
death
tend
high
p
howev
signific
differ
clinic
symptom
blood
test
marker
abdomin
ultrasonographi
find
first
visit
furthermor
risk
death
high
patient
elev
bun
level
note
day
treatment
p
sensit
specif
addit
risk
death
high
patient
thrombocytopenia
platelet
count
treatment
p
sensit
specif
import
monitor
bun
level
platelet
count
period
prognost
factor
ap
disclosur
disclosur
report
canin
chronic
enteropathi
ce
idiopath
gastrointestin
disord
character
chronic
gastrointestin
sign
leucin
rich
lrg
recent
identifi
novel
biomark
human
inflammatori
bowel
diseas
crohn
diseas
ulcer
coliti
uc
serum
lrg
concentr
correl
well
clinic
endoscop
diseas
activ
uc
unlik
protein
protein
lrg
reportedli
express
hepatocyt
also
intestin
epitheli
cell
express
lrg
protein
elev
intestin
mucosa
patient
uc
therefor
aim
studi
examin
express
lrg
mrna
protein
duoden
mucosa
dog
ce
dog
diagnos
ce
enrol
biopsi
sampl
duodenum
evalu
lrg
express
quantit
polymeras
chain
reaction
qpcr
immunohistochemistri
control
cryopreserv
biopsi
sampl
duodenum
ten
healthi
control
dog
clinic
sign
gastrointestin
diseas
use
wilcoxon
rank
sum
test
use
compar
lrg
mrna
express
two
group
relationship
lrg
mrna
express
canin
chronic
enteropathi
clinic
activ
index
ccecai
histopatholog
score
grade
accord
guidelin
wsava
intern
gastrointestin
standard
group
evalu
spearman
rank
correl
coeffici
statist
signific
defin
p
express
lrg
mrna
significantli
higher
ce
dog
healthi
control
express
lrg
mrna
significantli
higher
high
ccecai
group
low
ccecai
group
contrast
correl
lrg
mrna
express
wsava
score
immunohistochemistri
lrg
protein
express
higher
intestin
epitheli
cell
duoden
mucosa
ce
dog
healthi
control
conclus
studi
demonstr
lrg
mrna
protein
express
increas
duoden
mucosa
dog
ce
lrg
mrna
express
also
associ
high
clinic
score
futur
studi
evalu
clinic
util
measur
serum
lrg
concentr
dog
ce
disclosur
disclosur
report
studi
report
ileocol
mass
cat
etiolog
context
main
caus
describ
includ
lymphoma
felin
infecti
periton
felin
gastrointestin
eosinophil
scleros
fibroplasia
felin
intestin
mast
cell
tumor
case
hemangiosarcoma
case
actinomycetoma
case
intussuscept
moreov
often
associ
poor
prognosi
inclus
criteria
retrospect
studi
presenc
ileocol
mass
icm
diagnos
abdomin
ultrasonographi
surgic
excis
biopsi
icm
laparotomi
standard
preoper
investig
histolog
evalu
icm
perform
eight
cat
male
femal
recruit
studi
mostli
domest
shorthair
versu
main
coon
chartreux
six
neuter
male
femal
median
age
year
old
rang
median
weight
kilogram
rang
main
clinic
sign
present
chronic
digest
disord
vomit
diarrhea
dysorexia
weigh
loss
ultranosograph
featur
lack
specif
etiolog
could
determin
cat
consid
previou
differenti
lymphoma
felin
infecti
periton
case
ileum
wall
ileocol
lymph
node
enlarg
ileocol
lymph
node
median
size
mm
rang
mm
six
cat
underw
complet
surgic
remov
enterectomi
via
ileocol
junction
resect
two
cat
submit
biopsi
laparotomi
histopatholog
analysi
icm
reveal
felin
gastrointestin
eosinophil
fibroplasia
inflammatori
lesion
fibrosi
secondari
presum
prior
foreign
bodi
inflammatori
lesion
associ
campylobacteriosi
tritrichomonosi
fibrosi
postop
granuloma
two
cat
die
period
septic
periton
dissemin
intravascular
coagul
six
month
surgeri
other
cat
still
aliv
nt
show
digest
disord
knowledg
first
studi
report
eight
case
felin
icm
main
purpos
case
seri
highlight
icm
cat
neither
alway
associ
neoplast
etiolog
desper
prognosi
unjustifi
euthanasia
consid
etiolog
characteris
disclosur
disclosur
report
comput
tomograph
angiographi
cta
consid
highli
accur
diagnosi
human
pancreat
due
abil
complet
evalu
pancrea
contrast
enhanc
pattern
region
vasculatur
along
rapid
acquisit
time
properti
valuabl
dog
due
morbid
acut
pancreat
current
method
aim
studi
compar
cta
ultrasonographi
diagnost
tool
canin
acut
pancreat
dog
met
inclus
criteria
prospect
enrol
includ
pilot
project
studi
inclus
base
fulfil
two
three
criteria
strong
clinic
suspicion
pancreat
ultrasonograph
evid
pancreat
andor
snapr
posit
canin
pancreat
lipas
cpli
test
specr
cpli
obtain
abdomin
ultrasound
perform
follow
within
hour
sedat
abdomin
three
phase
cta
result
show
cta
visual
entir
pancrea
dog
ultrasonographi
visual
entir
pancrea
dog
dog
heterogen
contrast
enhanc
pancrea
cta
significantli
identifi
portal
vein
thrombos
ultrasound
ct
ultrasound
p
valu
dog
heterogen
contrast
enhanc
significantli
like
portal
vein
thrombosi
p
valu
studi
suggest
dog
acut
pancreat
heterogen
pancreat
contrast
enhanc
may
predispos
portal
vein
thrombos
cta
accur
identifi
find
adrian
et
al
j
vet
intern
med
jan
ridexx
laboratori
disclosur
disclosur
report
prostaglandin
prostanoid
play
import
homeostat
function
yet
also
respons
regul
pain
inflamm
implic
develop
progress
variou
cancer
deleteri
action
inhibit
vari
degre
drug
nsaid
howev
administr
drug
also
lead
signific
gastrointestin
gi
side
effect
grapipr
new
drug
piprant
class
function
select
inhibitor
propos
associ
less
gi
side
effect
aim
studi
determin
valu
canin
jejun
tissu
well
novel
vitro
model
canin
intestin
epithelium
enteroid
futur
vitro
investig
possibl
gi
side
effect
drug
priprant
class
briefli
tissu
piec
acquir
jejunum
healthi
dog
euthan
unrel
project
full
thick
tissu
fix
formalin
salin
routin
process
embed
paraffin
enteroid
cultur
minc
sampl
wash
crypt
enrich
use
edta
chelat
embed
matrigel
grown
intestin
stem
cell
media
full
epitheli
differenti
day
cultur
rna
situ
hybrid
acdbio
use
evalu
full
thick
sampl
canin
healthi
jejunum
well
enteroid
deriv
tissu
quantifi
signal
tissu
section
advanc
digit
patholog
imag
analysi
system
halo
indica
lab
util
data
express
copi
number
signal
compar
housekeep
target
posit
control
gene
jejun
sampl
evalu
univers
posit
express
identifi
epithelium
well
lamina
propria
immun
cell
copi
number
averag
per
cell
express
enteroid
show
similar
express
epithelium
compar
epitheli
express
full
thick
sampl
wilcoxon
sign
rank
test
result
report
mrna
express
canin
jejunum
enteroid
healthi
dog
confirm
util
canin
enteroid
investig
effect
nsaid
gi
epithelium
disclosur
disclosur
report
chronic
enteropathi
ce
common
cat
intestin
microbiom
recogn
import
contributor
intestin
inflamm
peopl
dog
ce
aim
studi
perform
untarget
analysi
fecal
microbiom
cat
ce
fecal
sampl
obtain
cat
histolog
confirm
ce
healthi
control
cat
amplif
sequenc
variabl
region
rrna
gene
perform
util
illumina
sequenc
illumina
miseq
platform
softwar
quantit
insight
microbi
ecolog
qiim
use
data
process
analysi
differ
speci
rich
group
calcul
use
u
test
differ
microbi
commun
group
evalu
phylogeni
base
unweight
unifrac
distanc
metric
statist
perform
analysi
similar
anosim
linear
discrimin
analysi
effect
size
lefs
util
identifi
bacteri
popul
associ
ce
result
show
significantli
lower
speci
rich
cat
ce
compar
healthi
control
cat
p
chronic
enteropathi
associ
bacteria
famili
streptococcacea
enterobacteriacea
analysi
show
significantli
differ
cluster
cat
ce
compar
healthi
control
cat
p
similar
result
peopl
dog
result
show
decreas
bacteri
divers
cat
ce
studi
evalu
differ
differ
form
ce
develop
dysbiosi
index
character
global
chang
microbiom
warrant
disclosur
disclosur
report
marsilio
r
pilla
ja
lidburi
jm
steiner
js
suchodolski
affili
texa
gastrointestin
laboratori
offer
test
evalu
fecal
microbiom
test
gastrointestin
function
basi
canin
inflammatori
bowel
diseas
ibd
frequent
sometim
challeng
condit
although
implic
immun
system
intestin
microbiota
document
intestin
proteolyt
activ
never
measur
canin
ibd
object
studi
compar
intestin
activ
elastas
trypsin
ibd
healthi
dog
eight
ibd
healthi
dog
recruit
dog
complet
chemistri
panel
blood
count
fecal
flotat
immunoreact
folat
duoden
ileal
biopsi
endoscop
biopsi
forcep
diseas
activ
quantifi
use
ccecai
score
tissu
elastas
trypsin
activ
quantifi
intestin
tissu
sampl
use
quench
fluoresc
assay
report
mumg
protein
wilcoxon
spearman
rank
test
use
statist
analysi
result
present
median
rang
ibd
dog
median
ccecai
compar
healthi
dog
significantli
higher
vs
vs
mumg
vs
p
vs
p
posit
correl
ccecai
dutryp
iltryp
neg
correl
folat
ilela
also
albumin
dutryp
observ
intestin
proteolyt
activ
canin
ibd
upregul
correl
clinic
sever
proteas
like
involv
pathogenesi
canin
ibd
may
repres
possibl
therapeut
target
case
standard
therapi
disclosur
disclosur
report
hypercobalaminemia
underestim
classic
consid
clinic
signific
howev
hypercobalaminemia
found
peopl
seriou
underli
patholog
solid
neoplasm
myeloprolif
blood
disord
liver
diseas
kidney
failur
recent
link
hepat
neoplast
diseas
cat
hepat
diseas
dog
aim
present
studi
evalu
preval
signific
hypercobalaminemia
small
anim
result
serum
cobalamin
measur
retrospect
review
sampl
anim
evalu
differ
diseas
two
veterinari
hospit
sampl
measur
outsid
laboratori
idexx
barcelona
use
chemiluminesc
assay
refer
rang
cat
studi
includ
sampl
dog
cat
patient
measur
femal
male
median
age
year
year
four
felin
breed
canin
breed
repres
preval
hypercobalaminemia
sampl
dog
cat
among
five
patient
receiv
previou
cobalamin
inject
patient
underli
diseas
confirm
includ
ibd
pancreat
liver
diseas
antibiot
respons
enteropathi
food
respons
enteropathi
hyperthyroid
protein
lose
enteropathi
gluten
intoler
cardiac
diseas
thrombocytopenia
leishmaniasi
gastroduoden
ulcer
exocrin
pancreat
insuffici
ulcer
coliti
foreign
bodi
patient
presumpt
diagnosi
like
underli
diseas
chronic
enteropathi
underli
diseas
found
anim
hypercobalaminemia
present
studi
includ
previous
describ
etiolog
interestingli
common
encount
diseas
ibd
ard
pancreat
potenti
explan
find
could
presenc
reactiv
hepat
diseas
fact
anim
examin
suspect
cobalamin
defici
although
consensu
human
medicin
interpret
find
emphas
methylmalon
acid
valu
measur
present
studi
better
reflect
cobalamin
statu
function
cobalamin
defici
still
occur
anoth
limit
retrospect
design
previou
cobalamin
administr
refer
patient
studi
highlight
import
evalu
patient
hypercobalaminemia
warn
sign
requir
exclus
underli
patholog
disclosur
disclosur
report
bodi
condit
score
bc
commonli
use
system
assess
nutrit
statu
dog
estim
bodi
fat
store
subject
visual
inspect
palpat
accuraci
reliabl
howev
inher
limit
better
assess
overal
bodi
condit
previous
develop
bc
palpat
model
help
visual
inspect
part
process
morphometr
method
estim
percent
bodi
fat
develop
howev
method
appli
breed
purpos
present
studi
therefor
develop
clinic
feasibl
new
morphometr
method
assess
bodi
condit
dog
dog
vari
bc
use
percent
bodi
fat
determin
deuterium
oxid
dilut
method
follow
three
length
measur
use
ruler
episternum
ischial
tuberos
b
cranial
angl
scapula
base
tail
c
cranial
angl
scapula
sacral
tuber
ilium
bodi
fat
percentag
adopt
ideal
bodi
fat
percentag
bc
scale
defin
ideal
bodi
weight
ibw
current
bodi
weight
bw
follow
bc
bw
bc
bw
ibw
bc
bw
ibw
bc
bw
ibw
bc
bw
ibw
correl
bodi
length
ibw
examin
pearson
correl
coeffici
test
high
correl
found
ibw
three
measur
posit
correl
coeffici
ibw
bodi
length
measur
b
c
respect
use
posit
bodi
length
sinc
highest
correl
coeffici
found
posit
ibw
regress
express
use
regress
equat
measur
posit
estim
ibw
dog
bodi
length
exampl
ibw
dog
bodi
length
would
dog
current
bw
time
ibwthi
give
us
bc
method
tri
sever
clinic
veterinarian
repli
method
ident
well
match
result
convent
bc
assess
disclosur
disclosur
report
electrocardiographi
ventricular
mean
electr
axi
mea
defin
averag
direct
myocardi
activ
vector
ventricular
depolar
dog
refer
interv
mea
frontal
plane
mea
valu
influenc
shape
thorax
sinc
dog
vertic
cardiac
axi
compar
broad
chest
dog
breed
differ
ecg
valu
describ
previou
studi
aim
studi
evalu
mea
healthi
doberman
pinscher
describ
normal
refer
rang
breed
hypothes
healthi
doberman
left
shift
mea
base
standard
valu
retrospect
multicent
observ
studi
dog
includ
consid
healthi
base
histori
physic
examin
chest
echocardiographi
standard
surfac
ecg
exclus
criteria
consist
cardiac
system
diseas
mea
calcul
use
isoelectr
lead
method
mea
less
defin
left
shift
mea
greater
right
shift
morpholog
qr
complex
lead
ii
also
analys
total
healthi
doberman
pinscher
includ
femal
male
mean
age
year
median
mea
rang
mea
deviat
dog
dog
mea
deviat
present
left
axi
deviat
median
valu
rang
influenc
sex
bodi
weight
mea
detect
dog
older
year
signific
left
axi
deviat
comparison
younger
dog
regard
qr
complex
morpholog
dog
qr
morpholog
qr
morpholog
qr
morpholog
qr
morpholog
qr
morpholog
qr
morpholog
among
dog
show
left
axi
deviat
dog
qr
qr
morpholog
refer
rang
mea
doberman
pinscher
differ
gener
canin
popul
signific
number
healthi
dog
present
left
shift
mea
base
standard
valu
especi
older
dog
mani
dog
mea
deviat
show
deep
q
wave
lead
ii
data
consid
electrocardiograph
evalu
perform
breed
disclosur
disclosur
report
accord
american
heart
associ
guidelin
exercis
reduc
mortal
hospit
readmiss
improv
symptom
qualiti
life
current
inform
effect
exercis
manag
myxomat
mitral
valv
diseas
dog
limit
studi
aim
evalu
effect
structur
exercis
program
sedentari
dog
asymptomat
myxomat
mitral
valv
diseas
fifteen
indoor
dog
six
control
nine
exercis
group
asymptomat
myxomat
mitral
valv
diseas
acvim
stage
includ
thorough
physic
examin
routin
blood
arteri
systol
blood
pressur
measur
later
ventrodors
thorac
radiographi
electrocardiographi
echocardiographi
perform
exclud
cardiac
system
diseas
owner
exercis
group
instruct
certifi
canin
rehabilit
therapist
guid
dog
exercis
program
exercis
protocol
combin
aerob
resist
exercis
level
low
moder
intens
interv
train
owner
control
group
instruct
maintain
dog
usual
routin
dog
qualiti
life
scale
appetit
demeanor
exercis
toler
faint
respiratori
effort
cough
nocturn
dyspneacough
walk
test
chest
radiograph
electrocardiograph
echocardiograph
examin
assess
everi
two
month
six
month
multipl
multivari
model
repeat
measur
use
multipl
comparison
exercis
studi
subject
group
vertebr
heart
sum
echocardiograph
variabl
fraction
shorten
left
ratio
show
signific
differ
control
exercis
group
exercis
intervent
day
control
vh
fs
laao
exercis
vh
fs
laao
six
month
exercis
qualiti
life
score
significantli
decreas
exercis
group
p
control
group
day
day
walk
distanc
significantli
increas
exercis
group
p
control
group
day
day
conclud
structur
exercis
program
sedentari
dog
asymptomat
myxomat
mitral
valv
diseas
program
may
improv
qualiti
life
without
impair
select
radiograph
echocardiograph
paramet
disclosur
disclosur
report
mean
electr
axi
mea
qr
complex
averag
instantan
mean
electr
vector
occur
sequenti
ventricular
depolar
rang
healthi
dog
human
indetermin
qr
axi
iqr
axi
defin
imposs
calcul
mea
qr
due
biphas
complex
equal
nearli
equal
posit
neg
compon
six
limb
lead
iqr
axi
rare
condit
human
occur
mea
perpendicular
frontal
plane
human
iqr
axi
found
healthi
subject
patient
ventricular
hypertrophi
aim
studi
describ
preval
iqr
axi
dog
look
associ
iqr
age
bodi
weight
thorac
morphotyp
well
presenc
cardiac
diseas
standard
ecg
retrospect
analys
clinic
databas
istituto
veterinario
novara
mea
qr
complex
calcul
isoelectr
lead
method
total
dog
includ
iqr
axi
identifi
dog
overal
preval
among
dog
present
iqr
axi
abnorm
remain
dog
sever
right
ventricular
enlarg
secondari
pulmon
stenosi
tricuspid
valv
dysplasia
among
healthi
dog
present
iqr
axi
thorac
morphotyp
signific
differ
found
dog
without
iqr
axi
regard
age
year
rang
year
versu
year
rang
year
bodi
weight
kg
rang
kg
versu
kg
rang
kg
conclus
iqr
axi
rare
condit
dog
seem
frequent
dog
thorac
morphotyp
vertic
cardiac
axi
perpendicular
frontal
plane
might
reason
iqr
axi
addit
accord
result
right
ventricular
enlarg
might
caus
iqr
axi
studi
need
better
identifi
associ
iqr
axi
cardiac
diseas
dog
disclosur
disclosur
report
natriuret
peptid
biomark
cardiac
stretch
best
characteris
indic
measur
dog
cat
differenti
cardiac
caus
respiratori
distress
indic
includ
prognost
screen
cardiomyopathi
cardiac
diseas
monitor
aim
studi
investig
clinic
sign
associ
measur
record
veterinarian
free
text
clinic
narr
cn
electron
health
record
ehr
dog
cat
present
veterinari
practic
small
anim
veterinari
surveil
network
savsnet
great
britain
cn
individu
appoint
includ
dog
cat
evalu
veterinari
practic
across
england
wale
april
may
reason
measur
categoris
follow
diseas
investig
diseas
monitor
discount
laboratori
promot
unknown
reason
measur
state
key
phrase
extract
use
simpl
text
filter
base
keyword
cn
patient
determin
clinic
sign
associ
measur
measur
dog
categoris
investig
monitor
discount
unknown
investig
heart
murmur
commonli
report
clinic
sign
sign
commonli
accompani
murmur
investig
cough
exercis
intoler
pant
cough
report
dog
murmur
arrhythmia
investig
follow
infrequ
report
tachypnoea
n
dyspnoea
lethargi
discomfort
unspecifi
malais
gag
retch
test
sole
state
reason
measur
dog
measur
cat
categoris
investig
monitor
unknown
investig
heart
murmur
commonli
report
clinic
sign
follow
infrequ
report
dyspnoea
weight
loss
tachypnoea
lethargi
cn
analysi
ehr
allow
summaris
motiv
measur
first
opinion
practic
investig
heart
murmur
appear
common
reason
measur
dog
cat
measur
commonli
use
diseas
monitor
either
dog
cat
despit
best
characteris
indic
rare
measur
dog
cat
present
tachypnoea
dyspnoea
disclosur
disclosur
report
studi
fund
grant
univers
bristol
veterinari
school
dr
hezzel
previous
receiv
research
fund
idexx
laboratori
inc
myxomat
mitral
valv
diseas
mmvd
common
heart
diseas
dog
small
breed
amlodipin
calcium
channel
blocker
benefici
treatment
heart
failur
hf
due
arteri
vasodil
effect
advers
effect
patient
mmvd
unclear
aim
studi
evalu
advers
effect
amlodipin
treatment
dog
mmvd
stage
c
clinic
trial
random
studi
dog
receiv
convent
therapi
mmvd
stage
c
furosemid
spironolacton
enalapril
pimobendan
random
two
group
amlodipin
placebo
amlodipin
mean
dose
mgkg
day
dog
follow
month
clinic
assess
echocardiogram
measur
system
arteri
blood
pressur
sabp
serum
biochemistri
main
side
effect
amlodipin
hypotens
may
lead
increas
serum
creatinin
bun
therefor
advers
effect
amlodipin
assess
measur
systol
sabp
vascular
doppler
method
serum
creatinin
bun
systol
sabp
measur
first
day
treatment
amlodipin
placebo
seven
day
one
month
three
month
begin
treatment
serum
creatinin
bun
measur
time
present
time
alreadi
enrol
dog
studi
differ
systol
sabp
amlodipin
placebo
group
four
time
assess
p
differ
systol
sabp
placebo
group
among
four
time
p
amlodipin
group
present
signific
increas
systol
sabp
signific
decreas
dog
group
present
hypotens
systol
sabp
mmhg
four
time
evalu
creatinin
bun
serum
valu
nt
present
differ
amlodipin
group
p
result
observ
placebo
group
p
also
differ
creatinin
bun
valu
group
p
preliminari
result
show
amlodipin
use
dose
nt
induc
hypotens
decreas
systol
sabp
compar
placebo
group
nt
increas
serum
creatinin
bun
valu
seven
first
day
treatment
disclosur
disclosur
report
pulmonari
hypertens
ph
common
comorbid
dog
infect
angiostrongylu
vasorum
aim
present
descript
studi
assess
echocardiograph
chang
indic
ph
outcom
dog
treat
angiostrongylosi
dog
posit
idexx
bearmann
analysi
echocardiographi
perform
diagnosi
retrospect
includ
median
age
rang
treatment
echocardiographi
perform
dog
either
within
diagnosi
median
andor
median
tricuspid
regurgit
pressur
gradient
trpg
main
pulmonari
arteri
aorta
ratio
mpaao
right
pulmonari
vein
pulmonari
arteri
ratio
pvpa
right
pulmonari
distens
index
rpad
acceler
eject
time
ratio
pulmonari
flow
et
retrospect
measur
compar
time
use
mix
linear
model
dog
treat
fenbendazol
day
median
day
follow
moxidectin
addit
dog
receiv
cardiac
treatment
ph
includ
sildenafil
pimobendan
furosemid
signific
improv
pvpa
vs
vs
mpaao
et
observ
differ
signific
paramet
signific
chang
rpad
trpg
time
trpg
measur
dog
trpg
indic
absent
mild
moder
sever
ph
respect
dog
diagnosi
dog
includ
aliv
time
write
die
death
relat
diseas
individu
surviv
time
dog
day
median
day
diagnosi
ph
moder
sever
respect
individu
echocardiograph
paramet
improv
recheck
result
studi
demonstr
mortal
rate
among
dog
angiostrongylosi
underw
echocardiographi
diagnosi
seem
associ
persist
moder
sever
ph
gener
improv
indirect
paramet
ph
note
recheck
despit
signific
differ
trpg
disclosur
disclosur
report
atrial
fibril
af
common
heart
rhythm
disturb
associ
poor
prognosi
outcom
encount
clinic
practic
dog
structur
electr
remodel
atria
well
known
factor
facilit
initi
mainten
af
littl
known
role
oxid
stress
process
uric
acid
ua
termin
enzymat
product
purin
metabol
human
serum
ua
level
strongli
correl
cardiovascular
risk
factor
includ
risk
atrial
fibril
also
consid
marker
increas
oxid
stress
via
xanthin
oxidas
pathway
purpos
studi
investig
concentr
uric
acid
serum
dog
advanc
chronic
heart
failur
dog
atrial
fibril
healthi
control
dog
complet
clinic
echocardiograph
examin
enrol
studi
fast
blood
sampl
collect
diagnost
purpos
sent
commerci
veterinari
laboratori
cbc
gener
biochemistri
includ
serum
uric
acid
concentr
evalu
dog
normal
kidney
liver
function
assign
chronic
heart
failur
group
chf
group
dog
chf
af
group
chfaf
group
dog
control
group
dog
analysi
follow
dunn
multipl
comparison
test
appli
test
statist
signific
differ
group
serum
ua
concentr
chfaf
group
median
rang
significantli
higher
chf
group
median
rang
control
group
median
rang
p
roc
analysi
ua
area
curv
point
associ
sensit
specif
respect
result
studi
suggest
af
dog
associ
increas
oxid
stress
via
xanthin
oxidas
pathway
moreov
serum
ua
level
could
potenti
biomark
af
dog
studi
support
innowacyjni
doktorat
phd
research
grant
wroclaw
univers
environment
life
scienc
grant
disclosur
disclosur
report
oxid
stress
imbal
product
endogen
reactiv
oxygen
speci
antioxid
defenc
import
contributori
factor
develop
progress
numer
cardiovascular
diseas
littl
known
role
oxid
stress
hypertroph
cardiomyopathi
hcm
common
heart
diseas
cat
therefor
studi
aim
evalu
activ
superoxid
dismutas
sod
catalas
cat
glutathion
peroxidas
gpx
serum
total
antioxid
capac
tac
plasma
cat
symptomat
asymptomat
hypertroph
cardiomyopathi
healthi
control
thirti
cat
complet
clinic
echocardiograph
examin
doppler
systol
blood
pressur
mmhg
normal
creatinin
thyroxin
concentr
enrol
studi
sampl
collect
diagnost
purpos
research
materi
appropri
excess
need
diagnost
patient
assign
clinic
hcm
group
hcm
asymptomat
hcm
group
control
group
activ
oxid
stress
enzym
plasma
tac
determin
use
commerci
avail
assay
kit
test
normal
test
data
analyz
group
anova
follow
tukey
post
test
analysi
follow
post
hoc
dunn
multipl
comparison
test
assess
statist
signific
differ
statist
signific
differ
among
group
respect
age
weight
sex
ratio
group
consist
variou
cat
breed
serum
sod
activ
significantli
lower
hcm
group
mean
uml
group
mean
uml
compar
healthi
control
mean
uml
p
serum
cat
activ
significantli
lower
group
mean
nmolminml
compar
hcm
group
mean
nmolminml
healthi
control
mean
nmolminml
p
signific
differ
serum
activ
gpx
plasma
tac
group
serum
sod
activ
correl
cat
activ
p
increas
oxid
stress
symptomat
asymptomat
hcm
cat
evid
base
statist
signific
decreas
serum
sod
cat
activ
cat
activ
also
tend
lower
symptomat
cat
compar
healthi
control
although
reach
signific
studi
support
innowacyjni
doktorat
phd
research
grant
wroclaw
univers
environment
life
scienc
grant
disclosur
disclosur
report
ambient
air
pollut
found
increas
cardiovascular
risk
mani
human
epidemiolog
studi
howev
littl
known
risk
pet
dog
aim
studi
investig
associ
environment
factor
cardiovascular
diseas
dog
live
indoor
lifestyl
retrospect
studi
conduct
dog
physic
examin
blood
pressur
measur
clinic
inform
thorac
radiographi
echocardiographi
andor
previou
diagnosi
obtain
medic
record
use
determin
presenc
absenc
cardiovascular
diseas
environment
inform
dog
household
presenceabs
indoor
air
pollut
ambient
temperatur
household
humid
obtain
databas
previou
project
involv
indoor
air
pollut
survey
dog
cardiovascular
diseas
chronic
valvular
heart
diseas
pulmonari
hypertent
aortic
insuffici
arrhythmia
borderlinesustain
system
hypertens
control
dog
compar
except
household
humid
vs
p
exposur
sever
indoor
air
pollut
smoke
p
cook
fume
p
incens
burn
p
averag
concentr
pet
hous
p
ambient
temperatur
p
statist
differ
dog
without
cardiovascular
diseas
among
signal
factor
dog
cardiovascular
diseas
significantli
older
p
like
overweight
bc
p
control
dog
multivari
logist
regress
analysi
show
age
adjust
p
overweight
adjust
p
associ
increas
risk
cardiovascular
diseas
dog
conclus
associ
environment
hazard
cardiovascular
diseas
found
pet
dog
disclosur
disclosur
report
studi
support
ministri
scienc
technolog
taiwan
longitudin
right
ventricular
rv
function
estim
deform
variabl
strain
strain
rate
evalu
speckl
track
echocardiographi
ste
healthi
dog
dog
myxomat
mitral
valv
diseas
mmvd
dog
pulmonari
hypertens
ph
therefor
evalu
longitudin
rv
strain
strain
rate
dog
ph
acquir
echocardiograph
cineloop
left
apic
view
optim
rv
analyz
longitudin
rv
strain
strain
rate
dog
healthi
dog
mmvd
dog
without
ph
dog
ph
use
xstraintm
softwar
dog
ph
classifi
base
tricuspid
regurgit
tr
jet
veloc
msec
degre
mmvd
healthi
dog
strain
rate
show
moder
neg
relationship
heart
rate
weak
posit
relationship
bodi
weight
strain
show
relationship
heart
rate
bodyweight
strain
strain
rate
show
weak
posit
relationship
la
ao
mmvd
dog
without
ph
strain
strain
rate
show
strong
posit
relationship
tr
veloc
dog
ph
tr
veloc
retain
multivari
model
predict
strain
strain
rate
dog
ph
heart
rate
bodyweight
la
ao
exclud
strain
strain
rate
show
good
sensit
modest
specif
identifi
sever
ph
data
suggest
longitudin
rv
deform
analysi
use
ste
identifi
dog
sever
ph
bodi
weight
heart
rate
mmvd
influenc
strain
strain
rate
valu
care
consid
dog
ph
disclosur
disclosur
report
degen
mitral
valv
diseas
dmvd
common
acquir
heart
diseas
dog
result
poor
apposit
mitral
valv
mv
leaflet
systol
lead
mv
regurgit
clinic
detect
left
apic
systol
heart
murmur
intens
classic
classifi
accord
scheme
past
studi
shown
increas
heart
murmur
intens
time
associ
worsen
dmvd
lesion
thrill
murmur
tm
ie
grade
vvi
vivi
associ
sever
diseas
object
retrospect
studi
character
epidemiolog
clinic
echocardiograph
featur
dog
tm
relat
dmvd
identifi
paramet
associ
surviv
case
record
dog
kg
diagnos
tm
relat
dmvd
review
studi
popul
consist
dog
median
age
detect
year
repres
breed
cavali
king
charl
spaniel
yorkshir
terrier
poodl
chihuahua
dog
concurr
hemodynam
compromis
system
cardiac
diseas
therefor
exclud
subsequ
analysi
accord
acvim
classif
stage
stage
c
stage
chorda
tendinea
ruptur
identifi
includ
dog
sever
pulmonari
hypertens
systol
pulmonari
arteri
pressur
mmhg
tachyarrhythmia
regurgit
fraction
rf
assess
use
pisa
method
dog
median
consist
moder
sever
mv
regurgit
among
dog
avail
die
death
cardiac
origin
cd
median
time
cd
month
diagnosi
univari
analys
reveal
rf
left
atrium
aorta
left
ventricular
dilat
acvim
stage
presenc
arrhythmia
collaps
significantli
associ
time
cd
dog
acvim
stage
b
median
time
decompens
month
median
time
cd
month
versu
dog
stage
c
conclus
studi
confirm
dog
tm
relat
dmvd
includ
dog
acvim
stage
b
usual
sever
form
diseas
major
dog
present
chorda
tendinea
ruptur
pulmonari
hypertens
sever
mv
regurgit
disclosur
disclosur
report
c
poissonni
fondat
un
coeur
vetoquinol
sponsor
clinic
project
unrel
studi
atrial
fibril
af
common
canin
cardiac
arrhythmia
left
atrial
appendag
thrombu
develop
associ
risk
thromboembol
common
complic
af
human
largescal
studi
investig
incid
thromboembol
diseas
dog
af
aim
retrospect
studi
identifi
evid
thromboembol
event
dog
diagnos
af
whether
affect
outcom
twenti
one
dog
includ
studi
follow
assess
cardiologist
enrol
criteria
requir
dog
diagnosi
af
confirm
electrocardiographi
direct
indirect
evid
thrombu
format
thromboembol
event
identifi
individu
case
base
analysi
clinic
note
diagnost
investig
statist
test
includ
unpair
student
mann
whitney
anova
test
signific
set
p
intracardiac
mass
consist
thrombi
identifi
echocardiograph
dog
case
clinic
sign
potenti
attribut
thromboembol
diseas
identifi
dog
case
howev
case
intracardiac
thrombu
detect
echocardiographi
associ
presenc
thrombu
gender
type
af
lone
vs
af
secondari
structur
heart
diseas
antiarrhythm
treatment
therapi
institut
four
case
three
case
thrombi
confirm
echocardiographi
receiv
clopidogrel
two
euthanas
due
progress
refractori
congest
heart
failur
third
die
natur
unknown
caus
fourth
case
receiv
aspirin
follow
suspect
thromboembol
event
neurolog
sign
consist
central
vascular
accid
cva
dog
still
aliv
time
studi
case
circumst
time
death
known
four
dog
die
suspect
thromboembol
signific
associ
identifi
median
age
time
death
median
surviv
time
af
diagnosi
dog
suffer
thromboembol
complic
compar
without
suggest
limit
impact
outcom
conclus
studi
found
thrombi
thromboembol
event
dog
diagnos
af
infrequ
although
low
sensit
screen
method
use
may
underestim
frequenc
thrombi
given
confirm
thromboembol
complic
dog
af
work
requir
understand
differ
factor
influenc
hypercoagul
thrombu
format
dog
human
disclosur
disclosur
report
sever
studi
perform
order
find
best
function
test
clinic
monitor
dog
hyperadrenocortic
hac
trilostan
therapi
despit
controversi
acth
stimul
test
one
therapeut
tool
current
use
purpos
use
exogen
acth
tetracosactid
adren
reserv
stimul
estim
maxim
administr
howev
acth
wide
avail
europ
sever
countri
depot
formul
purchas
author
knowledg
one
studi
evalu
acth
depot
conclud
better
stimul
adren
reserv
dog
hac
blood
peak
cortisol
drawn
post
stimul
acth
instead
use
convent
protocol
date
littl
known
use
acth
depot
dog
trilostan
therapi
studi
aim
assess
whether
blood
cortisolemia
higher
rather
stimul
acth
depot
dog
hac
trilostan
therapi
prospect
studi
perform
includ
dog
hac
trilostan
therapi
acth
stimul
test
perform
morn
pill
use
depot
formul
administ
intramuscularli
blood
sampl
basal
cortisol
stimul
statist
analysi
perform
use
test
friedman
test
wilcoxon
pair
sampl
eight
dog
enrol
mean
level
cortisol
respect
differ
cortisolemia
among
three
time
point
statist
signific
cortisol
level
significantli
higher
compar
studi
confirm
cortisolemia
higher
rather
stimul
acth
depot
dog
hac
trilostan
therapi
result
agreement
previous
publish
concern
use
compound
diagnosi
hac
suspect
case
probabl
due
longer
action
formul
consequ
latter
stimul
adren
reserv
compar
acth
summari
acth
depot
use
assess
adren
function
dog
hac
trilostan
therapi
acth
stimul
test
protocol
adapt
cortisol
level
measur
instead
stimul
disclosur
fund
project
ciisa
ioniz
calcium
measur
readili
avail
practic
total
calcium
tca
may
reliabl
indic
calcium
statu
cat
object
studi
predict
ioniz
calcium
cat
biochem
panel
valu
compar
diagnost
perform
predict
ioniz
calcium
pica
tca
cat
ioniz
calcium
biochemistri
panel
measur
perform
within
screen
year
case
complet
biochem
profil
avail
includ
train
set
cat
use
creat
multivari
adapt
regress
spline
model
calcul
pica
diagnost
perform
tca
pica
predict
interv
pi
compar
cat
includ
train
set
final
model
includ
creatinin
bun
albumin
tca
potassium
chlorid
cholesterol
age
bodi
condit
score
independ
variabl
hypercalcemia
pica
significantli
specif
specif
p
less
sensit
sensit
p
tca
howev
upper
limit
pi
sensit
tca
p
hypocalcemia
pica
also
significantli
specif
specif
p
less
sensit
sensit
p
tca
lower
limit
pi
sensit
tca
p
conclus
pica
may
help
confirm
suspect
hypercalcemia
cat
owe
high
specif
pi
may
use
screen
hypercalcemia
hypocalcemia
owe
high
sensit
disclosur
disclosur
report
hypoglycaemia
report
healthi
dog
goal
studi
determin
healthi
work
dog
experi
hypoglycaem
episod
night
appar
healthi
new
zealand
work
huntaway
dog
median
age
year
iqr
rang
fit
continu
blood
glucos
monitor
read
per
hour
day
time
dog
work
accord
usual
regimen
fed
complet
balanc
diet
daili
nocturn
hypoglycaemia
consid
serum
glucos
mmoll
point
nine
dog
median
age
year
iqr
rang
experienc
median
iqr
rang
hypoglycaem
episod
median
total
read
iqr
rang
dog
experienc
median
iqr
rang
sever
hypoglycaem
episod
median
total
read
iqr
rang
dog
glucos
night
respect
wherea
dog
glucos
night
respect
one
dog
glucos
second
dog
glucos
glucos
read
mmoll
respect
knowledg
first
studi
document
episod
nocturn
hypoglycaemia
appar
healthi
dog
find
suggest
episod
nocturn
hypoglycaemia
may
normal
physiolog
phenomenon
dog
disclosur
disclosur
report
frequent
appli
treatment
hyperthyroid
cat
oral
administ
drug
current
studi
evalu
compar
treatment
success
differ
thioamid
prepar
retrospect
studi
treatment
outcom
hyperthyroid
cat
evalu
cat
either
treat
oral
drug
methimazol
carbimazol
retard
carbimazol
licens
use
human
chm
data
concern
signal
age
gender
breed
concurr
diseas
number
dose
adjust
time
period
euthyroid
state
reach
occurr
advers
effect
surviv
time
caus
death
evalu
cat
compar
treatment
group
signific
differ
found
analys
paramet
three
group
advers
effect
frequent
observ
includ
gastrointestin
sign
cytopenia
facial
excori
increas
liver
enzym
group
group
chm
group
treat
cat
develop
advers
effect
median
surviv
time
day
day
day
chm
group
paramet
influenc
surviv
time
presenc
chronic
renal
diseas
crd
prior
therapi
cat
significantli
shorter
surviv
time
day
compar
cat
crd
occur
therapi
day
cat
without
crd
day
conclus
three
antithyroid
drug
equal
effect
treatment
felin
hyperthyroid
presenc
crd
prior
treatment
import
prognost
paramet
disclosur
disclosur
report
trilostan
current
medic
treatment
choic
hyperadrenocortic
dog
iatrogen
hypoadrenocortic
consid
infrequ
case
transient
case
perman
hypoadrenocortic
describ
adrenocort
necrosi
suspect
base
examin
adren
chang
ultrasonographi
goal
studi
report
find
case
iatrogen
hypoadrenocortic
follow
treatment
trilostan
hyperadrenocortic
medic
record
dog
treat
trilostan
sinc
review
dog
includ
clinic
sign
suggest
hypoadrenocortic
compat
acth
stimul
test
result
andor
serum
electrolyt
abnorm
case
consid
perman
long
term
treatment
hypoadrenocortic
requir
ten
dog
met
inclus
criteria
male
femal
age
rang
year
nine
dog
suspect
hyperadrenocortic
clinic
sign
time
hypoadrenocortic
diagnosi
lethargi
anorexia
vomit
diarrhea
tremor
time
begin
trilostan
treatment
hypoadrenocortic
occurr
rang
day
month
trilostan
dose
rang
mgkgday
five
dog
suspicion
concurr
infecti
diseas
time
hypoadrenocort
diagnosi
sodiumpotassium
ratio
dog
dog
dog
acth
stimul
test
perform
cortisol
concentr
trilostan
dosag
decreas
case
trilostan
withdrawn
case
without
relaps
clinic
sign
hyperadrenocortic
dog
die
time
diagnosi
glucocorticoid
mineralocorticoid
supplement
prescrib
case
three
dog
lost
diagnosi
perman
hypoadrenocortic
adren
gland
ultrasonogaphi
dog
show
progress
reduct
gland
size
heterogen
echogen
iatrogen
hypoadrenocortic
also
rare
popul
case
identifi
year
dose
durat
treatment
variabl
one
dog
die
least
suffer
perman
hypoadrenocortic
progress
adren
chang
ultrasonographi
seen
case
perman
hypoadrenocortic
suspicion
concomit
infect
half
case
hypoadrenocortic
occurr
interest
find
impair
abil
synthes
cortisol
respons
infect
might
trigger
clinic
sign
appear
dog
previous
subclin
hypoadrenocortic
disclosur
disclosur
report
combin
measur
total
free
use
cat
clinic
suspicion
hyperthyroid
normal
mildli
increas
moreov
measur
play
essenti
role
monitor
hyperthyroid
cat
treatment
although
measur
consid
gold
standard
time
consum
expens
wide
avail
measur
time
cost
effect
studi
assess
accuraci
scarc
object
studi
correl
measur
free
equilibrium
dialysi
antech
diagnost
irvin
ca
usa
veterinari
free
siemen
healthcar
diagnost
product
ltd
lanberi
gwynedd
uk
cat
one
month
treatment
consist
lower
median
differ
p
spearman
correl
respect
within
refer
interv
respect
refer
interv
refer
interv
respect
cat
within
refer
interv
decreas
base
classifi
suboptim
thyroid
function
within
refer
interv
take
consist
lower
valu
good
correl
two
techniqu
consider
adapt
current
refer
interv
measur
ceia
could
justifi
routin
use
assay
determin
disclosur
disclosur
report
financi
relationship
studi
support
idexx
laboratori
inc
felin
diabet
mellitu
relat
sever
alter
especi
cat
diabet
ketoacidosi
dka
electrolyt
unbal
frequent
mainli
hypokalemia
howev
role
hypokalemia
diabet
cat
diagnosi
unknown
aim
studi
calcul
preval
hypokalemia
cat
diagnos
diabet
mellitu
dm
evalu
relat
potassium
plasma
blood
level
pbl
clinic
paramet
first
visit
adequ
dosag
oral
potassium
supplement
hypokalem
cat
return
normal
refer
rang
nrr
also
evalu
cat
diagnos
dm
without
dka
veterinari
teach
hospit
complutens
includ
age
sex
reproduct
statu
weight
bodi
condit
score
bc
pbl
systol
blood
pressur
sbp
concurr
diseas
presenc
neuropathi
previou
corticosteroid
administr
record
hypokalem
cat
oral
potassium
supplement
time
need
return
pbl
nrr
also
record
data
analys
use
spss
program
statist
signific
set
age
rang
year
year
femal
male
neuter
bodi
weight
vari
kg
kg
accord
bc
anim
classifi
cat
cat
cat
pbl
rang
fifteen
cat
consid
hypokalem
pbl
sbp
rang
associ
pbl
differ
paramet
evalu
observ
sbp
significantli
higher
hypokalem
mmhg
normokalem
patient
mmhg
describ
human
medicin
eight
hypokalem
patient
avail
six
treat
oral
supplement
potassiun
glucon
potassium
glucohepton
receiv
supplement
treatment
due
owner
reject
time
normal
pbl
rang
day
mean
neg
correl
rho
initi
oral
potassium
supplement
dose
medium
dose
requir
normal
bpl
potassium
glucon
potassium
glucohepton
hypokalemia
occur
non
dka
diabet
cat
relat
system
hypertens
signific
reduct
sbp
increas
dietari
potassium
demonstr
human
oral
potassium
supplement
high
dose
cat
dm
might
use
safe
tool
manag
hypokalemia
system
hypertens
disclosur
disclosur
report
trilostan
drug
frequent
use
dog
diagnos
pdh
dosag
recommend
variabl
amongst
literatur
object
studi
assess
evolut
trilostan
dosag
td
dog
pdh
relationship
clinic
variabl
dog
natur
occur
pdh
initi
treat
low
dose
trilostan
rang
includ
td
adjust
base
clinic
sign
result
acth
stimul
test
hour
recheck
perform
day
thereaft
everi
month
sever
paramet
age
sex
clinic
laboratori
find
concurr
diseas
clinic
sign
diagnosi
evalu
relat
evolut
td
dog
divid
two
group
accord
initi
td
sex
age
clinic
laboratori
find
concurr
diseas
significantli
differ
group
p
dog
need
increas
td
need
decreas
maintain
initi
dosag
among
dog
td
modifi
need
singl
adjust
sever
diabet
dog
pdh
need
increas
td
compar
dog
signific
differ
observ
group
regard
td
adjust
one
year
adequ
control
hac
obtain
dog
dosag
time
sd
correl
initi
td
percentag
variat
initi
final
dose
obtain
dog
rang
significantli
differ
group
group
group
b
basal
cortisol
bodi
condit
score
diagnosi
posit
correl
td
one
year
dog
pant
diagnosi
need
proport
higher
increas
td
despit
statist
signific
use
low
dosag
trilostan
treatment
dog
pdh
td
need
adjust
pdh
case
dog
dm
higher
basal
cortisol
diagnosi
andor
elev
bodi
condit
score
like
need
increas
td
disclosur
disclosur
report
royal
canin
kindli
support
research
hyperadrenocortic
veterinari
teach
hospit
complutens
hyperadrenocortic
hac
common
endocrin
diseas
dog
character
chronic
endogen
cortisol
excess
result
progress
deterior
untreat
patient
object
studi
assess
median
surviv
time
mst
dog
hac
diagnosi
potenti
relationship
age
sex
type
hac
adren
adh
pituitari
pdh
concurr
diseas
systol
blood
pressur
bodi
condit
score
bc
clinic
laboratori
find
diagnosi
newli
diagnos
dog
hac
januari
decemb
veterinari
teach
hospit
complutens
includ
diagnosi
hac
base
clinic
laboratori
abnorm
adren
function
test
accord
acvim
guidelin
four
dog
previous
misdiagnos
hypothyroid
treatment
discontinu
dog
initi
treat
trilostan
recheck
perform
everi
month
surviv
analysi
caus
death
includ
kaplan
meier
curv
test
obtain
variabl
review
time
studi
closur
dog
aliv
one
dog
lost
overal
mst
dog
aliv
respect
mst
dog
diagnos
pdh
higher
adh
respect
bc
correl
surviv
dog
bc
lower
mst
dog
bc
obes
dog
dog
calcinosi
cuti
diagnosi
mst
live
shorter
without
age
p
cortisol
concentr
diagnosi
neg
correl
surviv
use
multivari
model
age
diagnosi
adh
hr
iatrogen
hyperthyroid
calcinosi
cuti
neg
correl
surviv
whilst
bc
posit
correl
surviv
present
studi
surviv
time
dog
pdh
slightli
higher
previous
report
dog
adh
reduc
surviv
probabl
due
presenc
metastas
diagnosi
dog
age
cortisol
neg
correl
surviv
previous
report
knowledg
first
time
reduc
bc
presenc
calcinosi
cuti
iatrogen
hyperthyroid
report
poor
prognost
factor
hac
disclosur
disclosur
report
royal
canin
kindli
support
research
hyperadrenocortic
veterinari
teach
hospit
complutens
canin
b
cell
neoplasm
insulinoma
frequent
neuroendocrin
tumor
pancrea
secret
excess
amount
insulin
lead
hypoglycemia
subsequ
clinic
sign
human
multitarget
tyrosin
kinas
inhibitor
sunitinib
proven
efficaci
patient
pancreat
neuroendocrin
tumor
anecdot
report
suggest
antitumor
activ
toceranib
phosphat
dog
insulinoma
aim
studi
evalu
efficaci
safeti
tyrosin
kinas
inhibitor
toceranib
dog
insulinoma
stage
iii
iv
eighteen
dog
diagnos
insulinoma
veterinari
teach
hospit
complutens
madrid
includ
diagnosi
base
clinic
sign
serum
glucos
insulin
level
abdomin
ultrasonographi
au
comput
tomographi
ct
insulinoma
classifi
tnm
stage
system
european
neuroendocrin
tumor
societi
enet
dog
surgic
medic
treat
depend
clinic
stage
follow
death
efficaci
medic
treatment
base
recist
criteria
diagnosi
dog
classifi
stage
ii
iii
iv
dog
stage
iii
underw
pancreatectomi
remain
refus
surgic
procedur
dog
recurr
tumor
observ
follow
total
dog
stage
iiiiv
diagnosi
surgeri
treat
palli
treatment
control
toceranib
phosphat
toceranib
phosphat
palli
treatment
consist
diet
exercis
restrict
prednison
octreotid
dog
tg
receiv
addit
toceranib
phosphat
mean
dosag
dog
stage
iii
surgic
treat
recurr
occur
median
surviv
time
df
remain
dog
recurr
observ
death
among
dog
stage
iiiiv
median
overal
surviv
time
ost
tg
significantli
higher
median
ost
dog
cg
tg
stabl
diseas
partial
respons
observ
day
treatment
toceranib
phosphat
maintain
progress
diseas
sever
advers
effect
occur
grade
gastrointestin
sign
occur
initi
week
grade
month
caus
treatment
withdraw
toceranib
phosphat
might
role
treatment
dog
insulinoma
stage
iiiiv
increas
surviv
dog
provid
adequ
qualiti
life
disclosur
disclosur
report
diabet
mellitu
disord
persist
hyperglycemia
induc
seri
underli
caus
one
common
endocrin
diseas
diagnos
cat
variabl
preval
worldwid
rang
cat
extens
research
aspect
felin
diabet
mellitu
diagnosi
etiopathophysiolog
therapi
etc
led
larg
amount
data
thu
motiv
research
develop
artifici
neural
network
use
predict
glucos
concentr
felin
diabet
mellitu
studi
data
obtain
diabet
cat
undergo
routin
blood
glucos
monitor
insulin
treatment
continu
glucos
monitor
perform
cgm
sensor
cat
follow
record
glucos
level
minut
sampl
period
number
unit
insulin
input
three
type
insulin
denot
b
c
use
food
intak
kcal
visual
inspect
data
reveal
patient
ideal
stabl
behavior
would
impli
mgdl
constraint
evolut
glucos
level
time
qualiti
data
statist
evalu
identifi
possibl
outlier
patient
popul
neural
base
method
bioscienc
prove
power
tool
transform
intellig
avail
inform
valuabl
knowledg
model
studi
consid
two
type
ann
perceptron
mlp
radial
basi
function
rbf
known
univers
approxim
bound
continu
function
train
data
network
built
ad
record
low
intercorrel
relev
entir
dataset
input
neural
vector
form
consid
adjust
lag
data
sampl
captur
dynam
behavior
model
process
neural
network
design
singl
hidden
layer
number
neuron
induct
experiment
tune
multipl
test
conduct
train
data
vari
patient
experiment
result
reveal
confid
type
ann
regardless
type
insulin
accuraci
perform
obtain
train
valid
dataset
prove
use
adopt
neural
network
vector
relev
dynam
glycem
evolut
felin
diabet
mellitu
result
suggest
predict
model
feasibl
establish
adjust
insulin
dose
improv
treatment
effect
increas
diabet
remiss
rate
consequ
obtain
better
qualiti
life
diabet
cat
disclosur
disclosur
report
human
medicin
liquid
chromatographi
tandem
mass
spectrometri
actual
consid
gold
standard
measur
mani
hormon
concentr
wide
use
clinic
practic
diagnost
perform
never
investig
dog
hypothyroid
dwh
aim
studi
determin
whether
serum
concentr
measur
abl
differenti
dwh
dog
ill
dnti
septic
dog
sd
healthi
dog
hd
hypothyroid
diagnos
base
consist
clinic
sign
laboratori
find
total
ctsh
concentr
refer
interv
ri
respect
dog
normal
ctsh
rhtsh
stimul
test
perform
confirm
diagnosi
dnti
hypothyroid
exclud
upon
neg
result
rhtsh
stimul
test
sd
diagnos
base
alter
temperatur
cardiac
respiratori
frequenc
differenti
leukocyt
count
protein
concentr
ri
hd
consid
healthi
upon
histori
physic
examin
hormon
evalu
perform
surplu
serum
store
ctsh
measur
use
valid
immunoassay
differ
consid
signal
age
bodi
weight
found
group
median
serum
concentr
significantli
higher
p
hd
compar
dnti
dwh
sd
median
serum
concentr
significantli
lower
dwh
dnti
compar
sd
p
respect
hd
p
respect
median
serum
concentr
significantli
lower
dwh
compar
sd
hd
median
serum
concentr
significantli
higher
dwh
compar
dnti
hd
differ
regard
median
serum
concentr
among
dog
four
group
use
roc
curv
analysi
differenti
dwh
dntisd
auc
obtain
respect
valu
better
discrimin
hypothyroid
sensit
ci
specif
ci
accuraci
ci
although
serum
shown
better
perform
serum
identifi
dwh
overlap
dwh
dntisd
unfortun
relev
also
thyroid
hormon
measur
despit
introduct
new
analyt
method
use
dynam
test
eg
rhtsh
stimul
test
remain
better
method
discrimin
dwh
dnti
disclosur
disclosur
report
flash
glucos
monitor
system
fgm
freestyl
libr
abbott
uk
recent
evalu
stabl
diabet
dog
aim
retrospect
studi
assess
perform
fgm
dog
diabet
ketoacidosi
dka
determin
effect
bodi
condit
score
bc
perfus
sever
ketosi
acidosi
accuraci
devic
fgm
place
clip
clean
area
dorsal
part
neck
dog
dka
within
hour
present
interstiti
glucos
measur
compar
blood
glucos
bg
measur
obtain
valid
portabl
glucomet
optium
xceed
abbott
uk
overal
accuraci
determin
fulfil
iso
criteria
calcul
mean
absolut
differ
mad
mean
absolut
rel
differ
mard
median
absolut
rel
differ
mard
mean
rel
differ
mrd
percentag
result
within
mgdl
bg
valu
glucos
mgdl
within
bg
valu
glucos
mgdl
clinic
accuraci
also
illustr
use
park
error
grid
plot
sensor
perform
chang
metabol
variabl
lactat
ph
bicarbon
evalu
use
spearman
rank
correl
four
hundr
pair
result
diabet
dog
dka
avail
analysi
good
agreement
interstiti
glucos
measur
bg
obtain
slope
mgdl
clinic
accuraci
fgm
demonstr
result
zone
result
zone
b
overal
mard
mard
mrd
percentag
valu
within
mgdl
low
glucos
rang
bg
mgdl
mad
mgdl
higher
glucos
rang
mgdl
mard
variat
lactat
ph
bicarbon
affect
sensor
perform
signific
interpati
variabl
accuraci
devic
observ
test
p
fgm
tend
overestim
glucos
level
dog
underestim
dog
despit
iso
requir
partial
fulfil
fgm
provid
clinic
accur
estim
bg
dog
dka
accuraci
system
appar
unaffect
metabol
variabl
make
suitabl
stabl
diabet
dog
also
dog
dka
disclosur
disclosur
report
pituitari
radiotherapi
rt
treatment
macroadenoma
induc
neurolog
complic
previou
studi
report
concurr
pituitari
depend
hyperadrenocortic
pdh
affect
outcom
dog
undergo
rt
howev
pdh
associ
multipl
comorbid
author
hypothesis
dog
pdh
would
poorer
surviv
without
pdh
retrospect
studi
recruit
dog
underw
pituitari
rt
singl
centr
signal
time
rt
tumour
characterist
rt
protocol
pdh
statu
record
dog
enrol
male
femal
median
age
year
iqr
dog
pdh
underw
definit
rt
median
tumour
size
sd
median
radiat
dose
gy
iqr
imag
avail
four
dog
experienc
tumour
volum
reduct
median
surviv
time
patient
without
pdh
iqr
iqr
day
respect
variabl
p
univari
cox
regress
analysi
gender
age
diagnosi
includ
multivari
analysi
assess
patient
characterist
associ
surviv
gender
remain
signific
male
hr
ci
male
femal
surviv
time
day
respect
rt
result
pituitari
tumour
reduct
four
patient
imag
tumour
characterist
patient
age
time
rt
pdh
statu
affect
outcom
gender
might
influenc
surviv
dog
undergo
pituitari
rt
disclosur
disclosur
report
system
hypertens
present
approxim
dog
hyperadrenocortic
hac
must
manag
independ
hac
manag
object
studi
compar
two
antihypertens
treatment
dog
hac
eleven
hypertens
dog
diagnos
hac
prospect
includ
vthc
madrid
systol
blood
pressur
sbp
assess
doppler
method
hypertens
defin
sbp
mmhg
dog
randomli
includ
group
telmisartan
group
tg
includ
dog
treat
initi
dose
daili
mgkg
daili
benazepril
group
bg
includ
dog
treat
initi
dose
daili
mgkg
twice
daili
group
amlodipin
ad
daili
sbp
remain
uncontrol
sbp
evalu
month
dog
evalu
one
week
adjust
antihypertens
medic
mean
initi
sbp
similar
tg
bg
tg
month
dog
need
telmisartan
dose
increas
daili
dog
achiev
good
control
initi
dose
month
dog
need
amlodipin
multitherapi
month
sbp
remain
control
telmisartan
monotherapi
tm
dog
multitherapi
amlodipin
maximum
dose
telmisartan
replac
benazepril
due
inadequ
sbp
control
month
amlodipin
ad
telmisartan
dog
remain
control
tm
month
dog
normotens
telmisartan
telmisartan
amlodipin
bg
month
dog
need
increas
frequenc
twice
daili
month
dog
adequ
sbp
control
whilst
need
multitherapi
amlodipin
month
dog
maintain
adequ
sbp
control
benazepril
monotherapi
whilst
dog
dosag
benazepril
increas
multitherapi
dog
amlodipin
dosag
also
increas
month
dog
need
increas
benazepril
amlodipin
dosag
sbp
control
dog
month
conclus
telmisartan
use
monotherapi
mean
dosag
daili
provid
good
sbp
control
dog
benacepril
mgkg
twice
daili
telmisartan
might
use
antihypertens
treatment
hypertens
dog
hac
better
control
obtain
benacepril
dose
propos
higher
dose
telmisartan
mustcan
assess
disclosur
disclosur
report
boehring
merial
financ
drug
owner
dog
includ
studi
mycoplasma
speci
readili
isol
healthi
dog
oropharyng
accept
commens
organ
oral
caviti
howev
pathogen
role
debat
lower
respiratori
tract
lrt
could
part
normal
flora
repres
oral
bacteri
contamin
perform
studi
compar
preval
mycoplasma
speci
dog
show
sign
lrt
diseas
healthi
control
studi
identifi
databas
mycoplasma
presenc
assess
pcr
cultur
perform
sampl
lrt
seroconvers
use
pair
sampl
qualiti
evid
rate
use
modifi
scale
stratifi
four
common
speci
mycoplasma
dog
cyno
spuman
cani
edwardii
report
retriev
initi
met
inclus
criteria
mycoplasma
cyno
significantli
preval
among
symptomat
dog
among
control
odd
ratio
confid
interv
ci
p
hand
presenc
cani
edwardii
significantli
associ
lrt
sign
ci
ci
respect
although
trend
detect
associ
spuman
presenc
lrt
sign
ci
associ
statist
signific
result
suggest
pathogen
role
mycoplasma
cyno
canin
lrt
diseas
oppos
mycoplasma
speci
primer
specif
cyno
pcr
perform
sampl
lrt
dog
disclosur
disclosur
report
canin
idiopath
pulmonari
fibrosi
cipf
progress
parenchym
lung
diseas
unknown
origin
poorli
understood
pathophysiolog
mainli
occur
old
west
highland
white
terrier
whwt
dog
whwt
breed
develop
cipf
suggest
involv
trigger
factor
onset
andor
progress
diseas
assess
potenti
trigger
onlin
survey
submit
whwt
owner
questionnair
access
period
differ
languag
english
french
dutch
distribut
whwt
owner
breeder
social
medial
email
question
divid
section
regard
owner
dog
clinic
diagnost
data
cipf
environ
hous
surround
compost
ventil
air
condit
humidif
asbestosi
smoke
household
mainten
groom
veterinari
care
vaccin
deworm
comorbid
complet
questionnair
receiv
whwt
owner
variou
countri
includ
princip
usa
australia
franc
uk
belgium
questionnair
discard
due
lack
essenti
data
result
total
amount
exploit
respons
concern
cipf
affect
whwt
median
age
report
cipf
diagnosi
year
rang
inspiratori
crackl
notic
dog
cipf
whwt
dead
time
questionnair
complet
overal
surviv
time
diagnosi
year
caus
death
case
order
assess
potenti
trigger
associ
cipf
cipf
dog
match
one
unaffect
whwt
age
univari
logist
regress
analysi
use
group
comparison
cipf
vs
ctrl
statist
signific
set
paramet
significantli
associ
cipf
includ
genet
relationship
anoth
dog
affect
cipf
live
old
hous
absenc
ventil
system
p
frequent
groom
dedic
facil
cipf
dog
increas
risk
cardiac
diseas
like
due
develop
secondari
pulmonari
hypertens
decreas
risk
endocrin
diseas
compar
ctrl
preliminari
result
survey
suggest
associ
cipf
genet
background
environment
factor
old
hous
groom
habit
analysi
result
questionnair
ongo
disclosur
disclosur
report
canin
idiopath
pulmonari
fibrosi
cipf
mimic
human
idiopath
pulmonari
fibrosi
ipf
affect
old
dog
west
highland
white
terrier
whwt
breed
due
difficulti
diagnos
earli
follow
cours
pulmonari
fibrosi
numer
biomark
studi
speci
human
mucin
kreb
von
den
lungen
consist
found
increas
serum
patient
interstiti
lung
diseas
includ
ipf
possibl
involv
ipf
pathophysiolog
process
cipf
yet
assess
studi
assess
diagnost
valu
serum
concentr
cipf
well
associ
serum
concentr
breed
predisposit
diseas
blood
obtain
group
dog
whwt
affect
cipf
femal
f
male
mean
rang
healthi
whwt
healthi
dog
breed
predispos
cipf
jack
russel
terrier
jr
malinoi
belgian
shepherd
mb
king
charl
spaniel
kc
serum
store
batch
analysi
concentr
measur
commerci
avail
elisa
test
canin
kreb
von
den
lungen
elisa
kit
amsbio
result
compar
use
covari
analysi
includ
group
defin
gender
interact
group
gender
togeth
effect
age
analysi
follow
comparison
group
use
result
show
effect
group
signific
serum
concentr
higher
healthi
whwt
ngml
compar
kc
ngml
mb
ngml
respect
higher
jr
ngml
compar
kc
differ
cipf
ngml
healthi
whwt
conclus
differ
serum
concentr
found
amongst
breed
healthi
dog
higher
concentr
observ
terrier
breed
whether
may
reflect
predispos
factor
cipf
develop
merit
investig
unlik
found
human
ipf
good
serum
biomark
diagnosi
differ
cipf
unaffect
whwt
disclosur
disclosur
report
studi
evalu
cobalamin
folat
iron
statu
pregnant
bitch
associ
anemia
pra
neonat
surviv
ns
complet
blood
count
serum
folat
cobalamin
concentr
total
iron
bind
capac
tibc
measur
bitch
effect
pregnanc
stage
breed
age
pariti
breeder
variabl
determin
gener
estim
equat
test
linear
correl
variabl
assess
pearson
correl
test
serum
cobalamin
decreas
vs
p
tibc
increas
vs
p
serum
folat
decreas
insignificantli
vs
late
pregnanc
breed
significantli
p
affect
serum
cobalamin
folat
concentr
tibc
breeder
significantli
p
affect
folat
concentr
tibc
neutrophil
platelet
leukocyt
count
significantli
increas
red
blood
cell
count
rbc
significantli
decreas
p
late
pregnanc
decreas
rbc
significantli
albeit
weakli
correl
serum
folat
decreas
serum
tibc
increas
none
measur
associ
ns
conclus
although
serum
cobalamin
significantli
decreas
pregnanc
decreas
unassoci
pra
ns
pregnant
bitch
contrari
pregnant
women
tibc
increas
pregnanc
progress
prospect
studi
warrant
investig
whether
prophylact
folat
administr
mitig
pra
consid
signific
correl
decreas
serum
folat
concentr
rbc
progress
pregnanc
note
herein
disclosur
disclosur
report
human
consist
repeat
respiratori
physic
examin
difficult
reflect
poor
moder
agreement
among
clinician
aim
prospect
observ
studi
assess
reliabl
respiratori
physic
examin
dog
cat
determin
influenc
time
studi
begin
differ
clinic
experi
agreement
dog
cat
abnorm
breath
pattern
present
fregi
univers
missouri
univers
pennsylvania
veterinari
hospit
recruit
one
year
anim
includ
evalu
three
clinician
therapeut
intervent
andor
diagnost
test
impact
respiratori
sign
recognit
agreement
assess
via
fleiss
kappa
coeffici
influenc
time
studi
begin
clinic
experi
differ
agreement
evalu
via
logist
regress
stratifi
speci
dog
cat
enrol
dog
overal
agreement
moder
regard
breath
pattern
recognit
vari
depend
pattern
best
agreement
obtain
respiratori
nois
goos
honk
stertor
stridor
agreement
fair
moder
abnorm
auscult
lung
sound
crackl
wheez
expiratori
snap
similar
trend
observ
cat
overal
lower
agreement
dog
agreement
improv
time
lower
differ
experi
associ
better
agreement
stridor
tracheal
sensit
recognit
dog
care
taken
interpret
physic
examin
find
regard
respiratori
sign
low
agreement
disclosur
disclosur
report
bronchoscopi
import
diagnost
procedur
evalu
mani
respiratori
diseas
remov
foreign
bodi
bronchoscopi
fundament
know
precis
bronchial
topographi
order
recogn
abnorm
anatomi
patholog
chang
author
treat
bronchial
anatomi
dog
mani
limit
descript
lobar
bronchi
without
consid
branch
current
endoscop
anatomi
base
paper
therefor
aim
studi
obtain
descript
topograph
anatomi
morphometr
valu
introduc
new
standardis
nomenclatur
draw
correct
bronchial
map
dog
twelv
dog
differ
age
sex
breed
die
spontan
reason
pulmonari
diseas
includ
studi
owner
consent
distinguish
weight
group
subject
examin
endoscop
systemat
manner
hd
flexibl
endoscop
endoscopi
focus
intracorpor
ic
extracorpor
ec
exam
ec
perform
isol
lung
order
obtain
better
examin
cranial
lobe
difficult
ic
orient
consid
visualis
abil
pass
lumen
branch
endoscop
lung
cast
polyurethan
foam
made
diamet
length
bronchial
branch
measur
digit
callip
furthermor
name
structur
draw
bronchial
map
defin
look
direct
posit
cast
conform
orient
branch
pattern
topograph
relationship
bronchial
system
lung
lobe
possibl
defin
new
descript
nomenclatur
first
three
seri
bronchial
divis
morphometr
examin
allow
obtain
mean
valu
diamet
length
bronchi
group
weight
confirm
monopodi
branch
system
bronchoscopi
possibl
locat
andor
move
princip
lobar
segment
bronchi
signific
differ
group
comparison
previou
studi
draw
new
bronchial
map
gave
descript
nomenclatur
first
three
seri
canin
bronchial
divis
moreov
analys
access
airway
diamet
flexibl
endoscop
differ
group
final
result
provid
accur
refer
valu
use
diagnost
imag
procedur
especi
bronchoscopi
disclosur
disclosur
report
domest
cat
ab
blood
group
system
consist
three
type
b
c
also
call
ab
vari
frequenc
among
breed
geograph
region
mismatch
caus
acut
hemolyt
transfus
reaction
neonat
isoerythrolysi
cytidin
acid
hydroxylas
cmah
convert
acid
type
b
acid
type
type
c
erythrocyt
express
antigen
sixteen
variant
cmah
gene
describ
associ
type
b
differ
breed
breed
ragdol
siberian
turkish
angora
variant
correl
well
phenotyp
studi
felin
cmah
code
region
blood
type
ragdol
type
type
b
sanger
sequenc
andor
taqman
snp
genotyp
compar
sequenc
publish
cmah
sequenc
four
novel
cmah
variant
g
c
g
identifi
besid
seven
previous
report
variant
g
c
three
previous
describ
variant
associ
blood
type
b
cosegreg
ragdol
howev
seven
cat
homozyg
mutant
allel
variant
caus
earli
stop
codon
found
homozyg
anoth
type
b
cat
remain
type
b
ragdol
compound
heterozygot
type
cat
homozyg
one
variant
conclus
type
b
ragdol
caus
two
cmah
variant
homozyg
compound
heterozyg
state
gener
particularli
ragdol
genotyp
screen
includ
variant
disclosur
disclosur
report
laboklin
penngen
offer
blood
type
blood
compat
test
patent
submit
molecular
genet
marker
panel
test
discov
investig
describ
abstract
faecal
occult
blood
fob
test
wide
use
colorect
cancer
screen
human
dog
report
abl
detect
fob
oral
administr
mg
haemoglobinkg
bodi
weight
mghgbkgbw
autolog
blood
routin
use
aim
work
evalu
abil
detect
fob
healthi
dog
assess
influenc
two
diet
ii
assess
influenc
time
faecal
sampl
test
result
iii
find
lowest
canin
haemoglobin
concentr
achiev
posit
test
initi
five
healthi
dog
enrol
dog
fed
protein
diet
ha
switch
gastrointestin
diet
en
day
extra
food
permit
apart
fresh
whey
chees
faec
dog
test
assay
day
start
ha
diet
start
day
six
everi
day
progress
dose
autolog
blood
mghgbkgbw
administ
oral
faec
daili
test
faec
mix
wooden
spatula
collect
thereaft
schedul
describ
appli
dog
fed
en
diet
faec
one
dog
collect
hour
singl
mghgbkgbw
meal
seven
test
card
faecal
sampl
prepar
test
assess
everi
two
day
collect
final
canin
whole
blood
ghgbdl
progress
dilut
salin
solut
directli
appli
set
three
test
card
neg
result
found
first
aim
total
test
examin
twelv
posit
associ
posit
test
administ
amount
blood
found
none
stool
specimen
posit
regard
second
set
sampl
one
result
posit
final
lowest
concentr
achiev
posit
test
conclus
influenc
ha
en
diet
reproduc
detect
fob
stool
unsatisfactori
although
abl
detect
directli
ad
card
individu
blood
digest
bowel
transit
time
may
play
role
poor
reproduc
disclosur
disclosur
report
eosinophil
lung
diseas
dog
associ
parasit
diseas
occur
due
presum
primari
hypersensit
aim
studi
report
clinic
variat
larg
popul
affect
dog
retrospect
studi
dog
diagnos
eosinophil
lung
diseas
base
airway
cytolog
bronchoalveolar
lavag
eosinophil
histopatholog
record
review
clinic
radiograph
find
mean
bodi
weight
dog
dog
dog
dog
german
shepherd
labrador
standard
poodl
commonli
affect
clinic
complaint
includ
cough
nasal
discharg
dog
thorac
radiograph
normal
dog
variabl
pulmonari
pattern
remain
dog
common
bronchoscop
find
hyperemia
increas
airway
mucu
airway
collaps
bronchiectasi
inspiss
intralumin
materi
observ
dog
one
dog
airway
eosinophil
demonstr
histolog
evid
eosinophil
infiltr
median
airway
eosinophilia
remain
dog
rang
bronchoalveolar
lavag
total
nucleat
rang
median
neoplasia
pulmonari
parasit
diagnos
dog
dog
concurr
bacteri
infect
aspergillu
spp
detect
aerob
cultur
dog
consid
probabl
contamin
group
dog
eosinophil
lung
diseas
rare
associ
identifi
underli
caus
disclosur
disclosur
report
increas
incid
bacteri
pneumonia
bp
identifi
irish
wolfhound
iwh
recurr
bp
occur
commonli
breed
etiolog
larg
unestablish
immunoglobulin
iga
defici
suggest
underli
factor
purpos
studi
investig
serum
bronchoalveolar
lavag
fluid
balf
iga
igg
igm
concentr
iwh
recurr
bp
well
healthi
dog
prospect
observ
studi
includ
iwh
median
age
year
iqr
year
recurr
bp
median
number
previou
bp
rang
healthi
dog
includ
control
iwh
dog
sighthound
breed
dog
breed
median
age
year
iqr
respect
six
healthi
laboratori
beagl
includ
control
balf
immunoglobulin
analysi
igg
iga
igm
measur
elisa
method
serum
balf
statist
analysi
perform
analysi
covari
model
ancova
serum
immunoglobulin
concentr
iga
affect
iwh
mgdl
iqr
mgdl
healthi
iwh
healthi
sighthound
healthi
dog
breed
igg
igm
respect
differ
significantli
healthi
affect
iwh
balf
immunoglobulin
differ
significantli
affect
iwh
healthi
beagl
result
indic
immunoglobulin
defici
unlik
predispos
factor
recurr
bp
iwh
disclosur
disclosur
report
sj
viitanen
receiv
research
grant
finnish
foundat
veterinari
research
finnish
veterinari
foundat
cat
lungworm
aelurostrongylu
abstrusu
caus
lower
respiratori
tract
diseas
cat
worldwid
bronchoscopi
import
tool
diagnosi
respiratori
diseas
cat
howev
role
diagnosi
aelurostrongylosi
remain
unclear
investig
use
bronchoscopi
cat
aelurostrongylosi
bronchoscop
bronchoalveolar
lavag
bal
find
cat
itali
abstrusu
aa
compar
cat
us
felin
bronchial
diseas
fbd
bronchoscop
lesion
bacteri
isol
record
presentabs
inflamm
type
classifi
differenti
cytolog
bal
data
analyz
use
fisher
exact
test
age
aa
cat
male
femal
rang
month
median
age
fbd
cat
male
femal
rang
month
median
bronchoscop
differ
detect
aa
fbd
cat
bronchial
mucu
vs
nodular
region
vs
airway
collaps
vs
howev
airway
hyperemia
epitheli
irregular
stenosi
observ
less
frequent
aa
fbd
cat
vs
vs
vs
p
bronchiectasi
observ
aa
none
fbd
cat
p
aa
fbd
cat
neutrophil
eosinophil
mix
inflamm
vs
vs
vs
respect
report
lymphocyt
inflamm
found
aa
versu
fbd
cat
cytolog
normal
aa
cat
signific
differ
cytolog
inflamm
detect
group
bacteria
isol
bal
aa
fbd
cat
cytolog
evid
sepsi
aa
cat
larva
abstrusu
detect
cytolog
aa
cat
studi
suggest
bronchoscop
abnorm
cat
variou
form
lower
respiratori
tract
diseas
similar
although
lesion
common
fbd
interestingli
bronchiectasi
rel
common
cat
aelurostrongylosi
cytolog
find
overlap
inflammatori
lungworm
diseas
inabl
bal
cytolog
detect
abstrusu
larva
confirm
bronchoscopi
enhanc
diagnosi
aelurostrongylosi
repres
use
tool
detect
bronchial
abnorm
might
affect
manag
prognosi
disclosur
disclosur
report
studi
conduct
part
project
financ
bayer
anim
health
leverkusen
germani
rs
employe
veterinari
patient
multifoc
bone
marrow
lesion
typic
neoplast
lymphoma
multipl
myeloma
commonest
caus
report
describ
two
dog
multifoc
bone
marrow
diseas
histolog
analysi
demonstr
osteomyel
without
evid
infect
neoplasia
case
present
investig
back
pain
lethargi
physic
examin
identifi
multifoc
vertebr
pain
neurolog
deficit
magnet
reson
imag
mri
scan
dog
reveal
lesion
multipl
vertebra
ilium
diaphysi
humeru
also
affect
case
lesion
hyperintens
stir
imag
hypointens
imag
hyperintens
follow
contrast
administr
bone
marrow
aspir
biopsi
evalu
cytolog
histopatholog
reveal
pyogranulomat
osteomyel
featur
neoplasia
infecti
agent
thorac
radiograph
abdomin
ultrasonographi
unremark
serolog
test
neg
infecti
diseas
case
treat
immunosuppress
dose
prednisolon
improv
rapidli
complet
resolut
clinic
sign
maintain
throughout
period
dose
taper
relaps
follow
cessat
treatment
six
month
case
initi
treat
doxycyclin
carprofen
result
temporari
improv
follow
relaps
cessat
treatment
complet
recoveri
follow
instig
immunosuppress
dose
prednisolon
case
recurr
dose
taper
case
demonstr
steril
osteomyel
rare
import
differenti
diagnosi
dog
multifoc
bone
marrow
lesion
appear
carri
favor
prognosi
disclosur
disclosur
report
felin
asthma
fa
felin
chronic
bronchiti
cb
common
condit
cat
often
refer
felin
lower
airway
diseas
howev
littl
known
differ
regard
signal
clinic
sign
laboratori
find
cat
two
condit
therefor
aim
studi
investig
potenti
differ
two
diseas
could
insight
establish
diagnosi
either
condit
studi
popul
includ
cat
felin
asthma
cat
chronic
bronchiti
case
diagnos
base
upon
typic
clinic
sign
characterist
balf
cytolog
result
physic
examin
find
laboratori
valu
radiograph
compar
group
patient
fa
present
median
age
year
cat
cb
year
femal
male
cat
includ
male
anim
overal
overrepres
fa
cb
group
common
clinic
sign
cough
fa
cb
abnorm
respiratori
sound
fa
cb
dyspnoea
fa
cb
laboratori
analysi
cat
fa
cat
cb
eosinophilia
radiograph
chang
detect
cat
fa
cat
cb
studi
show
differenti
fa
cb
mean
clinic
sign
laboratori
chang
radiograph
abnorm
inconclus
reliabl
diagnosi
would
render
possibl
cytolog
examin
balf
disclosur
disclosur
report
felin
asthma
fa
chronic
bronchiti
cb
common
condit
cat
still
unknown
whether
diseas
respond
equal
well
treatment
therapi
commonli
initi
without
clear
distinct
condit
aim
studi
compar
respons
initi
therapi
treatment
success
advers
effect
owner
satisfact
group
highlight
possibl
differ
studi
inclus
criterion
cytolog
diagnosi
fa
eosinophil
inflamm
cb
neutrophil
inflamm
fluid
balf
cat
compat
clinic
sign
owner
cat
meet
inclus
criteria
thereaft
ask
fill
standard
questionnair
owner
cat
fa
cat
cb
complet
questionnair
cat
initi
start
treatment
oral
corticosteroid
fa
cb
addit
oral
bronchodil
fa
cb
antibiot
fa
cb
given
patient
treatment
later
shift
inhal
corticosteroid
fa
cb
patient
cb
like
receiv
oral
corticosteroid
fa
cb
bronchodil
fa
cb
antibiot
fa
cb
patient
fa
therapi
advers
effect
polyuriapolydipsia
fungal
infect
diabet
mellitu
occur
four
patient
fa
one
patient
cb
owner
satisfi
control
clinic
sign
group
fa
cb
necess
medic
diseas
differ
thu
knowledg
underli
diseas
help
manag
cat
chronic
bronchial
diseas
disclosur
disclosur
report
canin
idiopath
pulmonari
fibrosi
cipf
affect
mainli
west
highland
white
terrier
whwt
chronic
progress
interstiti
lung
diseas
share
mani
similar
human
idiopath
pulmonari
fibrosi
ipf
cipf
character
exagger
accumul
extracellular
matrix
ecm
lung
parenchyma
mmp
proteolyt
enzym
capabl
degrad
ecm
human
ipf
found
potenti
diagnost
prognost
biomark
aim
studi
compar
activ
serum
cipf
whwt
healthi
whwt
breed
healthi
dog
analyz
activ
use
casein
zymographi
serum
whwt
cipf
healthi
whwt
healthi
dog
breed
cipf
diagnosi
base
high
resolut
comput
tomographi
lung
histopatholog
cipf
whwt
healthi
whwt
typic
clinic
find
health
breed
dog
verifi
clinic
examin
activ
significantli
higher
cipf
whwt
median
interquartil
rang
iqr
rang
compar
healthi
whwt
median
iqr
rang
activ
detect
one
breed
healthi
dog
median
iqr
rang
result
indic
potenti
biomark
also
whwt
cipf
howev
note
increas
activ
also
healthi
whwt
connect
breed
suscept
cipf
disclosur
disclosur
report
bronchoalveolar
lavag
bal
cytolog
cultur
use
character
respiratori
diseas
dog
includ
inflammatori
diseas
eosinophil
lung
diseas
chronic
bronchiti
littl
known
clinic
relev
underli
diseas
process
associ
increas
percentag
lymphocyt
bal
fluid
aim
retrospect
studi
report
clinic
find
larg
popul
dog
bal
lymphocytosi
lymphocyt
document
dog
record
review
clinic
bronchoscop
find
respiratori
diagnos
includ
eosinophil
lung
diseas
pneumonia
chronic
bronchiti
aspir
injuri
airway
collaps
lymphocyt
inflamm
absenc
airway
eosinophilia
neutrophilia
present
dog
lymphocyt
percentag
rang
median
bacteria
observ
cytolog
dog
howev
pneumonia
confirm
dog
base
identif
pathogen
cultur
aspir
injuri
suspect
dog
concurr
eosinophil
airway
inflamm
bal
eosinophil
document
dog
lymphocyt
dog
neutrophil
airway
inflamm
found
lymphocyt
pneumonia
diagnos
dog
chronic
bronchiti
dog
tracheobronchomalacia
document
significantli
often
dog
lymphocyt
inflamm
alon
versu
concurr
eosinophil
neutrophil
inflamm
p
mix
airway
inflamm
common
infecti
inflammatori
airway
diseas
howev
lymphocyt
inflamm
alon
found
dog
relationship
airway
inflamm
tracheobronchomalacia
requir
investig
disclosur
disclosur
report
immunomodulatori
drug
mycophenol
mofetil
mmf
use
treatment
number
immun
mediat
diseas
dog
work
target
antiprolif
effect
activ
lymphocyt
mmf
gain
popular
perceiv
swift
onset
action
easi
access
multipl
prepar
includ
capsul
liquid
intraven
formul
mmf
report
caus
gastrointestin
side
effect
appropri
caution
use
due
poorli
characteris
natur
advers
event
object
studi
characteris
advers
event
associ
use
mmf
use
treatment
diseas
dog
studi
retrospect
descript
studi
look
dog
administ
mmf
davi
veterinari
specialist
unit
kingdom
twenti
seven
dog
avail
analysi
treat
imha
imtp
evan
syndrom
ibd
impa
mg
fifti
six
percent
dog
receiv
mmf
experienc
advers
event
gastrointestin
natur
dog
receiv
mmf
experienc
diarrhoea
experienc
melena
haematochezia
experienc
vomit
becam
anorex
nauseou
gastrointestin
sign
signific
effect
start
dose
dose
frequenc
mmf
incid
advers
event
delay
diagnosi
begin
mmf
signific
effect
likelihood
experienc
advers
event
omeprazol
administ
nine
dog
experienc
advers
event
includ
diarrhoea
vomit
haematochezia
melena
anorexia
seven
individu
omeprazol
administ
advers
event
document
concurr
medic
includ
glucocorticoid
associ
develop
advers
event
incid
advers
event
experienc
cohort
dog
treat
mmf
immun
mediat
diseas
high
exclus
gastrointestin
natur
disclosur
disclosur
report
felin
hemoplasma
group
haemotrop
mycoplasma
known
caus
felin
infecti
anemia
group
compound
mycoplasma
haemof
mhf
consid
pathogen
candidatu
mycoplasma
haemominutum
mhm
candidatu
mycoplasma
turicensi
mtc
whose
pathogen
appear
influenc
concurr
diseas
infect
pathogen
high
preval
worldwid
capabl
caus
subclin
infect
felin
blood
donor
suppos
potenti
risk
infect
recipi
blood
transfus
studi
aim
widen
avail
inform
preval
subclin
infect
haemotrop
mycoplasma
healthi
indoor
cat
elig
becom
blood
donor
iberian
peninsula
blood
sampl
indoor
healthi
cat
select
potenti
blood
donor
anim
blood
bank
spain
portug
obtain
area
portug
complet
blood
count
serum
biochemistri
felin
inmunodefici
viru
fiv
leukemia
viru
felv
speci
specif
qualit
polimeras
chain
reaction
mycoplasma
perform
potenti
donor
data
obtain
routinari
procedur
perform
anim
blood
bank
unnecessari
procedur
done
blood
donor
blood
sampl
collect
sign
inform
owner
consent
sampl
posit
one
mycoplasma
speci
specif
preval
mhf
mhm
mtc
respect
coinfect
differ
mycoplasma
speci
mhf
mtc
detect
cat
mycoplasma
posit
sampl
fiv
posit
one
coinfect
mhf
mhm
one
felv
posit
coinfect
mhm
infect
cat
present
normal
pcv
median
valu
free
clinic
sign
evid
hemolysi
blood
smear
evalu
previous
report
preval
felin
mycoplasma
healthi
anim
barcelona
spain
portug
specif
preval
mhf
mhm
mtc
barcelona
spain
respect
portug
lower
preval
studi
may
due
fact
healthi
indoor
strict
cat
enrol
former
studi
admit
stray
ill
cat
conclud
test
potenti
felin
blood
donor
felin
mycoplasma
indic
even
clinic
sign
present
pcv
valu
within
normal
rang
disclosur
disclosur
report
hyperplasia
suprarytenoid
pharyng
fold
hspf
rare
unreport
respiratori
diseas
affect
brachycephal
brachycephal
toy
dog
dorsal
pharyng
fold
might
caus
obstruct
dorsal
portion
laryng
aditu
cover
cornicul
process
arytenoid
cartilag
limit
block
abduct
inspir
hspf
might
seen
concurr
laryng
collaps
elong
soft
palat
aim
work
describ
clinic
endoscop
treatment
outcom
ten
dog
diagnos
hspf
fourdog
pug
two
dog
pomeranian
one
mix
breed
three
chihuahua
seven
dog
femal
three
male
mean
age
year
main
clinic
sign
inspiratori
dyspnea
inspiratori
stridor
nine
dog
five
dog
exhibit
stertor
breath
two
dog
nocturn
apnea
mean
durat
clinic
sign
month
mo
dog
gener
anesthesia
underw
endoscop
evalu
upper
lower
airway
main
find
hspf
reduct
laryng
abduct
laryng
collaps
dog
three
dog
soft
palat
hyperplasia
three
dog
stenot
nare
two
dog
bronchomalacia
dog
pharyng
hyperplast
fold
lift
cotton
swab
improv
laryng
abduct
inspir
dog
two
pug
underw
surgic
correct
hspf
signific
improv
inspiratori
stridor
resolut
nocturn
apnea
one
dog
die
unrel
caus
four
month
surgeri
pug
euthan
due
econom
restraint
endoscop
alter
remain
seven
dog
consid
mild
medic
option
inhal
corticosteroid
result
clinic
improv
mean
month
mo
hspf
might
underestim
diseas
upper
airway
clinician
awar
condit
evalu
brachycephal
toy
dog
obstruct
sign
upper
airway
also
consid
muscl
relax
induc
anaesthesia
mucos
oedema
might
overestim
degre
hspf
subsequ
degre
laryng
collaps
abduct
pharyng
fold
mean
cotton
swab
result
signific
improv
laryng
abduct
surgic
correct
hspf
consid
dog
sever
inspiratori
dyspnea
less
sever
case
conserv
therapi
improv
clinic
sign
larger
case
seri
dog
hspf
warrant
better
character
condit
indic
surgic
versu
conserv
manag
disclosur
disclosur
report
ua
scil
anim
care
compani
instrument
design
routin
analysi
canin
felin
urin
analysi
base
dipstick
read
dual
wavelength
reflect
aim
studi
compar
urinari
proteincreatinin
upc
ratio
measur
ua
measur
done
veterinari
refer
laboratori
gold
standard
autom
spectrophotomet
examin
agreement
method
classifi
dog
cat
np
borderlin
proteinur
bp
proteinur
p
accord
iri
guidelin
stage
chronic
kidney
diseas
urin
sampl
collect
via
cystocentesi
free
catch
dog
cat
refer
vari
diseas
condit
part
diagnost
routin
urinalysi
done
upc
ratio
measur
perform
veterinari
refer
laboratori
laboratoir
collard
belgium
simultan
urin
sampl
second
upc
ratio
measur
done
use
ua
upc
ratio
measur
veterinari
refer
laboratori
ua
significantli
differ
dog
median
iqr
rang
vs
median
iqr
rang
p
cat
median
iqr
rang
vs
median
iqr
rang
p
dog
upc
ratio
classifi
np
bp
p
agreement
method
found
case
bp
dog
classifi
np
pocketchemtm
ua
p
dog
respect
classifi
np
bp
instrument
addit
np
dog
classifi
bp
ua
cat
upc
ratio
classifi
np
bp
p
agreement
method
found
case
bp
cat
classifi
np
ua
p
cat
p
cat
respect
classifi
np
bp
instrument
addit
np
cat
classifi
bp
ua
overal
upc
ratio
classif
differ
gold
standard
refer
laboratori
classif
case
ua
reliabl
test
measur
upc
ratio
cohort
dog
cat
disclosur
disclosur
report
chronic
kidney
diseas
ckd
common
problem
felin
practic
earli
diagnosi
help
influenc
outcom
improv
prognosi
current
reliabl
biomark
earli
diagnosi
ckd
sinc
fibrosi
main
tissu
alter
ckd
assum
transform
growth
factor
beta
initi
molecul
tissu
fibrosi
may
use
earli
indic
ckd
aim
prospect
studi
evalu
diagnost
valu
felin
ckd
healthi
cat
cat
ckd
includ
studi
measur
serum
use
quantikin
human
immunoassay
r
system
healthi
cat
median
serum
concentr
ngml
cat
suffer
ckd
median
ngml
differ
group
signific
p
ckd
affect
cat
intern
renal
interest
societi
iri
stage
median
serum
concentr
ngml
cat
iri
stage
median
ngml
cat
iri
stage
median
ngml
signific
correl
serum
concentr
differ
furthermor
signific
correl
serum
platelet
count
even
though
cell
highest
intracellular
concentr
blood
cat
diagnos
ckd
show
lower
serum
concentr
healthi
cat
anoth
studi
serum
also
higher
healthi
cat
compar
cat
ckd
higher
express
kidney
accompani
higher
synthesi
extracellular
matrix
detect
histolog
human
miss
rise
serum
cat
ckd
could
attribut
fact
cytokin
synthesis
directli
kidney
local
fibrosi
process
possibl
use
serum
diagnost
tool
ckd
could
valid
studi
disclosur
disclosur
report
obes
implic
risk
factor
develop
asymptomaticsubclin
bacteriuria
sb
human
dog
aim
studi
investig
whether
overweight
andor
obes
predispos
cat
sb
studi
carri
univers
hospit
companion
anim
copenhagen
octob
march
cat
year
present
caus
unrel
lower
urinari
tract
elig
enrol
bodi
condit
score
bc
perform
scale
overweight
defin
bc
obes
bc
urin
collect
cystocentesi
subject
aerob
bacteri
cultur
correl
presenc
sb
variabl
sex
healthyil
age
bc
categori
analyz
binomin
logist
regress
studi
popul
consist
cat
femal
male
age
year
median
healthi
diseas
cat
score
overweight
among
obes
sb
identifi
nine
cat
escherichia
coli
commonli
cultur
bacterium
femal
sex
signific
risk
factor
sb
femal
rr
vs
male
overweight
signific
risk
factor
overweightobes
rr
vs
lean
neither
obes
compar
lean
overweight
cat
despit
case
sb
detect
data
indic
overweight
obes
predispos
cat
sb
disclosur
disclosur
report
antibiot
dog
suspect
cystiti
decis
prescrib
may
affect
reliabl
diagnost
coher
test
result
aim
studi
investig
impact
commerci
cultur
suscept
test
cs
decis
treat
dtt
antibiot
choic
antibiot
agent
cot
compar
routin
microscopi
stain
urin
sediment
ua
studi
design
random
control
trial
primari
veterinari
practic
dog
clinic
sign
cystiti
enrol
random
one
two
diagnost
group
cs
ua
antibiot
withheld
cultur
result
avail
day
consult
cs
group
excess
urin
submit
refer
laboratori
quantit
bacteri
cultur
qbc
antibiot
prescript
consid
appropri
dtt
case
signific
bacteriuria
refer
qbc
appropri
cot
defin
prescrib
antibiot
vitro
suscept
choos
agent
agent
fifteen
clinic
enrol
dog
case
random
cs
ua
respect
cystiti
present
dog
accord
qbc
appropri
dtt
occur
significantli
dog
cs
compar
ua
group
ci
cs
improv
cot
ci
conclus
cs
withhold
antibiot
cultur
result
avail
reduc
antibiot
dog
without
cystiti
disclosur
disclosur
report
previou
studi
perform
norwegian
univers
life
scienc
nmbu
larg
proport
posit
cultur
result
ejacul
healthi
male
dog
regist
prompt
examin
present
studi
perform
nmbu
decemb
februari
fifteen
healthi
intact
male
dog
age
year
includ
three
urin
sampl
collect
within
eight
hour
order
dog
void
void
clean
extern
genit
tap
water
clean
void
cystocentesi
urin
sampl
complet
urinalysi
perform
includ
urin
dipstick
microscopi
sediment
bacteri
cultur
clean
prepuc
ejacul
collect
submit
cytolog
bacteri
cultur
fluid
obtain
clean
prepuc
also
collect
bacteri
cultur
radiologist
perform
ultrasound
examin
urogenit
tract
dog
one
dog
ultrasound
perform
sinc
owner
declin
sedat
bacteri
growth
found
void
urin
sampl
clean
void
one
cystocentesi
sampl
cultur
neg
bacteri
growth
ejacul
posit
correl
age
bacteri
growth
detect
rs
p
five
dog
neg
cultur
urin
sampl
dog
posit
ejacul
cultur
similar
cultur
result
obtain
seven
dog
examin
ultrasound
chang
compat
benign
prostat
hyperplasia
six
posit
ejacul
cultur
bacteria
grown
differ
sampl
urin
ejacul
pasteurella
spp
mycoplasma
cani
staphylococcu
pseudintermediu
prevotella
sp
anaerob
rod
streptococcu
cani
staphylococcu
spp
mix
flora
consist
one
mention
studi
reveal
neg
cultur
clean
void
urin
sampl
clinic
relev
sinc
neg
cultur
use
regardless
sampl
method
result
suggest
one
prudent
interpret
ejacul
cultur
sinc
larg
proport
ejacul
healthi
dog
bacteri
growth
addit
concord
cultur
result
respect
lavag
fluid
ejacul
whether
bacteria
grown
ejacul
repres
actual
bacteri
colon
prostat
contamin
prepuc
distal
urethra
yet
determin
studi
includ
prostat
sampl
eg
aspir
need
disclosur
disclosur
report
present
retrospect
studi
urolith
remov
analyz
minnesota
urolith
center
data
record
speci
breed
gender
age
materi
year
withdraw
type
diagnost
imag
urolith
struvit
layer
result
urin
cultur
sensit
record
urin
sampl
collect
cystocentesi
consid
signific
count
cfuml
regard
speci
canin
urolith
frequent
felin
n
vs
n
among
dog
male
repres
n
vs
n
male
cat
twice
like
suffer
urolithiasi
femal
n
vs
n
concern
frequenc
composit
canin
urolith
calcium
oxal
male
yorkshir
terrier
miniatur
schnauzer
age
yr
struvit
femal
cocker
spaniel
crossbre
age
yr
urat
male
dalmatian
age
yr
cystin
male
basset
hound
age
yr
calcium
phosphat
xanthin
silic
cat
urolith
compos
calcium
oxal
male
age
yr
struvit
male
age
mo
yr
urat
almost
exclus
affect
dog
cat
struvit
urolith
cultur
sensit
perform
get
posit
result
neg
neg
dog
cat
frequent
pathogen
isol
staphylococcu
pseudointermediu
n
staphylococcu
intermediu
n
follow
streptococcu
cani
n
staphylococcu
spp
n
staphylococcu
aureu
n
streptococcu
spp
n
escherichia
coli
n
staphylococcu
carnosu
n
pasteurellacani
n
proteu
n
nitrofurantoin
effect
antibiot
n
sensit
staphylococcu
spp
isol
report
resist
cefovecin
cephalexin
summar
studi
show
canin
urolith
frequent
felin
affect
mostli
male
speci
calcium
oxal
urolith
repres
huge
amount
urin
isol
suscept
nitrofurantoin
disclosur
disclosur
report
marbofloxacin
one
fluoroquinolon
develop
exclus
veterinari
medicin
primari
aim
studi
identifi
assess
evid
relat
clinic
efficaci
marbofloxacin
treatment
urinari
tract
infect
small
anim
practic
dog
cat
refer
intern
medicin
depart
polyclin
lower
urinari
tract
symptom
nt
receiv
antimicrobi
therapi
previou
day
includ
studi
diagnosi
confirm
clinic
find
urinalysi
imag
rectal
temperatur
appetit
urinari
sign
pain
abdomin
palpat
monitor
two
visit
day
day
timet
depend
diagnosi
two
urinalys
two
bacteri
examin
antibacteri
suscept
test
per
case
perform
bacteri
uti
confirm
dog
cat
urin
sampl
collect
first
referr
demonstr
presenc
variou
bacteria
mark
predomin
p
mirabili
coagulas
posit
staphylococci
canin
felin
urin
sampl
respect
antimicrobi
suscept
test
result
reveal
dog
isol
cat
isol
suscept
marbofloxacin
treatment
uti
gener
challeng
small
anim
practition
antimicrobi
usag
necess
especi
bacteri
cultur
suscept
test
import
treatment
success
marbofloxacin
usag
reward
treatment
uti
dog
cat
thu
reveal
current
statu
turkey
first
time
key
word
antimicrobi
cat
dog
marbofloxacin
urinari
tract
infect
disclosur
disclosur
report
previou
prospect
randomis
trial
examin
effect
dietari
phosphat
restrict
healthi
cat
year
gedd
et
al
cat
assign
test
control
diet
protein
gmcal
gmcal
phosphat
gmcal
blood
sampl
taken
baselin
week
month
diet
effect
phosphat
restrict
observ
plasma
fibroblast
growth
factor
phosphatur
hormon
shown
predict
develop
azotaemia
cat
year
understand
normal
plasma
concentr
develop
group
healthi
adult
cat
fed
mainten
diet
median
concentr
pgml
result
review
data
trial
determin
whether
feed
senior
diet
reduc
plasma
concentr
cat
top
percentil
healthi
adult
cat
cat
baselin
plasma
concentr
record
cat
divid
test
control
diet
group
categoris
group
baselin
pgml
pgml
data
present
median
percentil
data
log
transform
concentr
compar
timepoint
use
repeat
measur
anova
cat
receiv
control
diet
attend
visit
baselin
cat
pgml
pgml
pgml
pgml
group
mean
differ
significantli
time
point
cat
receiv
test
diet
attend
visit
baselin
cat
pgml
pgml
pgml
pgml
group
baselin
pgml
mean
concentr
differ
significantli
time
point
group
baselin
pgml
mean
concentr
differ
significantli
time
point
wilk
lambda
f
p
post
hoc
test
reveal
plasma
concentr
significantli
decreas
baselin
month
pgml
p
plasma
concentr
deceas
rel
baselin
cat
fed
senior
diet
month
preliminari
data
suggest
posit
effect
moder
phosphat
restrict
cat
studi
requir
characteris
disturb
phosphat
homeostasi
cat
benefit
feed
moder
diet
disclosur
disclosur
report
hj
sargent
support
grant
royal
canin
sa
ym
chang
conflict
interest
declar
j
elliott
receiv
fund
consult
elanco
ltd
ceva
anim
health
ltd
boehring
ingelheim
ltd
bayer
anim
health
orion
incorp
idexx
ltd
nextvet
ltd
waltham
centr
pet
nutrit
grant
fund
elanco
ltd
waltham
centr
pet
nutrit
royal
canin
sa
zoeti
ltd
ceva
anim
health
member
intern
renal
interest
societi
receiv
grant
elanco
ltd
r
jepson
receiv
fund
petplan
felin
foundat
renal
research
rvc
intern
grant
petsav
consult
agreement
boehring
ingelheim
merial
ceva
speak
honoraria
boehring
ingelheim
hill
pet
nutrit
ceva
leptospir
infect
associ
acut
nephriti
sever
urin
electrolyt
wast
particularli
magnesium
phosphat
potassium
human
tubular
damag
dysfunct
acut
canin
leptospirosi
scarc
document
studi
aim
evalu
urin
chemistri
biomark
tubular
damag
dog
intrins
acut
kidney
injuri
iaki
associ
leptospirosi
iaki
caus
differ
aetiolog
order
potenti
defin
peculiar
pattern
dog
histori
clinic
clinicopatholog
sign
consist
iaki
serum
creatinin
mgdl
andor
urinari
output
absenc
report
stage
guidelin
prospect
includ
group
accord
aetiolog
diagnosi
leptospirosi
diagnos
posit
microagglutin
test
mat
titr
upon
admiss
increas
convalesc
mat
titr
andor
posit
qpcr
bloodurin
routin
laboratori
analys
urin
chemistri
includ
fraction
excret
fe
electrolyt
sodium
potassium
magnesium
phosphat
calcium
urin
neutrophil
lipocalin
ungal
perform
upon
admiss
data
report
median
rang
refer
interv
ri
group
compar
use
statist
p
consid
signific
studi
includ
dog
inflammatori
diseas
toxic
sepsi
neoplasia
trauma
diabet
ketoacidosi
renal
function
sever
compromis
compar
dog
serum
creatinin
mgdl
vs
ri
urin
protein
electrolyt
loss
detect
group
howev
signific
differ
identifi
urin
protein
creatinin
ratio
upc
vs
ri
fe
electrolyt
potassium
vs
ri
magnesium
vs
ri
phosphat
vs
ri
sodium
vs
p
ri
calcium
vs
vs
ri
similarli
signific
differ
detect
ungal
concentr
ungal
pgml
vs
ri
ungal
creatinin
ratio
ungalc
vs
ri
pattern
tubular
damag
dysfunct
dog
leptospirosi
resembl
one
report
human
howev
neither
fe
electrolyt
ungal
abl
featur
infect
disclosur
disclosur
report
human
medicin
concentr
serum
increas
hypertens
ckd
also
urinari
correl
sever
renal
diseas
magnitud
proteinuria
dog
increas
concentr
evalu
indirectli
precursor
big
seem
associ
sever
ckd
hypertens
aim
studi
gain
inform
serum
urinari
level
cat
ckd
without
hypertens
proteinuria
measur
solid
phase
sandwich
elisa
develop
human
ibl
intern
gmbh
hamburg
germani
twenti
serum
sampl
urinari
sampl
obtain
cat
differ
iri
stage
sampl
sampl
twice
sampl
thrice
month
follow
assess
kit
use
measur
valid
urin
serum
sinc
almost
serum
sampl
fail
yield
result
detect
limit
method
result
differ
group
cat
statist
compar
use
u
test
virtual
absent
serum
sampl
ratio
significantli
posit
correl
serum
creatinin
concentr
ratio
significantli
differ
risk
ckd
cat
significantli
differ
iri
stage
wherea
ratio
significantli
higher
iri
group
ratio
differ
significantli
risk
cat
remain
stabl
risk
cat
develop
ckd
stage
iri
monitor
period
group
accord
sbp
higher
lower
mmhg
signific
differ
found
ratio
normotens
hypertens
cat
differ
significantli
sampl
proteinuria
accord
iri
guidelin
convers
significantli
higher
proteinur
cat
compar
non
proteinur
cat
result
suggest
sbp
proteinuria
import
determin
level
cat
surpris
sinc
peopl
urinari
consid
reflect
mainli
renal
product
instead
circul
level
autocrin
paracrin
action
specif
inform
avail
physiolog
cat
studi
need
explain
low
serum
concentr
disclosur
disclosur
report
work
support
winn
felin
foundat
grant
n
heartworm
diseas
dirofilaria
immiti
character
intim
prolifer
pulmonari
arteri
pulmonari
hypertens
heart
failur
furthermor
immiti
also
caus
renal
damag
primarili
defin
develop
prolif
glomerulonephr
howev
studi
exist
evalu
preval
renal
injuri
dog
heartworm
aim
assess
specif
serum
urinari
renal
paramet
dog
infect
immiti
evalu
impact
parasit
burden
microfilaremia
pulmonari
pressur
dog
evalu
microfilaremia
establish
knott
test
parasit
burden
pulmonari
pressur
determin
echocardiographi
urinari
serum
creatinin
microalbumin
well
serum
urea
determin
spectrophotometr
system
urin
reactiv
strip
use
determin
urinari
paramet
glucos
bilirrubin
urobilinogen
keton
blood
ph
nitrogen
leucocyt
color
turbid
densiti
urinari
protein
concentr
determin
pyrogallol
method
microalbuminurin
creatinin
ratio
c
ratio
urin
proteincreatinin
ratio
upc
ratio
calcul
microfilaremia
present
dog
pulmonari
hypertens
present
parasit
burden
high
low
anim
patholog
concentr
microalbuminuria
mgl
present
dog
c
ratio
refer
rang
upc
ratio
evalu
dog
borderlin
proteinur
present
overt
proteinuria
serum
urea
creatinin
within
normal
rang
dog
dog
microfilaremia
high
parasit
burden
pulmonari
hypertens
show
higher
incid
abnorm
urin
reactiv
strip
also
microalbumin
c
ratio
upc
ratio
higher
dog
although
differ
statist
signific
result
studi
show
evid
kidney
damag
dog
heartworm
confirm
measur
urinari
paramet
sensibl
earli
detect
renal
alter
best
feasibl
assess
clinic
signific
renal
alter
use
method
consid
first
choic
evalu
renal
statu
dog
infect
immiti
although
urinari
paramet
higher
dog
clinic
alter
result
signific
larger
sampl
studi
determin
influenc
microfilaremia
parasit
burden
pulmonari
hypertens
disclosur
disclosur
report
dog
babesiosi
present
multipl
complic
includ
acut
kidney
injuri
aki
aim
character
aki
babesia
dog
present
treatment
use
routin
novel
biomark
kidney
injuri
dysfunct
dog
babesia
healthi
control
dog
enrol
prospect
observ
studi
blood
urin
collect
group
present
dog
hour
dog
month
routin
renal
biomark
includ
serum
creatinin
scr
urinari
protein
creatinin
upc
novel
kidney
injuri
biomark
determin
valid
immunoassay
includ
urinari
immunoglobulin
g
uigg
protein
ucrp
protein
urbp
urinari
plasma
neutrophil
lipocalin
upngal
urinari
biomark
normal
urinari
creatinin
serum
symmetr
dimethylarginin
sdma
idexx
sdmatm
test
measur
novel
function
renal
biomark
test
compar
biomark
dog
without
babesiosi
wilcoxon
test
compar
biomark
infect
dog
consid
signific
urinari
biomark
pngal
significantli
higher
dog
compar
healthi
control
scr
sdma
differ
upc
urbp
ungal
decreas
significantli
decreas
signific
urinari
biomark
reach
valu
differ
healthi
control
signific
chang
scr
sdma
pngal
seen
treatment
babesia
dog
show
transient
kidney
injuri
detect
urinari
biomark
pngal
remain
undetect
function
biomark
disclosur
disclosur
report
osmot
diuresi
current
accept
mechan
polyuria
diabet
mellitu
ostens
lead
function
volum
deplet
consequ
compensatori
increas
glomerular
filtrat
rate
gfr
expect
latter
document
hypothes
glucosuria
would
increas
gfr
aim
measur
gfr
model
isol
renal
glycosuria
random
eight
cat
crossov
design
receiv
mg
dapagliflozin
sodium
glucos
transport
inhibitor
four
treatment
period
separ
washout
period
assess
gfr
total
bodi
water
content
tbwc
via
iohexol
clearanc
tracer
dilut
method
respect
studi
power
detect
differ
ml
daili
urin
output
analyz
result
mix
effect
model
includ
treatment
period
treatment
fix
effect
control
effect
repeat
measur
cat
random
intercept
cat
autoregress
process
correl
structur
fit
statist
signific
set
dapagliflozin
induc
profound
glucosuria
without
increas
daili
urin
output
mean
iohexol
clearanc
nontreat
cat
respect
p
mean
tbwc
normal
bodi
weight
treat
cat
respect
p
conclud
model
observ
increas
gfr
associ
concomit
preserv
tbwc
disclosur
disclosur
report
inflamm
mediat
cyclooxygenas
enzym
support
develop
cancer
stimul
angiogenesi
inhibit
apoptosi
promot
cell
prolifer
motil
enzym
convert
arachidon
acid
prostaglandin
activ
product
prostaglandin
drive
cell
prolifer
apoptosi
angiogenesi
interact
specif
receptor
receptor
receptor
particular
express
associ
develop
malign
poor
prognosi
multipl
human
cancer
express
confirm
canin
osteosarcoma
character
canin
complet
howev
express
canin
osteosarcoma
evalu
aim
studi
character
mrna
express
canin
osteosarcoma
rna
situ
hybrid
acdbio
use
evalu
canin
osteosarcoma
sampl
mrna
express
canin
rnascop
technolog
modif
situ
hybrid
detect
rna
tissu
section
quantifi
rnascop
signal
tissu
section
advanc
digit
patholog
imag
analysi
system
halo
indica
lab
util
softwar
allow
determin
target
rna
copi
number
cellular
level
data
express
copi
number
signal
compar
housekeep
target
posit
control
gene
ethic
approv
obtain
studi
involv
prospect
evalu
util
tissu
sampl
follow
patient
clinic
treatment
amput
diagnost
biopsi
procedur
osteosarcoma
canin
osteosarcoma
sampl
evalu
univers
posit
express
identifi
copi
number
averag
per
cell
result
confirm
mrna
express
canin
canin
osteosarcoma
cell
subsequ
studi
evalu
protein
express
via
immunohistochemistri
vitro
effect
antagonist
grapipr
canin
osteosarcoma
cell
line
data
clinic
relev
therapeut
blockad
antagonist
grapipr
tablet
approv
use
dog
us
may
novel
treatment
option
dog
osteosarcoma
disclosur
disclosur
report
musser
aratana
therapeut
inc
antagonist
gallipr
us
receiv
research
support
unrel
gallipr
elanco
primari
distributor
antagonist
gallipr
us
receiv
research
support
relat
gallipr
differ
type
cancer
transit
cell
carcinoma
urinari
bladder
c
johann
aratana
therapeut
inc
antagonist
gallipr
us
former
employe
speak
engag
advisori
board
consult
receiv
honorarium
travel
research
support
unrel
gallipr
elanco
primari
distributor
antagonist
gallipr
us
receiv
research
support
relat
gallipr
differ
type
cancer
transit
cell
carcinoma
urinari
bladder
variou
human
cancer
cell
line
opioid
receptor
activ
enhanc
efficaci
antineoplast
drug
concurr
doxorubicin
increas
opioid
receptor
methadon
enhanc
cellular
doxorubicin
uptak
aim
studi
investig
potenti
synerg
opioid
receptor
agonist
methadon
doxorubicin
canin
cancer
cell
line
canin
transit
cell
carcinoma
ctcc
cell
incub
variou
concentr
methadon
doxorubicin
order
test
clinic
achiev
dose
level
inhibit
cell
prolifer
measur
hour
cell
prolifer
assay
drug
alon
differ
combin
opioid
receptor
densiti
assess
flow
cytometri
drug
nativ
doxorubicin
cell
analysi
reveal
presenc
opioid
receptor
ctcc
cell
line
receptor
densiti
increas
mildli
upon
hour
pretreat
doxorubicin
intend
methadon
given
dose
inhibit
prolifer
doxorubicin
inhibit
prolifer
cell
pretreat
doxorubicin
methadon
ad
hour
potenti
took
place
convers
methadon
given
hour
doxorubicin
tendenc
potenti
doxorubicin
inhibitori
effect
prolifer
found
present
ctcc
cell
may
increas
pretreat
doxorubicin
tendenc
methadon
potenti
respons
doxorubicin
ctcc
intrigu
investig
cell
line
diseas
clinic
treat
doxorubicin
combin
methadon
disclosur
disclosur
report
ctvt
frequent
tumor
dog
ukrain
without
age
sex
breed
predisposit
ctvt
often
transmit
sexual
contact
affect
genit
extragenit
ctvt
locat
skin
nasal
oral
caviti
metastas
lung
region
lymph
node
largest
previous
publish
studi
nasal
ctvt
includ
analysi
case
aim
studi
analyz
describ
clinic
manifest
respons
therapi
patient
nasal
form
ctvt
dog
natur
occur
ctvt
includ
retrospect
studi
patient
enter
treatment
differ
region
ukrain
receiv
therapi
zoovetservi
clinic
kiew
patient
enter
visual
neoplasm
diagnosi
made
basi
cytolog
case
addit
histolog
investig
male
femal
includ
studi
neuter
time
ctvt
detect
none
patient
genit
ctvt
lesion
patient
owner
stray
dog
guardian
dog
breed
bichon
spaniel
dog
mixbre
clinic
symptom
nasal
tvt
includ
sneez
epistaxi
unilater
bilater
purul
hemorrhag
discharg
nose
patient
hard
skull
infiltr
format
oronos
fistula
observ
patient
patient
skin
fistula
observ
back
nose
spontan
disappear
treatment
ctvt
none
patient
ctvt
planum
nasal
lesion
dog
receiv
monochemotherapi
vincristin
weekli
dosag
mg
cours
consist
cycl
patient
oronas
fistula
sneez
discharg
maintain
resolut
fistula
neg
cytolog
control
none
patient
hematolog
toxic
requir
transfer
chemotherapi
dog
respond
therapi
complet
clinic
remiss
dog
year
later
relaps
inform
one
dog
month
treatment
relaps
intranas
ctvt
deepli
affect
nasal
caviti
hard
palat
skin
fistel
nut
without
planum
nasali
involv
well
amen
therapi
regardless
sever
diseas
disclosur
disclosur
report
nignatenko
present
lectur
sponsor
bayer
ukrain
bayer
involv
studi
retrospect
studi
efficaci
electrochemotherapi
ect
dog
tumour
head
includ
oral
caviti
patient
privat
own
pet
tumour
treat
mast
cell
tumour
paitnik
grade
one
grade
squamou
cell
carcinoma
spindl
cell
tumour
malign
melanoma
ameloblastoma
histiocytoma
basal
cell
tumour
carcinoma
epuli
plasmacytoma
case
treat
use
bleomycin
iusq
intraven
electropor
use
either
cytopuls
pa
cytopuls
oncovet
signal
gener
puls
vcm
either
hz
appli
start
minut
drug
administr
treatment
appli
gener
anaesthesia
ect
appli
either
sole
therapi
tumour
margin
surgeri
surgic
scar
roughli
week
surgeri
adjuv
whilst
one
case
initi
treat
sole
therapi
repeat
surgeri
two
patient
receiv
second
treatment
whilst
receiv
singl
treatment
treatment
appli
use
gehl
array
electrod
two
row
needl
mm
apart
treatment
appli
cytoreduct
attempt
excis
margin
case
macroscop
tumour
present
treat
volum
mast
cell
tumour
case
receiv
sole
therapi
ect
show
endur
cr
receiv
adjuv
ect
show
censor
respons
ect
squamou
cell
carcinoma
show
depend
site
premaxilla
extern
nare
show
respons
oral
lesion
cr
pr
surgic
remov
ect
cr
recur
treat
second
time
lead
state
censorship
pr
recur
result
spindl
cell
tumour
disappoint
one
small
fibrosarcoma
show
cr
sole
therapi
overal
respons
cr
diseas
control
ameloblastoma
epulid
show
cr
sole
therapi
melanoma
gave
rel
poor
result
cr
sole
therapi
ect
show
good
result
mast
cell
tumour
fair
result
oral
squamou
cell
carcinoma
involv
rostral
portion
mouth
cosmet
function
result
excel
scar
appar
case
skin
treat
heal
oral
lesion
even
bone
expos
rapid
complet
disclosur
disclosur
report
author
work
practic
techniqu
describ
carri
gain
hemangiosarcoma
chemodectoma
repres
frequent
type
cardiac
mass
tumor
cardiac
mass
mimick
neoplasia
also
report
establish
definit
diagnosi
import
prognost
therapeut
implic
cardiac
ultrasonographi
good
specif
sensit
detect
cardiac
mass
dog
pericardi
effus
howev
report
agreement
ultrasound
mass
locat
definit
histolog
diagnosi
hemangiosarcoma
chemodectoma
cytolog
examin
pericardi
fluid
also
limit
interest
cardiac
mass
cytolog
potenti
diagnost
tool
inform
safeti
spars
diagnost
accuraci
yet
evalu
aim
studi
evalu
feasibl
safeti
fine
needl
aspir
fna
cardiac
mass
determin
correl
cytolog
histopatholog
diagnosi
dog
diagnos
cardiac
mass
februari
octob
includ
inclus
criteria
anatom
locat
allow
sampl
achiev
owner
consent
fna
perform
sedat
procedur
dog
monitor
simultan
electrocardiogram
blood
pressur
measur
dog
kept
hospit
hour
follow
fna
slide
cellular
qualiti
assess
diagnost
yield
evalu
percentag
case
cytolog
diagnosi
could
achiev
accord
histopatholog
determin
possibl
cytolog
histopatholog
slide
review
blindli
respect
one
clinic
pathologist
two
pathologist
thirteen
dog
includ
mean
weight
kg
rang
kg
ten
mass
right
wall
three
sampl
possibl
case
time
sampl
rang
minut
complic
observ
cellular
fna
smear
good
excel
permit
reach
diagnosi
case
ten
mass
diagnos
sarcoma
suspect
hemangiosarcoma
three
endocrin
tumor
suspect
chemodectoma
histopatholog
diagnosi
avail
dog
hemangiosarcoma
chemodectoma
confirm
cytolog
diagnosi
case
studi
fna
cardiac
mass
feasibl
safe
diagnost
use
good
achiev
sampl
perfect
accord
histopatholog
cytolog
evalu
could
consid
diagnost
approach
disclosur
disclosur
report
leishmaniosi
one
preval
parasit
canin
diseas
wide
spread
temper
zone
canin
leishmaniosi
may
manifest
subclin
ill
diseas
sever
chronic
diseas
multipl
organ
involv
infect
dog
consid
main
reservoir
human
viscer
leishmaniasi
studi
aim
evalu
relationship
two
current
diagnost
method
canin
leishmania
infect
name
antibodi
ab
assay
elisa
immunosorb
assay
assay
pcr
polymeras
chain
reaction
blood
sampl
avail
materi
tissu
swab
obtain
dog
suspect
leishmania
infect
histori
importationtravel
germani
analys
total
blood
sampl
respect
leishmania
ab
assay
total
sampl
respect
leishmania
dna
assay
overal
sampl
overal
sampl
respect
specif
concern
sampl
subject
pcr
ab
assay
observ
follow
ab
profil
seroposit
leishmania
unit
le
respect
pcr
cohort
versu
respect
cohort
notabl
pcrab
cohort
show
ab
titr
mean
time
higher
cohort
le
versu
le
summari
sampl
almost
sampl
case
sampl
approxim
twice
higher
ab
titr
sampl
data
suggest
may
consid
diagnost
gener
confirm
activ
leishmaniosi
repres
studi
overal
test
sampl
sampl
might
case
persistentresidu
antibodi
present
due
exposit
parasit
past
leishmania
infect
regardless
clinic
statu
dog
disclosur
disclosur
report
authour
breu
guthardt
j
empley
laboklin
gmbh
co
kg
germani
e
ownermangar
laboklin
gmch
co
kg
babesia
gibsoni
increasingli
recogn
import
canin
diseas
worldwid
howev
clinic
studi
natur
acquir
infect
avail
besid
publish
report
mix
distinct
speci
ie
b
conrada
assort
b
gibsoni
sinc
phylogenet
analys
rrna
gene
tick
consid
import
vector
although
parasit
also
transmit
dog
fight
particular
pit
bull
terrier
report
usa
also
romania
retrospect
studi
enrol
dog
diagnos
b
gibsoni
infect
confirm
pcr
nation
taiwan
univers
veterinari
teach
hospit
januari
decemb
averag
age
dog
ci
year
old
dog
includ
male
femal
seventeen
differ
breed
includ
observ
speci
mongrel
follow
maltes
miniatur
poodl
miniatur
schnauzer
beagl
none
dog
associ
dog
fight
common
clinic
sign
observ
dog
inappet
apathi
pale
mucou
membran
discolor
urin
splenomegali
hyperthermia
predomin
hematolog
abnorm
anemia
dog
sever
anemia
rang
dog
correspond
categori
hct
mild
hct
moder
hct
sever
hct
sever
hct
respect
seventi
percent
dog
carri
hct
less
wherea
dog
hct
regen
anemia
observ
wherea
anemia
occur
case
respect
thrombocytopenia
common
hematolog
abnorm
main
biochem
abnorm
hyperglobulinemia
hyperbilirubinemia
elev
hepat
enzym
activ
conclus
result
studi
provid
detail
clinic
profil
b
gibsoni
infect
sick
dog
infect
tick
bite
play
import
role
taiwan
disclosur
disclosur
report
detect
bacteraemia
blood
cultur
essenti
definit
diagnosi
correct
empir
therapi
sepsi
sepsi
often
associ
infect
oral
caviti
urogenit
tract
skin
soft
tissu
abdomen
respiratori
tract
gastrointestin
tract
bone
aim
studi
earli
detect
bacteraemia
name
bacteria
mdr
dog
cat
associ
sepsi
sampl
dog
cat
submit
blood
cultur
sever
veterinari
hospit
clinic
genevet
laboratori
sampl
collect
accord
proper
asepsi
rule
trichotomi
disinfect
venipunctur
site
bottl
extrem
blood
inocul
paediatr
aerob
blood
cultur
bottl
bacteria
isol
growth
haemocultur
bottl
grew
select
media
staphyloccoccu
spp
mr
produc
esbl
enterobacteriacea
antimicrobi
suscept
test
perform
disc
diffus
method
andor
minimum
inhibitori
concentr
clsi
clinic
breakpoint
appli
blood
cultur
posit
blood
cultur
bacteria
strain
isol
divers
bacteri
agent
found
mainli
staphyloccoccu
spp
serratia
marcescen
klebsiella
spp
among
other
frequent
antimicrobi
resist
toward
amoxicillinclavulan
acid
tetracyclin
trimethoprimsulfamethoxazol
fluoroquinolon
high
number
isol
ie
resist
differ
antimicrobi
class
isol
process
blood
cultur
also
note
isol
mr
one
staphylococcu
aureu
one
staphylococcu
pseudintermediu
isol
esbl
produc
enterobacteriacea
resist
third
gener
cephalosporin
isol
studi
high
number
posit
blood
cultur
detect
detect
mr
esbl
produc
bacteria
caus
great
concern
inher
therapeut
limit
studi
illustr
blood
cultur
key
tool
earli
diagnosi
sepsi
well
orient
antimicrobi
therapi
disclosur
disclosur
report
diagnosi
chronic
kidney
diseas
ckd
usual
achiev
use
urea
creatinin
howev
well
recogn
diseas
usual
present
biomark
elev
biomark
neutrophil
lipocalin
ngal
design
earlier
diagnosi
ngal
link
tubular
damag
ngal
observ
alter
dog
acut
renal
failur
idiopath
ckd
canin
leishmaniasi
cl
highli
preval
diseas
mani
mediterranean
countri
kidney
one
organ
affect
evalu
kidney
function
assess
creatinin
urea
degre
proteinuria
togeth
presenc
sever
clinic
sign
key
aspect
diseas
classif
leishvet
classfic
therapeut
guidelin
aim
studi
evalu
whether
dog
cl
absenc
azotaemia
may
suffer
earli
renal
damag
especif
tubular
whether
plasma
urin
ngal
may
potenti
use
biomark
character
dog
cl
ethic
approv
owner
consent
use
blood
urin
sampl
dog
grant
three
group
dog
establish
group
includ
healthi
dog
staff
member
group
includ
dog
cl
ckd
stage
leishvet
group
includ
dog
posit
quantit
serolog
mild
absent
clinic
sign
mild
absent
proteinuria
upc
absenc
azotemia
stage
leishvet
hematolog
biochemistri
plasma
ngal
measur
blood
full
urin
analysi
includ
urinari
proteincreatinin
ratio
measur
urin
ngal
also
carri
ngal
measur
use
canin
ngal
abcam
usa
result
express
ngalcreatinin
ratio
plasma
ngal
significantli
differ
group
ngml
ngml
p
differ
group
other
p
urin
ngal
elev
ngg
p
compar
ngg
p
urinari
ngal
also
increas
ngg
compar
two
group
p
conclus
urin
plasma
ngal
may
use
marker
earli
renal
damag
cl
studi
also
provid
evid
cl
dog
leishvet
stage
ii
may
suffer
earli
renal
damag
disclosur
disclosur
report
felin
leukemia
viru
felv
felin
immunodefici
viru
fiv
retrovirus
caus
signific
morbid
mortal
cat
epidemiolog
data
necessari
design
optim
strategi
manag
prevent
infect
virus
unfortun
limit
data
avail
seroepidemiolog
retrovir
infect
cat
greec
aim
studi
determin
seroepidemiolog
felv
fiv
infect
differ
popul
cat
greec
total
cat
prospect
includ
divid
three
group
stray
cat
live
shelter
catteri
signal
histor
data
collect
use
standard
questionnair
thorough
physic
examin
perform
cat
blood
sampl
obtain
jugular
venipunctur
serum
store
analysi
seropreval
felv
fiv
determin
use
snap
fivfelv
combotm
test
idexx
compar
among
group
male
femal
intact
neuter
male
femal
clinic
healthi
sick
cat
cat
present
least
one
clinic
sign
compat
felv
andor
fiv
test
fischer
exact
test
well
possibl
associ
age
cat
student
cat
found
seroposit
felv
fiv
respect
risk
seroposit
felv
significantli
higher
sick
clinic
healthi
cat
cat
least
one
clinic
sign
compat
felv
risk
seroposit
fiv
significantli
higher
male
femal
cat
neuter
intact
male
cat
older
cat
sick
clinic
healthi
cat
p
cat
least
one
clinic
sign
compat
fiv
due
high
preval
seroposit
felv
fiv
greek
felin
popul
necessari
defin
prophylact
manag
strategi
take
particular
consider
group
cat
increas
risk
seroposit
thu
infect
disclosur
disclosur
report
felin
dirofilariasi
dirofilaria
immiti
progress
regain
import
year
due
heighten
awar
diseas
speci
scientif
progress
provid
better
diagnost
tool
howev
diagnosi
challeng
present
huge
difficulti
mainli
due
absent
symptom
presenc
low
parasit
burden
immatur
worm
object
determin
incid
symptom
presenc
felin
viru
well
radiograph
echocardiograph
abnorm
cat
seroposit
immiti
blood
sampl
cat
live
hyperendem
area
test
presenc
immiti
antibodi
felin
immunodefici
viru
fiv
felin
leukaemia
viru
felv
antibodi
test
posit
cat
show
compat
symptom
dirofilariosi
versu
seroneg
cat
p
regard
felin
viru
posit
fiv
felv
statist
signific
correl
found
immiti
seroposit
presenc
felin
viru
half
immiti
seroposit
cat
submit
thorac
radiographi
echocardiographi
lung
radiograph
chang
compat
heartworm
present
cat
bronchial
pattern
unstructur
interstiti
pattern
vascular
pattern
enlarg
pulmonari
arteri
lung
hyperinfl
abnorm
present
cardiac
silhouett
anim
radiograph
abnorm
display
symptomat
cat
asymptomat
cat
p
presenc
adult
worm
observ
echographi
cat
asymptomat
present
normal
thorac
radiographi
one
cat
indoor
one
cat
outdoor
one
cat
indooroutdoor
result
show
import
imag
diagnosi
help
correct
diagnosi
felin
dirofilariosi
indistinctli
presenc
absenc
symptom
furthermor
greater
awar
felin
dirofilariosi
need
cat
state
prophylaxi
kitten
week
immiti
infect
includ
differenti
diagnosi
cat
show
compat
clinic
sign
combin
serolog
imag
diagnosi
techniqu
perform
felin
heartworm
suspect
correct
diagnosi
properli
rule
diseas
disclosur
disclosur
report
felin
liver
diseas
consist
differ
diseas
entiti
cholangiohepat
cg
hepat
lipidosi
hl
neoplasia
lymphoma
l
neoplasia
common
featur
cat
variabl
clinicopatholog
featur
requir
differ
therapeut
strategi
endoscop
liver
biopsi
current
gold
standard
establish
diagnosi
owner
complianc
limit
invas
refin
diagnost
criteria
obtain
minim
invas
method
need
ensur
best
possibl
patient
care
aim
retrospect
studi
identif
use
clinic
laboratori
featur
differenti
inflammatori
metabol
neoplast
hepat
diseas
record
cat
retrospect
evalu
inclus
criteria
full
physic
exam
complet
laboratori
profil
fine
needl
aspir
fna
liver
gallbladd
fna
bacteri
cultur
accord
result
respons
treatment
patient
alloc
group
lymphoma
l
mix
cholang
mc
neutrophil
cholang
nc
lymphoplasmacellular
cholang
lpc
hepat
lipidosi
hl
neoplasia
miscellan
inferenti
statist
perform
look
signific
differ
group
p
consid
statist
signific
age
bodi
temperatur
neutrophilia
left
shift
monocytosi
identifi
potenti
use
discrimin
diseas
entiti
p
compar
group
disclosur
disclosur
report
